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Abstract 
 
 
Mutations  in  PRPF31  (RP11  locus)  cause  autosomal  dominant  retinitis  pigmentosa 
(adRP),  an  inherited  disorder  of  the  retina  characterised  by  degeneration  of  rod 
photoreceptors.  PRPF31  is  ubiquitously  expressed  and  encodes  a  splicing  factor 
involved in the spliceosome assembly. Interestingly, the phenotype caused by mutations 
in PRPF31 is restricted to the retina. 
This study aims to identify  protein interactants of  PRPF31, to contribute to a better 
understanding of the disease mechanism of RP11. 
Three  potential  interacting  candidates  were  isolated  through  the  yeast  two-hybrid 
technique. Two of them (MAGI3, TRAK2) were confirmed to interact with PRPF31 
using  co-immunoprecipitation  experiments  after  overexpression  of  the  proteins;  
co-immunoprecipitation of the endogenous proteins was not carried out. MAGI3  and 
TRAK2  expression  in  human  retina  was  proven  by  RT-PCR,  however  they  are  not  
retina-specific. MAGI3 and TRAK2 human retina transcripts did not appear to present 
major differences to the transcripts deposited in the Ensembl database.  
Tagged  proteins  were  overexpressed  in  epithelial  cells,  and  co-localisation  between 
PRPF31  and  each  partner  was  mainly  nuclear.  In  epithelial  cells,  both  endogenous 
PRPF31  and  MAGI3  localised  to  intercellular  junctions  but  did  not  co-localise; 
however, after stress treatments, the proteins appeared to co-localise to the nucleus. In 
neuroblastoma  cells,  endogenous  PRPF31  and  TRAK2  did  not  co-localise. 
Immunohistochemistry experiments identified PRPF31 to be present largely in the inner 
segment and in the outer plexiform layer of murine retina. 
AdRP patients’ DNA was screened to detect mutations in MAGI3 that could be linked to 
retinal degeneration, but none was identified. 
The results are not conclusive of the molecular mechanism of RP11, but instead provide 
new grounds for research on PRPF31. These insights into the type of interacting partners 
and the localisations observed within the cell and the retina may cast new light into the 
function(s) of PRPF31, which may (or may not) link to retinal degeneration.  
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Abbreviations 
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C  Cytosine 
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CDK  Cyclin-dependent kinase 
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EDC  Exon definition complex 
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HAP  Huntingtin-associated protein 
HEK293  Human embryonic kidney cell line 
hnRNP  Heterogeneous ribonucleoprotein 
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IMPDH1  Inosine-5'-monophosphate dehydrogenase 1 
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IPL  Inner plexiform layer 
IRBP  Interphotoreceptor retinoid-binding protein  
IS  Inner segment 
K
+  Potassium ions 
L  Leucin 
LRAT  Lecithin:retinol acyl transferase  
MAGI3  Membrane-associated guanylate kinase with inverted orientation 3 
MAGUK  Membrane-associated guanylate kinase 
MDCK  Madin Darby canine kidney cell line 
mRNA  Messenger ribonucleic acid 
Na
+  Sodium ions 
NADP
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NLS  Nuclear localisation signal 
NMD  Nonsense mediated decay  
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NOSIC  Central domain in Nop56/SIK1-like proteins 
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OLM  Outer limiting membrane 
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PCR  Polymerase chain reaction 
PDE  Phosphodiesterase 
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PRPF  Pre-mRNA processing factor 
Prp28p  Pre-mRNA-splicing ATP-dependent RNA helicase PRP28 
Prp8  Pre-mRNA processing factor 8 
RAL  Retinal   
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Rec  Recoverin 
RHO  Rhodopsin 
RK  Rhodopsin kinase 
RNA  Ribonucleic acid 
ROL  Retinol   
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RPE  Retinal pigment epithelium 
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RT-PCR  Reverse transcription polymerase chain reaction 
SDS  Sodium dodecyl sulphate 
snoRNA  Small nucleolar RNA 
snRNA  Small nuclear RNA 
snRNP  Small nuclear ribonucleoprotein 
SPLICE  Swift PCR for ligating in vitro constructed exons 
SR (protein)  Serine/arginine-rich (protein) 
T  Thymine 
TF  Transcription factor 
TOPORS  Topoisomerase I binding RS domain protein 
TRAK2  Trafficking protein, kinesin-binding 2 
U  Uracil 
UAS  Upstream activation sequence 
UTR  Untranslated region 
UV  Ultra violet 
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W  Tryptophan 
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1.  Introduction 
 
 
 
1.1  The Eye 
The eye is the sensory organ responsible for the detection of light, hence allowing an 
individual  to  perceive  the  surrounding  environment.  This  sensory  system  detects 
external light stimuli, originating from various sources, and converts them into electric 
signals. These are sent along the optic nerve and converge to specific regions of the 
brain where they are  further processed into the images  we ultimately  perceive. This 
complex system allows visual perception by means of a precise cellular organisation and 
a fine-tuned electrical net. 
The human eye has a spherical shape, being 22-24 mm in diameter (Figure 1.1). The 
cornea forms the clear part of the visible area of the eye, and it protrudes from the main 
globe; the rest of the eye is formed by the sclera, which is a white and opaque membrane 
partially visible in  the frontal part of the eye. Three layers compose the eye: 1)  the 
external layer, formed by the cornea (transparent) and the sclera; the latter is mainly 
composed of collagen which protects the inner parts and helps maintain the spherical 
structure;  2)  the  choroid:  a  highly  vascularised  tissue  which  provides  oxygen  and 
nutrients;  and  3)  the  retina:  the  innermost  layer  formed  by  neurons,  which  is  the 
photosensitive component of the eye involved in detecting and part processing visual 
information. In the cavity formed by the three layers (the posterior chamber) lies the 
vitreous humour, a thick gel-like substance which helps maintain the shape of the eye. It 
is separated from the frontal part by the lens. The space between the lens and the cornea 
(known as the anterior chamber) is filled with aqueous humour; the iris lies in front of 
the lens, and regulates the aperture of the pupil (Bron et al., 1997). 
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Figure 1.1. Anatomy of the human eye. 
Anteroposterior  section of  the  bulb. Two  chambers  are distinguishable,  the  anterior  and  the  posterior 
chambers, followed by the vitreous body and last by a series of membranes (present also on the sides). On 
the outside the anterior chamber is delimited by the cornea, on the inside it is limited by the lens and the 
iris. The posterior chamber is comprised between the iris and the formations which constrain the lens. At 
the back is the vitrous body. The membranes which encase the bulb are the retina, the choroid and the 
sclera. (Image adapted from http://www.blundelloptometry.com). 
 
 
     1. Introduction 
 
  18 
1.2  The Retina 
The human retina is a thin transparent tissue located at the back of the eye, between the 
vitreous  humour  and  the  retinal  pigment  epithelium.  It  is  responsible  for  detecting 
photons of light and converting them to electrical impulses that are sent along the optic 
nerve to the brain. The human retina is approximately 0.5 mm thick, it is part of the 
central  nervous  system  and  composed  of  six  different  types  of  neural  cells: 
photoreceptor cells, horizontal cells, bipolar cells, amacrine cells, interplexiform cells 
and ganglion cells. These cells are organised in a neuronal network which detects the 
visual  stimuli,  allowing  for  high  sensitivity  (rod  photoreceptor  pathway)  and  high 
precision (cone photoreceptor pathway).  Along with neurons, other cells are present, 
such as Müller cells and epithelial cells. 
 
1.2.1  Organisation of the Retina 
The retina can be divided into several layers (Figure 1.2), including (following a ray of 
light, from the front to the back): 
-  internal limiting membrane (ILM); 
-  nerve fibre layer (NFL); 
-  ganglion cell layer (GCL); 
-  inner plexiform layer (IPL); 
-  inner nuclear layer (INL); 
-  outer plexiform layer (OPL); 
-  outer nuclear layer (ONL); 
-  outer limiting membrane (OLM) 
-  inner and outer segments of photoreceptors (IS and OS); 
-  retinal pigment epithelium (RPE). 
 
A ray of light has to cross several layers of cells before reaching the photoreceptors, the 
light-sensitive cells in the penultimate layer of the retina. The retina itself is separated 
from the vitreous humour by the internal limiting membrane (ILM). Behind the ILM are 
the ganglion cell fibres, which project axons to the brain via the optic nerve relaying the 
gathered  visual  information.  The  INL  contains  the  nuclei  of  bipolar,  horizontal,     1. Introduction 
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Figure 1.2. Structure of the human retina. 
Schematic representation of the layers composing the mammalian retina (adapted from Wässle, 2004). 
(OS: outer segment; IS: inner segment; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner 
nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer; NFL: nerve fibre layer). 
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amacrine and interplexiform cells; bipolar cells contact photoreceptors and transmit the 
signal to ganglion cells; the remaining cells help regulate the transduction of the signal; 
Müller glia cells are mainly present in the INL, but their processes spread across the 
adjacent layers: they play a role in the metabolism of the retina, and in its development, 
as  they  help  orienting,  disposing  and  displacing  the  developing  neurons.  The  outer 
nuclear layer (ONL) contains the soma and nuclei of photoreceptors cells, with their 
outer segment extending outwards towards the retinal pigment epithelium (RPE). The 
RPE is a single layer of epithelial cells that lies at the back of the retina, adjacent to the 
photoreceptors, next to the choroid. The cells are polarised and tightly packed and are 
involved in crucial functions such as nourishing and protecting the retinal environment. 
The  RPE  facilitates  transport  and  exchange  of  nutrients,  oxygen  and  by-products 
between the retina and the choroid. It contacts and engulfs the tips of photoreceptor OS, 
providing not only a structural support but is also involved in the renewal of the OS by 
phagocytosing  the  photoreceptor  tips  and  metabolising  their  content  (Figure  1.3). 
Consequently, it plays a role in the generation of the visual chromophore (11-cis-retinal, 
see section 1.3.2). Finally, the melanin granules present throughout the RPE help absorb 
the scattered light, preventing inner reflection and any damage due to phototoxicity. 
When a photon of light is absorbed by the photoreceptor cell, the stimulus is conveyed 
to bipolar cells first, and then to ganglion cells which eventually convey the information 
via the optic nerve to the brain. Hence one recognises a transverse organisation among 
the retinal layers: a receptor can activate more than one bipolar cell, and one single 
bipolar cell can activate more than one ganglion cell. The signal is amplified as it is 
spread horizontally, while it moves vertically towards the optic nerve. The amplification 
is tuned by the neighbouring horizontal cells, together with amacrine and interplexiform 
cells, all of them playing a modulatory role within the system. 
 
1.2.2  Photoreceptor Cells 
Photoreceptor cells are responsible for the processing of the visual stimuli into electric 
signals.  They  constitute  the  penultimate  layer  of  the  retina,  lined  by  RPE  on  the 
outermost side and making contact with bipolar cells on the other.     1. Introduction 
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Figure 1.3. Photoreceptor disc shedding. 
The tips of the photoreceptor outer segments are phagocytosed by the RPE cells and metabolised. Image 
adapted from webvision.med.utah.edu 
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There are two types of photoreceptors: rod cells and cone cells. They have different 
photopigment, phototransduction and chromophore regeneration dynamics, explaining 
why rods are responsible for vision in dim lighting conditions (scotopic vision, i.e. at 
night) and cones for colour or bright light conditions (photopic vision). 
Both rods and cones share a basic structure comprising four distinct sections: the axon 
terminal, the nuclear region (cell body), the inner segment (IS) and the outer segment 
(OS) (Figure 1.4). The axon terminal synapses upon bipolar cells in the OPL; the cell 
body contains the nucleus and is found in the ONL. The IS is rich in mitochondria, 
Golgi bodies and ribosomes, being where metabolic reactions take place; the OS is the 
site of the phototransduction and it is rich in visual pigment. The rod OS is cylindrical 
and composed of a stack of flattened membranous discs; they originate from the plasma 
membrane, and eventually are pinched off, and then lay free one on top of the other 
within the plasma membrane. Conversely, the cone OS tapers off and its discs remain 
attached to the plasma membrane along the entire length of the outer segment. The discs 
are replaced on a daily basis, as the older ones at the tip of the OS are phagocytosed by 
the RPE in a process known as disc shedding. The OS is entirely renewed within ten 
days, as new discs constantly originate at the base of  the OS. The protein synthesis 
mechanisms in the IS have to be highly efficient in order to produce the large amount of 
proteins  required  for  the  renewal  (in  rods,  more  than  90%  of  the  OS  proteins  are 
rhodopsin; Palczewski, 2006). The IS and OS are connected by a nonmotile connecting 
cilium, which facilitates the trafficking of proteins (and other metabolites) between the 
two segments. The synaptic termini of both cone and rod are connected with the bipolar 
cells, which in turn are connected to the ganglion cells. The signal generated by the light 
travels through these three types of cells. 
Photoreceptors show a diverse distribution throughout the human retina: generally cones 
are numerous in the macula, an area approximately at the centre of the retina. In the 
macula is the fovea, a virtually rod-free pit involved in central vision; given its high 
abundance  of  cones,  the  macula  is  responsible  for  high  acuity  vision.  Towards  the 
peripheral  retina,  cones  decrease  gradually  in  favour  of  rods,  which  become  more 
abundant. Of all the photoreceptors, ~92 million are rods and ~4.6 million are cones 
(Bron et al., 1997).     1. Introduction 
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Figure 1.4. Rod and cone photoreceptors. 
Rods and cones are structurally comparable, both showing a partition in four sections (axon terminal or 
synaptic ending, the nuclear region, the inner segment and the outer segment). Cones are shorter than rods, 
although wider in diameter: the synaptic terminus and the nuclear region are larger, and the outer segment 
is shorter. Image adapted from thebrain.mcgill.ca. 
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The light signal is detected by the visual pigment found within the disc membrane of the 
OS of  rod  and  cone photoreceptors;  it  is  formed by  a protein  moiety  (opsin)  and  a 
chromophore (11-cis-retinal). Rods possess only one type of opsin, rhodopsin, with its 
absorption peak at 498 nm. Cones, however, contain different photo pigments: there are 
three different opsins, with peak absorptions at different wavelengths: short-wavelength 
opsin (420 nm – blue cones), medium-wavelength opsin (530 nm – green cones) and 
long-wavelength opsin (560 nm – red cones). Similarly, according to the opsin present in 
the  discs,  cones  are  categorised  as  short-wavelength,  medium-wavelength  or 
long-wavelength  cones,  respectively.  Since  rods  detect  only  one  wavelength,  they 
provide  monochromatic  vision,  whereas  cones  provide  colour  vision.  The  two 
photoreceptor types have different kinetics of signal transduction: rods have a longer 
recovery time than cones, showing more sensitivity to light and are therefore involved in 
vision in low lighting conditions. Cones show a faster recovery, allowing vision in bright 
light; they are less sensitive and discriminate between different light intensities, and the 
interaction between the responses of the different cone types determines colour, depth 
and intensity. 
 
1.3  Physiology of the Retina 
The  visual  pigments,  or  light-receptive  proteins,  are  the  opsins  found  on  the 
membranous discs of the OSs: rhodopsin in rods and cone-opsin(s) in cones. When a 
photon  of  light  is  captured  by  a  visual  pigment  such  as  rhodopsin,  it  initiates  the 
phototransduction cascade, which converts the stimulus into an electric response. Opsins 
belong  to  the  G-protein  coupled  receptor  (GPCR)  family;  these  proteins  are 
characterised  by  seven  transmembrane  helices,  whose  spacial  arrangement  gives  the 
receptor an elliptical shape (Figure 1.5). The N-terminal part is extracellular (it is located 
in the inner space of the disc), whereas the C-terminus is cytosolic. 
Rhodopsin  and  cone-opsin  pigments  consist  of  a  protein  moiety,  the  opsin,  and  a 
chromophore, 11-cis-retinal,  which  is embedded  within  the  transmembrane  domains, 
and  covalently  bound  to  a  lysine  residue.  Opsin  itself  does  not  absorb  light;  the 
light-sensitive molecule is the chromophore. 11-cis-retinal is non active, and its “bent” 
conformation allows the molecule to fit stably into the opsin.     1. Introduction 
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Figure 1.5. The rhodopsin molecule. 
Rhodopsin molecules (purple balls on top left) are embedded within the rod disc membrane (Blue and 
grey layer in  main image).  Each  molecule of  rhodopsin  has  seven  transmembrane domains,  with the 
chromophore retinal buried within them. Image adapted from webvision.med.utah.edu 
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When  the  visual  pigment  absorbs  a  photon  of  light,  the  photosensitive  molecule 
isomerises to all-trans-retinal, whose “straight” conformation acts as a spring and allows 
the molecule to break free from the opsin. This way the photo-activated receptor sets off 
the G-protein cascade, leading to the phototransduction. 
 
1.3.1  Phototransduction 
In the dark, photoreceptors are depolarised, and maintain a steady concentration of Na
+ 
and  K
+.  The  high  concentration  of  cGMP  keeps  cGMP-gated  Na
+-channels  open, 
allowing for an inward flux of Na
+, whereas non-gated channels allow for an outward K
+ 
flux, keeping the cell depolarised (Figure 1.6); these channels are located on the OS 
plasma membrane. This state of depolarisation allows an influx of Ca
2+. Light causes 
hyperpolarisation of the cell, because the Na
+ flux is blocked and the Ca
2+ concentration 
decreases. The hyperpolarised state results in the transmission of a signal to the optic 
nerve, through the layers of the retina. 
When the photon of light hits rhodopsin (Figure 1.6 A), the 11-cis retinal undergoes a 
conformational change to all-trans-retinal: the receptor switches to its activated form 
(R*),  catalysing  the  exchange  of  GDP  to  GTP  in  the  subunit    of  the  G-protein 
transducin  (G);  the  enzymatically  active  G*  binds  to  the  inhibitory  subunits  of 
phoshodiesterase  (E), which is  then able to  catalyse  the hydrolysis of  cGMP  (cG in 
Figure 1.6 A). The resulting decrease in cytoplasmic concentration of cGMP provokes 
the closure of cGMP-gated channels, therefore blocking the inward flux of Ca
2+ and 
Na
+. 
The  decreased  Ca
2+  concentration  triggers  three  mechanisms  of  recovery:  one  is 
regulated by  recoverin  (Rec,  Figure  1.6  B).  Recoverin has  an  affinity  for  rhodopsin 
kinase (RK) at normal Ca
2+ concentration, but when the Ca
2+ concentration drops, it 
frees  the  RK,  allowing  the  latter  to  phosphorylate  rhodopsin  (R*  to  R-P);  R-P  is  a 
substrate for arrestin (Arr) which binds and quenches rhodopsin activity. Another way is 
by inactivation of transducin (G, Figure 1.6 C), which is possible by the hydrolysis of 
GTP  to  GDP,  leading  to  the  inactivation  of  phosphodiesterase  (E).  A  third 
mechanism  is  controlled  by  a  guanylyl  cyclase  (GC,  Figure  1.6  A):     1. Introduction 
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Figure 1.6. Schematic view of phototransduction in vertebrate photoreceptor cells. 
A: the activation of the cascade and the quenching mediated by guanylyl cyclase; B and C: quenching 
mediated by recoverin and by inactivation of transducin respectively. Image from Pugh & Lamb 2000. 
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as Ca
2+ concentration drops, the guanylyl cyclase activating protein (GCAP) releases its 
Ca
2+  and  binds  to  GC increasing its  cyclase  activity,  raising  the cGMP cytoplasmic 
concentration, hence restoring the inward fluxes of Ca
2+ and Na
+ (Pugh & Lamb, 2000). 
 
1.3.2  The Visual Cycle 
In rod cells, once the chromophore has isomerised to all-trans-retinal, it can only return 
to  11-cis-retinal  through  an  enzyme  pathway  called  the  visual  cycle  (Figure  1.7). 
Following  photon  absorption,  rhodopsin  is  activated,  and  after  its  inactivation,  
all-trans-retinal dissociates and diffuses into the bilayer of the OS discs. It is transported 
into  the  cytoplasm  by  the  ATP-binding  cassette  transporter  ABCA4,  and  here  it  is 
reduced to all-trans-retinol (vitamin A) by a retinol dehydrogenase (RDH), likely to be 
in  a  NADPH-dependent  manner.  Following  this,  the  all-trans-retinol  reaches  the 
extracellular  space  and eventually  enters  the  RPE  cells.  All-trans-retinol  also enters 
when  the  shed  OS  are  phagocytosed  by  the  RPE  cells,  and  by  endocytosis  of 
interphotoreceptor retinoid-binding protein (IRBP). All-trans-retinol can also be taken 
up from the choroid, as it circulates in the blood stream. 
In the RPE, all-trans-retinol is esterified by lecithin:retinol acyl transferase (LRAT) and 
the ester is later converted to 11-cis-retinol by isomerase RPE65; the product binds to 
cellular  retinal-binding  protein  (CRALBP).  11-cis-retinol  is  finally  oxidised  to 
11-cis-retinal by 11-cis-retinol dehydrogenase (RDH5 and RDH11). The chromophore is 
then  transported  from  the  RPE  to  the  OS  to  regenerate  the  visual  pigments. 
Alternatively,  11-cis-retinol  can  be  esterified  by  LRAT  to  11-cis-  retinyl  ester,  and 
stored (Figure 1.7; as reviewed by Travis et al., 2007). 
Recent  studies  have  revealed  an  alternate  cone-cycle  (Figure  1.8)  to  regenerate  the 
chromophore in cone-dominated retina. This pathway does not depend on RPE but relies 
on Müller cells, and could explain the faster time of recovery of cone photoreceptors. 
Cone  cells  can  regenerate  the  visual  pigments  by  taking  up  both  11-cis-retinal  and 
11-cis-retinol, since a NADP
+/NADPH-dependent 11-cis-RDH activity was discovered, 
making them independent from RPE as a source of 11-cis-retinal, as opposed to rods. 
The  cone-visual  cycle  resembles  the  rod-visual  cycle:  all-trans-retinal  is  reduced  to 
all-trans-retinol  by  NADPH-dependent  all-trans-RDH  in  cone  OS;     1. Introduction 
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Figure 1.7. The visual cycle. 
The genes mutated in RP and involved in this pathway are shown in red. Image adapted from Travis et al., 
2007. (RAL: retinal; ROL: retinol; RE: retinyl ester; RPE: retinal pigment epithelium). 
 
 
 
Figure 1.8. The cone-visual cycle. 
Alternative cycle for regeneration of cone pigments. Image taken from Travis et al., 2007. (RAL: retinal; 
ROL: retinol; RE: retinyl ester).     1. Introduction 
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but  unlike  in  rods,  all-trans-retinol  enters  the  Müller  cell  and  is  isomerised  to 
11-cis-retinol which re-enter the cone OS and it is converted to 11-cis-retinal by the 
NADP
+-dependent 11-cis-RDH (Figure 1.8) (As reviewed by Muniz et al., 2007, Travis 
et al., 2007). 
 
1.4  Retinitis Pigmentosa 
1.4.1  Overview 
Retinitis  pigmentosa  (RP;  MIM#268000)  is  an  inherited  disorder  of  the  retina, 
characterised  by  progressive  degeneration  of  rod  photoreceptors  followed  by  cone 
degeneration,  eventually  resulting  in  severe  visual  impairment  to  loss  of  sight. 
Originally, the term “retinitis pigmentosa” was given to this type of disease believing 
that it was caused by retinal inflammation. However, now, it is well known that retinitis 
pigmentosa primary etiology is not inflammation but photoreceptor cell death. 
Inherited retinal degenerations are a group of disorders characterised by deterioration of 
the retina, causing loss of neuronal cells. These disorders range from the most common 
retinitis pigmentosa to Leber  congenital  amaurosis  (LCA), when  rods  and cones  are 
dead/non-functional at birth (Francois, 1968); macular degeneration, when only the rods 
and the cones of the macula degenerate, with preservation of the peripheral retina (Green 
& Enger, 1993); cone degeneration, when all three cone types die leaving rods alive and 
functional (To et al., 1998), leading to rod monochromacy in which vision is mediated 
by  rods only; hereditary optic atrophy, characterised by  a reduced number of retinal 
ganglion cells; stationary night blindness, characterised by a full complement of rods 
and cones, however rods are not as sensitive to dim light and therefore show longer 
adaptation times (Dryja, 2000). Other types of inherited retinal degenerations affect the 
macula, like the Best disease, also known as vitelliform macular dystrophy, which is 
caused by the deposition of lipofuscin-like material in the subretinal space, damaging 
irreparably  the  macula  (White  et  al.,  2000);  or  the  Doyne’s  honeycomb  retinal 
dystrophy, characterised by drusen deposits (white-yellow deposits) in the macular area 
and the optic nerve head (Gregory et al., 1996). 
Due to rod cells degeneration, RP initially manifests as difficulties in dark adaptation to 
night blindness, and with gradual loss of peripheral vision; RP is diagnosed through     1. Introduction 
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testing of visual field loss and photoreceptor activity (electroretinogram). RP is highly 
heterogeneous, both phenotypically and genetically: more than 40 genes associated with 
RP  have been  identified  (Daiger  et  al.,  2007),  with  autosomal dominant,  autosomal 
recessive and X-linked modes of inheritance  (see section 1.4.3);  affected  individuals 
may  experience  loss  of  vision  very  early  on  in  life,  whereas  other  patients  do  not 
manifest the disease until their 40s or 50s, or never become legally blind, retaining some 
sight late into their life. Although most of the cases are represented by non-syndromic 
RP, RP can manifest together with other non-ocular symptoms, such as deafness (Usher 
syndrome;  Boughman  et  al.,  1983),  or  cognitive  impairment,  obesity,  polydactyly, 
hypogenitalism and renal disease (Bardet-Biedl syndrome; Tieder et al., 1982; Beales et 
al., 1999), or nephronophthisis (Senior-Loken syndrome, Saunier et al., 2005); many 
other syndromes which associate with RP are reviewed in Hamel, 2006. 
 
1.4.2  Symptoms of Retinitis Pigmentosa 
Many of the patients suffering from RP experience two key symptoms: night blindness 
and progressive loss of visual field (tunnel vision, Figure 1.9) both due to early loss of 
rod cells in the peripheral retina. With progression of the disease, cone cells can be also 
affected  and  therefore  degenerate,  disturbing  day  vision  and  central  visual  acuity. 
Fundus examinations often reveal other symptoms of RP, which include: attenuation of 
retinal vessels, pallor of the optic nerve, and perivascular pigmentation in the form of 
bone-spicule deposits due to the migration of RPE cells into the neural retina (Li et al., 
1995),  in  response  to  photoreceptor  death  (Figure  1.10).  If  none  of  the  described 
symptoms is yet detectable, it is possible to diagnose RP via electroretinograms, which 
measure and record the electrical response of the retina to flashes of light. 
Histologically, RP leads to thinning of the outer nuclear layer, as photoreceptors die, 
whereas the inner nuclear layer and the ganglion cell layer remain intact (Figure 1.11). 
In most cases, patients only suffer retinal degeneration (non-syndromic RP), but there 
are  cases  in  which  RP  is  manifested  together  with  other  non-ocular  symptoms 
(syndromic RP), with an autosomal recessive mode of inheritance. There are several 
syndromes (30) and they account for the 20-30% of RP cases: Usher syndrome is the 
most  common,  accounting  for  10-20%  of  RP  cases  (Hartong  et  al.,  2006),  it  is    1. Introduction 
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Figure 1.9. Retinitis pigmentosa disease progression: tunnel vision.  
Peripheral vision is  gradually lost in  RP,  resulting in  tunnel  vision, as  only the  central  vision  is  left 
functioning. On the left, a representation of normal vision (unaffected patient). On the right what an RP 
patient might see. Image adapted from http://en.wikipedia.org/wiki/Tunnel_vision. 
 
 
 
 
 
 
 
 
Figure 1.10. Comparison between a normal fundus, left, and a RP patient fundus, right. 
In RP patients, waxy colour of the optic disc, attenuation of blood vessels and peripheral pigmentation are 
noticeable on the affected patient’s fundus. (Image from Hartong et al., 2006)     1. Introduction 
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Figure 1.11. Histology of healthy- (left) and RP-retina (right). 
There is a noticeable thinning of the photoreceptor nuclear layer in the RP retina, due to photoreceptor cell 
death. In contrast, bipolar cells and ganglion cells nuclei remain relatively intact. (Image from Hartong et 
al., 2006). 
     1. Introduction 
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characterised by retinal disorder (RP) and hearing loss (Boughman et al., 1983); Bardet-
Biedl syndrome is another major form of syndromic RP (5-6% of RP cases; Hartong et 
al., 2006), and patients display severe symptoms such as obesity, cognitive impairment, 
polydactyly, hypogenitalism and renal disease alongside RP (Tieder et al., 1982; Beales 
et al., 1999); the Senior-Loken syndrome, characterised by renal disease (Saunier et al., 
2005). 
 
 
1.4.3  Genetics of Retinitis Pigmentosa 
RP affects one in 4000 individuals worldwide, hence accounting for more than a million 
cases (Hartong et al., 2006). Most forms of RP are monogenic, and present a typical 
inheritance pattern: autosomal recessive RP (arRP) represents the ~30% of the cases, 
autosomal dominant RP (adRP) accounts for the ~20% of the cases and finally X-linked 
RP (xlRP) represents the ~15% of the cases (Daiger et al., 2007). A small proportion of 
cases show different modes of inheritance, such as mitochondrial inheritance, digenic 
diallelic and digenic triallelic inheritance (Rivolta et al., 2002).  Approximately 30% of 
RP cases have no family history (Daiger et al., 2007). Generally, xlRP is developed at an 
early  age  and  usually  shows  the  most  severe  phenotypes;  arRP  presents  a  milder 
phenotype  than  xlRP;  finally,  adRP  shows  the  latest onsets  and  a  milder phenotype 
(Hamel, 2006). However, among the affected for each pattern of inheritance, there may 
be phenotypical heterogeneity, due to different genetic background and environmental 
conditions, along with a different molecular cause. 
To  date,  53  loci  associated  with  RP  have  been  identified 
(http://www.sph.uth.tmc.edu/Retnet/sum-dis.htm#A-genes,  accessed  17/09/2009),  and 
more than 40 genes have been identified (Daiger et al., 2007). Most of the genes encode 
for proteins implicated in photoreceptor and RPE biology, with a currently small but 
growing  portion  encoding  ubiquitously  expressed  proteins.  Table  1.1  provides  an 
overview  of  the  majority  of  the  RP  genes,  categorised  according  to  their 
known/presumed function.     1. Introduction 
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Table 1.1 Retinitis Pigmentosa Genes. 
Retinitis Pigmentosa Genes  Inheritance  Reference 
Phototransduction Cascade     
RHO - Rhodopsin  Dominant,recessive  Hargrave 2001 
PDE6A - Rod cGMP-specific phosphodiesterase subunit   Recessive  Koutalos et al 1995 
PDE6B - Rod cGMP-specific phosphodiesterase subunit   Recessive  Koutalos et al 1995 
CNGA1 - cGMP-gated cation channel alpha-1  Recessive  Dhallan et al 1992 
CNGB1 - cGMP -gated cation channel beta-1  Recessive  Korschen et al 1999 
SAG - Arrestin  Recessive  Palczewski et al  1998 
Visual Cycle 
ABCA4 - Retinal-specific ATP-binding cassette transporter  Recessive  Weng et al 1999 
RLBP1 - Retinaldehyde-binding protein 1  Recessive  Saari et al 2001 
RPE65 - Visual cycle isomerase  Recessive  Xue et al 2004 
LRAT - Lecithin retinol acyltransferase  Recessive  Sue et al 2004 
RGR - RPE-retinal G protein-coupled receptor  Recessive  Chen et al 2001 
Structural, cytoskeletal, intracellular trafficking   
RDS - Peripherin-2  Dominant, digenic  Travis et al 1991 
ROM1 - Rod outer segment membrane protein 1  Dominant, digenic  Clarke et al 2000 
FSCN2 - Fascin-2  Dominant  Saishin et al 2000 
TULP1 - Tubby-related protein 1  Recessive  Xi et al 2005 
CRB1 - Crumbs homolog 1  Dominant  Pellikka et al 2002 
RP1 - Oxygen-regulated protein 1  Dominant,recessive  Liu et al 2004 
TOPORS - Topoisomerase I binding, arginine/serine-rich  Dominant  Chakarova et al 2007 
RPGR - Retinitis pigmentosa GTPase regulator  X-linked  Hong et al 2003 
EYS - Protein eyes shut homolog  Recessive  Abd El-Aziz et al 2008 
Signaling, cell-cell interaction, synaptic interaction 
SEMA4A - Semaphorin-4A  Dominant  Rice et al 2004 
USH2A - Usherin  Recessive  Reiners et al 2005 
RP2 - Protein XRP2  X-linked  Chapple et al 2003 
NRL - Neural retina-specific leucine zipper protein  Dominant  Swaroop et al 1992 
Splicing factors   
PRPF3 - Pre-mRNA processing factor 3  Dominant  Wang et al 1997 
PRPF8 - Pre-mRNA processing factor 8  Dominant  Umen et al 1995 
PRPF31 - Pre-mRNA processing factor 31  Dominant  Zhou et al 2002 
PAP1 - Pim-1-associated protein  Dominant  Maita et al 2004 
ASCC3L1 - RNA helicase BRR2  Dominant  Li et al 2009 
Other   
CERKL - Ceramide kinase-like protein  Recessive  Bornancin et al 2005 
MERTK - Proto-oncogene tyrosine-protein kinase MER   Recessive  Vollrath et al 2001 
NR2E3 - Retinal nuclear receptor transcription factor  Dominant,recessive  Kobayashi et al 1999 
CA4 - Carbonic anhydrase 4  Dominant  Yang et al 2005 
IMPDH1 - Inosine-monophosphate dehydrogenase 1  Dominant  Bowne et al 2002 
The table summarises most of the disease genes, their related product functions and mode of 
inheritance. 
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1.4.4  Autosomal Dominant Retinitis Pigmentosa 
Autosomal dominant retinitis pigmentosa (adRP) is caused by mutations in 16 known 
genes, and to date one locus (RP33) for which the gene may be ASCC3L1 (Li et al., 
2009; http://www.sph.uth.tmc.edu/Retnet/sum-dis.htm#A-genes, accessed 17/09/2009). 
The gene for rhodopsin (RHO) was the first gene to be found associated with RP. It 
encodes the photopigment rhodopsin which plays a pivotal role in the phototransduction 
cascade  as previously  discussed.  Mutations  in rhodopsin account for the majority of 
adRP cases (25%; Hartong et al., 2006): over 100 mutations have been found in the 
gene, all leading to aberrant protein products, with one or few amino acids deleted or 
changed (Wang et al., 2005). 
Mutations  in  retinal-specific  genes  (e.g.  photoreceptor-  or  RPE-specific  genes)  can 
understandably result in retinal degeneration. However there are a group of genes whose 
products are ubiquitously expressed, and yet mutations in them are only known to cause 
non-syndromic RP. For  adRP, these  include PRPF31 (Vithana et al.,  2001),  PRPF3 
(Chakarova  et  al.,  2002),  PRPF8  (McKie  et  al.,  2001),  PAP1  (Keen  et  al.,  2002), 
ASCC3L1 (Li et al., 2009), IMPDH1 (Bowne et al., 2002), and TOPORS (Chakarova et 
al.,  2007).  IMPDH1  is  a  dehydrogenase,  and  catalyses  the  synthesis  of  guanine 
nucleotides. TOPORS is a nuclear protein with ubiquitin and SUMO-1 E3 ligase activity 
which  localises  to  the  connecting  cilium  of  mouse  rod  photoreceptor  cells  (Dr  C. 
Chakarova personal communication). The five remaining ubiquitously expressed genes 
are all involved in pre-mRNA splicing, among them is PRPF31, which is the second 
most common gene known to be mutated in adRP (5% of adRP cases, Hartong et al., 
2006). Its disease mechanism is not understood yet, and before discussing its role in the 
pathogenesis of RP, the following section will provide an overview of splicing. To note, 
other ubiquitously expressed genes are found also in the arRP category – e.g. MERTK 
(Graham et al., 1994) or USH2A (Eudy et al., 1998) - and xlRP category – e.g. RPGR 
(Kirschner et al., 1999) or RP2 (Schwahn et al., 1998) - . 
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1.5  RNA Splicing 
The vast majority of eukaryotic genes contain regions which code for a protein (exons) 
and  regions  that  do  not  code  (introns).  A  protein  is  therefore  the  product  of  the 
translation of the coding regions only. In order for this to occur, the non-coding regions, 
introns,  must  be  removed.    After  the  transcription  of  a  gene,  a  primary  transcript  
(pre-mRNA)  is  produced,  having  the  same  organisation  of  the  gene  as  the  DNA, 
containing  both  coding  and  non-coding  regions.  To  generate  a  single  continuous 
molecule of joined exons, the pre-mRNA faces various modifications such as 5’ capping 
and the 3’ polyadenylation, and also the removal of the intronic regions. The critical 
process responsible for intron removal and the joining of exons is known as splicing. 
Hence,  splicing  is  defined  as  a  post-transcriptional  genetic  modification:  it  occurs 
naturally in eukaryotic cells, and takes place in the nucleus, along with the other RNA 
modifications. Splicing leads to a mature transcript (mRNA), which is then ready for 
downstream  processes  like  the  translation  into  a  protein,  allowing  the  gene  to  be 
expressed. 
 
1.5.1  Biology of Splicing 
Splicing  is  carried  out  by  a  multi-megadalton  ribonucleoprotein  enzyme,  the 
spliceosome:  it  is  a  large  complex  of  proteins  and  small  nuclear  RNA  (snRNA) 
molecules. Five snRNAs are involved in splicing: U1, U2, U4, U5, U6. Each of them 
associates with several different proteins, forming ribonucleoprotein particles (snRNPs). 
The proteins are either involved in the splicing reaction, take part in the assembly and 
the structure of the complex, or else help connections between the snRNPs. Many other  
non-snRNP proteins, generally termed “splicing factors”, also take part in the splicing 
assemblage, and more than 200 have been identified through mass spectrometry (Liu et 
al., 2006). From the number and type of elements implicated, it is comprehensible that a 
correct  and  functional  spliceosome  relies  on  RNA-RNA  interactions,  as  well  as  
RNA-protein  and  protein-protein  interactions,  building  evidence  for  the  high 
sophistication of the entire spliceosomal molecular machine. 
Introns show defined features in order to be recognised from exons, allowing for correct 
excision. In fact, the identification of the splice sites is mediated by highly conserved     1. Introduction 
 
  38 
sequences found at the intron boundaries only. The 5’ end is marked by a conserved 
dinucleotide, GU; the 3’ end is characterised by three elements: a branch site nucleotide 
A,  a  polypyrimidine  sequence  and  a  final  AG  dinucleotide.  The  GU-AG  sequences 
define the intron margins. 
The splicing reaction can be divided in two major steps: first, the recognition of  the 
consensus sequences, and second, the cleavage and ligation of the substrate RNA. The 
reaction consists of a first cut at the 5’ end of the exon-intron junction, with the release 
of the exon as a linear molecule (Figure 1.12); the intron bends on itself forming a lariat, 
linking its 5’ end to the target base A (branch site). Next, a cut at the 3’ end releases the 
intron  and  the  two  exons  are  ligated  together;  finally  the  intron  is  linearised  and 
degraded. Introns are not necessarily spliced sequentially from the 3’ to the 5’, but are 
spliced depending on the accessibility of the recognition sequences. 
The splicing complex forms de novo at each round of splicing. Figure 1.13 illustrates the 
splicing  dynamics,  including the  snRNPs. At  the beginning is complex  E, when  U1 
snRNP base-pairs to 5’ splice site GU, U2AF (U2 auxiliary factor) recognises the 3’ 
polypirimidine tract and 3’-terminal AG, and associates to it, SF1 binds to the branch 
site sequence. These associations bridge the intron and bring the flanking exons close to 
each other. Complex E evolves to A as soon as U2 snRNP is recuited, and its snRNA 
base-pairs with the branch point sequence in an ATP-dependent fashion. Subsequently, 
again through an ATP-dependent way,  U4/U6•U5  tri-snRNP  joins  to form  the  large 
spliceosome (complex B). Finally, molecular rearrangements of complex B, including 
the detachment of U1 and U4 snRNPs, allow the formation of the catalytic complex C, 
which performs the transesterification reactions, resulting in the ligation of the exons 
and the excision of the intron. 
Along with a major class of introns which show the features described above, a class of 
minor introns has been identified: they are spliced by a different spliceosome apparatus, 
termed  the  minor  spliceosome.  Minor  introns  rarely  display  the  common  GU-AG 
boundary, and they also have a different branch site sequence (Figure 1.14). The set of 
snRNPs involved is also different: U11, U12, U4/atac, U6/atac, which cover the same 
role  as  the  major  U1,  U2,  U4  and  U6;  U5  is  shared  with  both  spliceosomes.     1. Introduction 
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Figure 1.12. Two-step splicing reaction. 
The branch site A is first recognised by U2 snRNP (not depicted), with the intron sequence forming a 
lariat on itself; secondly, exon 1 (E1) is joined to exon 2 (E2). p is for phosphate groups. Image from Will 
& Luhrmann 2005. 
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Figure 1.13. Splicesome assembly. 
The U1 snRNP base pairs with the 5’ splice site and U2AF associates with the 3’ end region (complex E). 
U2AF  (not  shown)  recruits  U2  snRNP  which base  pairs  with  the  branchpoint  sequence  forming  the 
complex A. This is followed by the formation of the large spliceosome, the complex B, with the addition 
of U4/U6•U5 tri-snRNP. Subsequent rearrangements, such as the disassociation of U1 and U4 (complex 
B*), and transesterification reactions (complex C) result in an intron lariat and the spliced mRNA. SS: 
splice site; BP: branch point. Image adapted from Wahl et al., 2009.  
The distinction between introns and exons is achieved through the exon definition complexes (EDCs; not 
shown), which are a set of SR proteins bound along the length of the exon, defining it; the intron is 
recognised through its conserved sequences (GU-AG).  
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Figure 1.14. U2 and U12 type introns. 
U2 type introns present the conserved sequences AG/GURAGU at the 5’ splice site, CURACU at the 
branch site, a polypyrimidine tract (Yn) and the YAG/G sequence at the 3’ splice site (“/” denotes an 
exon-intron  boundary,  R  is a purine,  Y is a pyrimidine). U12  type introns  have different  and  longer 
recognition sequences: A(G)UAUCCUUU at the 5’ site, UCCUUAACU at the branch site and YAC(G) at 
the 3’ site; U12 type introns lack a polypirimidine tract. Bold letters represent the branch point. Image 
from Will & Luhrmann 2005. 
 
 
     1. Introduction 
 
  42 
This  minor  complex  is  named  U12-type  spliceosome,  whereas  the  major  apparatus 
described before, is named  U2-type  spliceosome  (as  reviewed by Will & Luhrmann 
2005).  
Major and minor spliceosomes appear to share most of the proteins composing them, 
and only  seven  are  specific  to  the minor:  essentially,  they  are  part of  the  U11•U12  
di-snRNP,  hence  they  could  be  involved  in  the  recognition  of  the 
splicing site. Regarding U11 and U12, they form a di-snRNP, which does not bind the 
pre-mRNA alone as U1 and U2, but together after association. 
Compared to the dynamics of the major counterpart, in the minor spliceosome assembly, 
the  complex  E  does  not  exist:  the  spliceosomal  machinery  assembles  straight  into 
complex  A.  Moreover,  U11  and  U4atac  snRNPs  do  not  appear  to  take  part  in  the 
catalytic  complex C.  A  distinct  feature  of  the  U12  spliceosome  is  its  lower  rate  of 
splicing compared to the U2 equivalent (Patel et al., 2002): because of that, it has been 
proposed  that  minor  splicing  is  involved  in  post-transcriptional  modulation  of  gene 
expression. Also, its presence is ~100-fold less than the U2 complex, and minor introns 
account for less than 1% of all introns (Will & Luhrmann 2005). 
 
The various snRNPs must be assembled beforehand: this process starts and finishes in 
the  nucleus  (Figure  1.15).  snRNPs  are  assembled  and  gathered  in  the  Cajal  bodies 
(CBs), which are non-membranous structures present within the nucleus. The initial step 
for  the  snRNP  biogenesis  is  the  transcription  of  the  snRNA,  which  happens  in  the 
nucleus; from here, all the snRNAs except U6 are transported to the cytoplasm, where 
they are modified and proteins are attached; finally they return to the nucleus (Figure 
1.15). U6 snRNA does not shuttle to the cytoplasm and back, as all its modifications 
happen  in  the  nucleus.  Once  the  snRNA  is  modified,  it  is  targeted  to  the  CB  and 
subjected to assembly with several proteins to form the complete snRNP particle (Figure 
1.15). It is likely that the minor snRNP particles also follow the same pathway, since the 
same set of proteins is shared (although this may not be true for U11 and U12, as they 
have  several  dedicated  splicing  factors  together  with  the  common  ones;  Stanek  & 
Neugebauer, 2006).     1. Introduction 
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Figure 1.15. snRNP biogenesis. 
After transcription and processing, the U1, U2, U4, U5 snRNAs are shuttled to the cytoplasm, where they 
undergo hypermethylation of the 5’ end (green circle) and an addition of Sm ring (blue circles). These 
modifications allow the import of the U snRNAs to the cajal body (CB) in nucleus where they undergo 
base  modifications  and  are  assembled  as  snRNPs.  U6  snRNA  follows  a  different  pathway:  after  its 
transcription and processing, a methyl cap is added; it is then shuttled to the nucleolus (No) where it 
undergoes base modification, and eventually, an LSm ring (yellow circles) is added and U6 is targeted to 
the cajal body, to complete snRNP assembly. Image from Stanek & Neugebauer 2006. 
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1.5.2  Splicing Regulation 
The splicing mechanism can be regulated to achieve either inclusion or exclusion of 
exons  in  the  mature  transcript,  a  process  known  as  alternative  splicing.  Alternative 
splicing  occurs  for  a  large  number  of  genes,  and  it  is  a  principal  mode  by  which 
organisms regulate the protein output, to create proteome diversity. 
Patterns of alternative splicing are illustrated in Figure 1.16: changes may affect the 5’ 
end,  with  alternative  promoters;  or  the  3’  end  with  different  poly-A  sites;  or  else, 
alternative 5’ or 3’ splice sites may be used; and also cassette exons, mutually exclusive 
exons, and introns that can be retained and become part of the final coding sequence. 
These  regions  are  selected  and  then  either  retained  or  excised  from  the  
pre-mRNA. There are auxiliary regions, which may be intronic or exonic, which either 
promote the recruitment of  the splicing  machinery  (splicing enhancers)  to retain  the 
sequence, or can cause exon skipping (splicing silencers) by disrupting the spliceosome. 
In the first instance, the SR set of proteins bind to exonic splicing enhancers (ESEs), 
favoring the exon inclusion, whereas a set of hnRNPs bind to exonic splicing silencers 
(ESSs), and repress exon inclusion (Black, 2003). However, SR proteins are thought to 
constantly bind exonic sequences, as they interact with U1 snRNP and U2AF, helping 
their  recruitment  to  the  pre-mRNA.  To  regulate  exon  exclusion,  as  SR  proteins  are 
already bound normally and their association with the ribonucleic sequence is not very 
strong, neighboring proteins can alter their association, shifting the splicing dynamics to 
exon exclusion. Hence, according to the protein species present in a given cell, there 
may be profound differences in the splicing pattern of the same gene. SR proteins are 
also involved in promoting the association between U6 snRNA and the 5’ splice site, 
hence they are likely to modulate this event as well, leading to a different outcome. On 
the  other  hand,  hnRNPs  are  thought  to  provide  a  steric  block,  preventing  snRNPs 
particles U1 and U2 from accessing the pre-mRNA (House & Lynch 2008). 
Other type of regulations include the modifications of the splicing factors constituting 
the snRNPs: for example, yeast Prp28, a DEAD-box helicase required to release U1 
from  the  spliceosome,  must  be  phosphorylated  to  be  recruited  to  the  splicoesome 
(Mathew et al., 2008). If Prp28 is not present, U1 snRNA cannot be exchanged with the    1. Introduction 
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Figure 1.16. Different patterns of alternative splicing. 
A,  alternative  promoters  generate  exons  (light  pink  and  dark  pink)  which  are  joined  to  a  common 
downstream exon. B, alternative poly-A sites generate alternative exons which are joined to a common 
upstream exon. Alternative 5’ and 3’ splice sites (C and D respectively) lead to exon shortening/extension. 
E, cassette exons can be included or excluded. F, mutually exclusive exons are particular cassette exons, 
whose inclusion depends whether or not the other has been included or skipped, as they are not both 
retained. G, a retained intron is generated when the intronic sequence is not excised and becomes part of 
the mRNA. (Image adapted from Li et al., 2007) 
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U6 snRNA at 5’ splice site in the event that the 5’splice site differs from the consensus 
(House & Lynch 2008). 
It is plausible that these and other forms of regulation happen during the first moments 
of spliceosome formation, i.e. at the pre-spliceosomal stage during complex E and A 
arrangement. There are also changes that may happen during the catalytic step. Bellare 
and  colleagues  (2008)  elegantly  showed  that  ubiquitination  of  Prp8  modulates  Brr2 
activity (in yeast), downregulating its action of unwinding U4/U6. 
This evidence strongly indicates that the spliceosome not only is a large structure, but it 
is also highly dynamic and responds to numerous changes in the cellular environment, 
whether they are due to action of neighboring proteins, post-translational modifications 
occurring  to  the  proteins  composing  it,  or  alterations  affecting  the  substrate.  It  is 
expected  that  many  other  implications  will  be  revealed  in  the  future  that  will  help 
elucidate further the splicing mechanism. 
 
1.6  Splicing Factors and Retinitis Pigmentosa 
As described in the previous section 1.4.3, the majority of genes known to be mutated in 
RP encode for products which play a crucial role in retina physiology. Nevertheless, 
some of  them  are  ubiquitously  expressed  in  a  wide  range of  tissues,  still causing  a  
retina-specific  phenotype.  Among  them  there  are  the  splicing  factor  genes  PRPF3, 
PRPF8, PRPF31, PAP1 and ASCC3L1. All gene products are involved in splicing, a 
genetic modification mechanism occurring in every cell, and they assist the assembly of 
the  spliceosome.  As  described  previously,  the  spliceosome  is  complex  machinery, 
therefore, it is likely that these mutant proteins affect the whole mechanism but due to 
the physiology of the retina, they are disadvantageous only for that tissue. The challenge 
is to uncover their roles in the rod photoreceptor cells that cause this specific phenotype. 
The hypotheses that can be put forward to explain RP are 1) haploinsufficiency, that is 
the expression of only one wild type allele of the gene is not sufficient to fulfil the 
metabolic  requirements;  2)  a  retina-specific  (splicing)  factor  interacting  with  the 
aforementioned  gene  products;  3)  the  splicing  factors  mutated  in  RP  may  have  a 
different, unknown role in retina, whose function is disrupted if a mutation occurs in the 
splicing  factor gene. The  first hypothesis  also opens to  the speculation  that a lower     1. Introduction 
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amount of PRPF31 may lead to less splicing of a gene particularly important for retina, 
and very susceptible to any splicing alteration such that it causes retinal degeneration. 
As the research work included in this project focuses on PRPF31, its characteristics are 
described first, followed briefly by each of the other splicing factor genes. 
 
1.6.1  PRPF31 (Pre-mRNA Processing Factor 31) 
Mutations in splicing factor genes account for ~12% of adRP cases, 5% of which are 
due to PRPF31, second only to the rhodopsin gene (30% of adRP cases; Hartong et al., 
2006). The RP11 locus was first identified in our laboratory in a large English family, 
known as ADRP5 (Al-Maghtheh et al., 1994). Later in 2001, Vithana and colleagues 
discovered PRPF31 as the gene responsible for RP11. PRPF31 maps to chromosome 
19q13.4, spanning approximately 18 kb of DNA (comprising 14 exons), and encoding a 
499  amino  acid  long protein  (~61  kDa).  cDNA  expression  profiles  showed  that  the 
splicing factor gene is expressed in a wide range of tissues (Vithana et al., 2001). To 
date  42  mutations  have  been  reported  and  include  missense  substitutions,  splice-site 
mutations, deletions and insertions (see following Table 1.2; Frio et al., 2009; Rio Frio 
et al., 2008b and references herein). Most of these mutations generate an unstable pre-
mRNA, which fails to be processed to mature mRNA through nonsense mediated decay 
(NMD); the remaining mutations result in production of truncated protein. 
A  characteristic  clinical  feature  of  PRPF31  is  the  non  penetrance  of  the  symptoms 
showed by carriers of the pathogenic allele. This form of incomplete penetrance was 
firstly reported to be linked to RP11 locus by Al-Mahghteh and colleagues in 1994, and 
was  later  confirmed  by  Vithana  and  colleagues  (2001)  at  the  time  PRPF31  was 
identified. These asymptomatic obligate carriers are difficult to identify since they never 
develop a significant phenotype, but may have affected parents and affected offsprings 
(Vithana et al., 2001). The incomplete penetrance may be due to wild type isoalleles, 
inherited from the non-affected parents; PRPF31 isoalleles then could be differentially 
expressed and not produce any appreciable phenotype, but when inherited together with 
a pathogenic allele may modulate its pathogenic effects. 
Past investigations (Vithana et al., 2003, Abu-Safieh et al., 2006, Rivolta et al., 2006, 
Rio Frio et al., 2008b) have provided data which suggests that haploinsufficiency is the     1. Introduction 
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    Table 1.2. Known mutations in the PRPF31 gene. 
n  Exon / Intron  Mutation 
1  15 kb usptream PRPF31  44.8 kb deletion 
2  Exon 1 / Intron 1  110bp del+39bp intron1, ins 640bp 
3  Intron 1  IVS1+1G>T 
4  Exon 2  c.79G>T 
5  Exon 2 / Intron 2  IVS2+1G>A 
6  Intron 2  IVS2+1delG 
7  Exon 3  c.220C>T 
8  Exon 4  c.319C>G 
9  Exon 4 to exon 8  4843 bp deletion 
10  Exon 4 to exon 13  11.3 kb deletion 
11  Intron 4  c.323-2A>G (IVS-2A>G) 
12  Exon 5  c.330-342del 
13  Exon 5  c.390delC 
14  Exon 5  c.412C>A 
15  Intron 5  IVS5-1G>A 
16  Exon 6 / Intron 6  c.522-527del, IVS6+1 to +10del 
17  Intron 6  IVS6+1G>T 
18  Intron 6  c.527+3A>G (IVS6+3A>G) 
19  Intron 6  IVS6-3 to -45del 
20  Intron 6  c.528-1G>A 
21  Exon 7  c.421G>T 
22  Exon 7  c.580-581dup33bp 
23  Exon 7  c.581C>A 
24  Exon 7  c.636delG 
25  Exon 7  c.646G>C 
26  Exon 8  c.758_767del 
27  Exon 8  c.732-737delins20bp 
28  Exon 8  c.769-770insA 
29  Exon 8  c.785delT 
30  Exon 8  c.828-829delCA 
31  Intron 8  IVS8+1G>C 
32  Intron 8  c.856-2A>G (IVS8-2A>G) 
33  Exon 9  c.877_910del 
34  Exon 10  c.973G>T 
35  Exon 10 / Intron 10  c.1049_IVS10+20delins 
36  Exon 10 / Intron 10  IVS10+1G>A 
37  Exon 11  c.1115-1125del 
38  Exon 11  c.1142delG 
39  Exon 11 / Intron 11  c.1146+2T>C 
40  Exon 12  c.1155to1159delins 
41  Intron 13  c.1374+654C>G 
42  Upstream exon 14  30 kb deletion 
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likely cause of RP11, as the large majority of mutations in PRPF31 result in null alleles. 
Hence, a non-mutant isoallele which allows for a higher expression may cover up the 
lack  of  expression  due  to  the  pathogenic  allele.  Recently,  Rio  Frio  and  coworkers 
(2008a) have investigated possible genetic elements determining the variable expression 
of PRPF31: they hypothesised two trans-acting elements: 1) a currently unidentified 
product  within  a  8.2  Mb  region  on  chromosome  14q  (identified  through  linkage 
analysis),  supposed  to  regulate  the  expression  of  both  PRPF31  alleles;  
2) RP11-associated isoalleles could act in cis and in trans, increasing the levels of pre-
mRNA from both alleles. 
PRPF31  codes  for  a  protein  involved  in  the  assembly  of  the  U4/U6•U5  tri-snRNP, 
contributing to the processing of pre-mRNA molecules into mature RNA. Initial studies 
reported that PRPF31 shares 25% identity and 60% similarity with Prp31p, a pre-mRNA 
splicing factor from S. cerevisiae (Makarova et al., 2002), hence suggesting that the two 
proteins  are  orthologues.  Yeast  Prp31p  is  associated  with  the  tri-snRNP  U4/U6•U5 
(Weidenhammer et al., 1997), and is also involved in the assembly of the tri-snRNP 
(Makarova  et  al.,  2002).  PRPF31  can  be  divided  into  three  regions  which  show 
similarity with the following domains, from N-terminus to C-terminus (Figure 1.17): 1) 
a NOSIC domain (aa 92-144 in PRPF31), which is usually found in Nop56/SIK1-like 
proteins; 2) a NOP domain (aa 186-334 in PRPF31) which shows RNP binding activity; 
3)  a  the C-terminal Nuclear Localisation Signal sequence  (aa 351-364; Deery et al., 
2002). 
Two roles have been assigned to PRPF31: one is to bridge U4 and U6 together with 
PRPF3 (Nottrott et al., 2002), the other is to tether  U5 to the  U4/U6 di-snRNP, by 
interacting with the U5-associated protein PRPF6. 
In fact, Makarova and co-workers (2002) showed that immunodepletion of PRPF31 in 
HeLa cell nuclear extracts stalled the spliceosome complex, and the mature complex B 
was not formed, halting the assemblage at complex A. Moreover, subsequent addition of 
PRPF31 restored the spliceosomal assembly and therefore the splicing activity. It was 
postulated  that  PRPF31  acted  as  a  bridge  between  the  U5  snRNP  and  the  U4/U6 
di-snRNP: in  fact,  PRPF31  interacts  with  PRPF6, which associates with U5 snRNP, 
allowing PRPF31 to join the di-snRNP to the U5 snRNP. Liu and colleagues (2006)    1. Introduction 
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N-terminal 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.17. PRPF31 protein domain structure. 
The NOSIC (central domain in Nop56/SIK1-like proteins), NOP (snoRNA binding domain), and NLS 
(nuclear  localisation  signal)  domains  are  indicated  along  the  sequence,  including  their  aminoacidic 
position. 
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demonstrated that the NOP domain is involved in RNP recognition and binding, but not 
in RNA binding, showing that PRPF31 associates with a snRNP, and not with snRNA 
alone, i.e. the surface contacting the RNP interacts with 15.5K protein and RNA, but it 
fails to bind one of them alone (Liu et al., 2006). 
 
1.6.2  The U4/U6•U5 tri-snRNP 
A core component of the U2-type spliceosome is the so called tri-snRNP, formed by 
three  snRNPs:  U4,  U5  and  U6.  The  human  tri-snRNP  is  a  protein-rich  particle, 
comprising at least 30 different proteins (Liu et al., 2006). 
Before joining the spliceosomal complex B, the mature tri-snRNP must form: both U4 
and U6 RNAs are base-paired forming two intermolecular RNA helices, thus the two 
snRNP are tightly associated, structuring the U4/U6 di-snRNP. Later this unit is joined 
by U5, forming the U4/U6•U5 tri-snRNP (Makarova et al., 2002). The formation of the 
tri-snRNP particle occurs in the Cajal Bodies (CBs): mono-snRNPs are shuttled to CBs, 
where  first  the  association  between  U4  and  U6  snRNP  occurs.  Subsequently  the 
di-snRNP  is  joined  by  the  U5  snRNP,  and  the  mature  particle  is  then  ready  to  be 
released from the CBs (Stanek & Neugebauer, 2006). 
Liu and colleagues (Liu et al., 2006) reported several interactions between the proteins 
associated to  the  tri-snRNP, drawing a network and cross-links among them  (Figure 
1.18). Among the proteins binding specifically to the U4/U6 particle there are PRPF31, 
PRPF3  and  PAP1,  whereas  PRPF8  and  PRPF6  are  specific  to  U5.  U4  and  U6  are 
bridged by PRPF31 and PRPF3 (Nottrott et al., 2002); little is known about interactions 
between U4/U6 and U5 snRNPs, apart from the unique interaction found between the 
U4/U6-specific PRPF31 and the U5-associated PRPF6 (Makarova et al., 2002). Liu and 
colleagues (2006) also showed, through yeast two-hybrid and in vitro binding assays, 
that PRPF6 interacts with some portions of PRPF8 and with PRPF3, and also with itself, 
suggesting that PRPF6 can dimerise. Therefore PRPF6 may be a key player in linking 
the di-snRNP with the U5 snRNP. 
Immunoprecipitation  studies  demonstrated  an  interaction  between  PAP1  and  PRPF3 
(Maita et al., 2005); however PAP1 was mostly located free from any complex, and 
bound only in little amount with U4/U6 and U4/U6•U5, whereas PRPF3 predominantly    1. Introduction 
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Figure 1.18. The human tri-snRNP particle. 
Black dots represent observed interactions between the protein species (black and white dots represent 
interactions observed in yeast othologue proteins). For a reference, see Liu et al., 2006, from which the 
image was taken. 
 
 
 
 
     1. Introduction 
 
  53 
associated with U4/U6 and poorly with U4/U6•U5. Hence, PAP1 should be associated 
with U4/U6, although it may be regarded as a non essential unit of the spliceosome, 
likely to be a modulator of splicing. 
So far no RNA-RNA  interactions have  been  reported between  U4/U6 and  U5, only 
RNA-protein links, suggesting that the whole tri-snRNP assembly is coordinated  via 
protein-protein interaction. This network remains to be fully ascertained. 
 
1.6.3  Other Splicing Factors Implicated in adRP 
Four other splicing factors genes have been identified to cause adRP. These are PRPF3 
(Chakarova et al., 2002), PRPF8 (McKie et al., 2001), PAP1 (Keen et al., 2002) and 
ASCC3L1 (Li et al., 2009). Like PRPF31, these genes are widely expressed in many 
tissues. 
PRPF3 comprises 16 exons and encodes for a 683 aa-long protein, of approximately 77 
kDa (Ensembl Genome Browser, December 2008). Along with PRPF31, PRPF3 splicing 
factor is involved in the assembly and the correct functioning of the tri-snRNP; in fact, 
PRPF3 is known to interact with PAP1 (Maita et al., 2005), PRPF4, U4/U6 snRNA, as 
well as U5-associated PRPF6 (Gonzalez-Santos et al., 2008). All these associations are 
mediated by its C-terminal region, which is highly conserved among numerous species. 
To date only three mutations have been found, which lead to three amino acid changes, 
respectively  P493S,  T494M  (Chakarova  et  al.,  2002)  and  the  more  recent  A498D 
(Gamundi et al., 2008). All changes are located within the C-terminal part of the protein. 
It is suggested that the C-terminal region is responsible for a crucial function, which may 
have  a  key  responsibility  in  spliceosome  assembly  (Mordes  et  al.,  2007). 
Gonzalez-Santos and colleagues proposed that the latter mutation affects the splicing, as 
a T to M change alters the phosphorylation state of the protein, likely modulating the 
splicing by destabilising the spliceosome complex. The other two mutations may disrupt 
the recognition motif which leads to the phosphorylation of the threonine 494. 
PRPF8 is the splicing factor gene responsible for RP13. PRPF8 comprises 43 exons and 
encodes a large protein of 2335 residues, of an approximate molecular weight of 220 
kDa  (Ensembl  Genome  Browser,  December  2008).  Various  point  mutations  lead  to 
single amino acid changes, and one mutation is a 6bp deletion with an 11bp insertion; all     1. Introduction 
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mutations have been found in exon 42. PRPF8 is a component of the U5 snRNP and of 
the U4/U6•U5 tri-snRNP, and also interacts with the pre-mRNA molecule. PRPF8 is 
present in different complexes in the spliceosome dynamics, as it is found associated 
with the complex containing reaction intermediates, or the excised intron; PRPF8 also 
associates with BRR2, an unwindase implicated in the unwinding of the base-pairing 
between U4 and U6 snRNAs (Grainger & Beggs 2005). Hence, as PRPF8 harmonises 
several associations between spliceosomal proteins and snRNAs, it is thought to adjust 
the coordination of the spliceosome dynamics. Given that the mutations are clustered in 
exon 42, the corresponding protein region should be the core centre for organising the 
network of associations of PRPF8, thus preventing the protein to perform its function. 
RP9 is caused by mutations in PAP1 gene. PAP1 comprises six exons and encodes a 
small protein of 181 residues, of an approximate molecular weight of 21 kDa (Ensembl 
Genome  Browser,  December  2008).  To  date,  only  two  point  mutations  have  been 
identified, both altering the protein sequence (H137L and D170G; Keen et al., 2002). 
PAP1 protein is also involved in the tri-snRNP formation, as reported by Maita and 
colleagues (2005), and it interacts with the C-terminal region of PRPF3. However, none 
of the two mutations affect the binding with PRPF3. The mechanism of RP9 remains to 
be elucidated with further investigations. 
Finally,  recently  Li and colleagues (2009) reported a single base pair  change in  the 
ASCC3L1 gene, resulting in an amino acid change (R1090L) in the protein sequence. 
ASCC3L1 comprises 45 exons and encodes the BRR2 protein, a 200 kDa RNA helicase 
involved in the unwinding of U4/U6 preceding the activation of the spliceosome. 
 
 
1.7  Aim of the Project 
The  aim  of  this  project  is  to  investigate  the  molecular  mechanisms  underlying  the 
retinitis pigmentosa 11 (RP11) locus. RP11 is caused by mutations in the PRPF31 gene, 
which encodes a ubiquitously expressed splicing factor; however, the mutant phenotype 
is only apparent in the eye with no other symptoms. The hypotheses to explain RP11 
could be 1) haploinsufficieny, or 2) a PRPF31 retina-specific partner, or 3) that PRPF31 
has  a  different  role  in  retina.  The  main  focus  of  this  project  is  to  test  the  second     1. Introduction 
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hypothesis,  aiming  to  the  identification  of  retina-specific  interacting  partners  of  the 
PRPF31  splicing  factor,  elucidating  its  function,  and  perhaps  shedding  light  on  the 
pathogenic mechanism(s) of RP11. 
Since  investigations  on  splicing  and  its  protein  network  are  conducted  mainly  in 
S.cerevisiae and do not allow for tissue specificity, this approach may provide a different 
perspective other than yeast. This rationale follows the steps of the finding of RPGRIP 
as  an  interacting  partner  of  the  ubiquitous  RPGR:  RPGR  is  involved  in  xlRP  and 
RPGRIP was later discovered as involved in Leber congenital amaurosis (Roepman et 
al., 2000a). Therefore it may be that also the ubiquitous PRPF31, like RPGR, may have 
a tissue-specific partner: in fact, the RPGR-interactig protein RPGRIP is expressed in 
testis and retina only (Boylan & Wright, 2000). 
The  yeast  two-hybrid  screen  is  then  to  be  followed  up  by  confirmation  of  these 
interacting  partners  using  different  methodologies,  in  addition  to  studies  regarding 
PRPF31 localisation in both cell lines and retinal tissue to better understand the role of 
PRPF31 in the retina and retinal degenerations. 
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2.  Materials and Methods 
 
 
2.1  Materials 
All  materials  and  reagents  were  purchased  from  Analar,  Applied  Biosystems,  BD 
Biosciences, Bio-Rad, Clontech, Eurogentec, Fisher Scientific, GE Healthcare, Gibco 
BRL,  Jackson  Immunoresearch  Labs,  Invitrogen,  Merck,  National  Diagnostics, 
Nunclon, Promega, Sigma, or VWR. All the reagents for cell culture were purchased 
from Invitrogen. 
 
2.2  Reagents and Buffers 
Table 2.1. Summary of all solutions, buffers and gels used 
Reagent  Composition 
Agarose Gel Electrophoresis   
TAE buffer 1x  2M Tris-Acetate, 0.05M EDTA (50x from Eppendorf) 
Gel Loading Dye 10x  0.14% Bromophenol Blue, 0.16% Orange G, 0.16% 
Xylene Cyanole FF, 15% Ficoll 400 
   
Bacteria   
TSB medium  10% PEG, 5% DMSO, 10mM MgCl2, 10mM MgSO4; in LB 
medium 
KCM Buffer 5x  0.5M KCl, 0.15M CaCl2, 0.25M MgCl2; 
   
Yeast   
TE/LiAc 1.1x  1.1x TE, 0.11M LiAc (10x TE and 1M LiAc from BD 
Biosciences) 
PEG/LiAc  1x TE, 0.1M LiAc, 40% PEG 3350 (10x TE, 1M LiAc, 50% 
PEG 3350 from BD Biosciences); 
Buffer S  10mM KPO4 pH7.2, 10mM EDTA pH 8.0, 50mM  
-mercaptoethanol, 200µg/ml lyticase (SIGMA); 
Lysis Buffer  0.25M Tris-HCl pH 7.5, 25mM EDTA pH 8.0, 2.5% SDS 
Z-Buffer  60mM Na2HPO4, 40mM NaH2PO4, 10mM KCl, 1mM 
MgSO4 
Cracking Buffer Stock solution  8M Urea, 5% w/v SDS, 40mM Tris-HCl pH 6.8, 0.1mM 
EDTA, 0.4mg/ml Bromophenol Blue 
X-α-Gal (Glycosynth)  20mg/ml in DMF 
X-β-Gal (SIGMA)  20mg/ml in DMF 
   
SDS-PAGE and Western Blot   
Acrylamide Stacking gel  3.75% acrylamide, 125mM Tris-HCl pH 6.8, 0.1% SDS, 
0.06% APS, 0.2% TEMED 
Acrylamide Resolving gel  7.5 -15% acrylamide, 375mM Tris-HCl pH 8.8, 0.1% SDS, 
0.06% APS, 0.16% TEMED 
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(continued from previous page)   
Reducing Sample Buffer 2x  125mM Tris-HCl pH 6.8, 20% Glycerol, 4% SDS, 10%  
-mercaptoethanol, 0.005% Bromophenol Blue 
Running Buffer 1x  25mM Tris, 192mM Glycine, 0.1% SDS (10x 
Tris/Glycine/SDS: 0.25M Tris, 1.92M Glycine, 1% SDS; 
from National Diagnostics) 
Transfer Buffer  25mM Tris, 192mM Glycine, 20% Methanol 
TBS 10x  200mM Tris Base, 1370mM NaCl, pH 7.6 
TBS-T  0.1% Tween-20 in TBS 1x 
Amido Black staining  0.1% amido black 10B in destaining solution 
Destaining solution  7.5% acetic acid, 20% methanol 
Blocking Buffer I  5% non fat dry milk, 0.1% NaN3 in TBS-T 
Blocking Buffer II  5% BSA, 0.1% NaN3 in TBS-T 
   
Co-immunoprecipitation, Immunocytochemistry (ICC), Immunohystochemistry (IHC) 
PBS-TX100, 0.1/0.5%  0.1/0.5% Triton X-100 in PBS 1x (OXOID; tablets) 
Protease and Phosphatase 
inhibitors cocktail (final 
concentrations) 
1mM  PMSF  (from  100mM  in  isopropanol);  10µg/ml 
Aprotinin;  50µg/ml  Benzamidin;  10µg/ml  Pepstatin; 
10µg/ml Leupeptin; 50mM NaF; 3mM Na-pyrophosphate; 
1mM Na-orthovanadate (Na3VO4) 
HEPES  0.5M pH 7.4  
Blocking solution (for ICC)  0.5% BSA, 20mM Glycine, 0.1% NaN3 in PBS 1x 
Blocking solution I (for IHC)  5% Goat Serum, 0.1% NaN3, in 0.1% PBS-TX100 
Blocking solution II (for IHC)  2% Goat Serum, 0.1% NaN3, in 0.1% PBS-TX100 
All solutions, buffers and gels were made using distilled water unless otherwise stated. 
 
Table 2.2. Summary of the different media used for bacteria and yeast 
Bacteria Culturing Media   
LB agar  25g of LB powder in 1L, 20% agar 
LB broth  25g of LB powder in 1L 
   
Yeast Culturing Media   
YPAD agar  50% YPD, 0.04% Adenine Hemisulfate salt, 20% agar 
YPAD broth  50% YPD, 0.04% Adenine Hemisulfate salt 
SD Synthetic Minimal agar  6.7% Yeast Nitrogen Base, 18.2% D-Sorbitol, 2% 
Glucose, 20% agar 
SD Synthetic Minimal broth  6.7% Yeast Nitrogen Base, 18.2% D-Sorbitol, 2% Glucose 
Dropout Solutions  To render the medium selective, both SD agar and broth 
were added Dropout Solutions (BD Biosciences), lacking 
the appropriate aminoacids. 
 All media were made using distilled water and autoclaved. 
 
 
 
2.3  Vectors 
All  the  cloning  work  was  performed  using  the  Gateway  Technology  developed  by 
Invitrogen. 
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2.3.1  Entry Vectors 
pDONR201, pDONR/Zeo (Invitrogen): entry vectors with attP1 and attP2 sequences, 
kanamycin and zeocin resistance respectively; these vectors were used as shuttle vectors 
for  subcloning  into  destination  vectors  (Yeast  Two-Hybrid  vectors  and  Mammalian 
Expression vectors, see following); 
 
2.3.2  Yeast Two-Hybrid Vectors 
1.  pAD-GAL4-Amp-DEST
*: GAL4 Activation Domain destination vector with attR1 
and attR2 sequences; LEU2 marker, ampicillin resistance; 
2.  pBD-GAL4-Cam-DEST
*:  GAL4  DNA-Binding  Domain  destination  vector  with 
attR1 and attR2 sequences; TRP1 marker, chloramphenicol resistance; 
3.  pAD-WT  (Stratagene):  AD-GAL4  and  aa  132–236  of  wild  type  fragment  C  of 
lambda cI repressor, ampicillin resistance; 
4.  pBD-WT  (Stratagene):  BD-GAL4  and  aa  132–236  of  wild  type  fragment  C  of 
lambda cI repressor, chloramphenicol resistance; 
5.  pAD-MUT (Stratagene): AD-GAL4 and aa 132–236 of E233K mutant fragment of 
lambda cI repressor, ampicillin resistance; 
6.  pBD-MUT (Stratagene): BD-GAL4 and aa 132–236 of E233K mutant fragment of 
lambda cI repressor, chloramphenicol resistance; 
7.  pBD-pLC  (Stratagene):  BD-GAL4  and  aa  67–230  of  human  lamin C,  ampicillin 
resistance; 
All the vectors listed in section 2.3.2 were a gift of Dr R. Roepman; 
*original  Stratagene  vectors  modified  with  att  sequences  to  be  used  with  the  Gateway 
Technology. 
 
2.3.3  Mammalian Expression Vectors 
1.  pDEST26  (Invitrogen):  destination  vector  with  attR1  and  attR2  sequences,  
N-terminal 6xHis tag, ampicillin resistance; 
2.  pcDNA3.1V5DEST (Invitrogen): destination vector with attR1 and attR2 sequences, 
N-terminal V5 epitope tag, ampicillin resistance; 
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2.4  Cells 
A number of different cell types were used throughout this project, details of the 
bacterial and yeast strains are as following.  
2.4.1  E.coli Host Strains 
1.  AG1: recA1, endA1, gyrA96, thi-1, hsdR17, (rk–, mk+), supE44, relA1 strain used 
for  maintenance  and  propagation  of  plasmid  DNA;  maintaned  in  LB  agar/broth 
without any selection; gift from Dr R. Roepman; 
2.  Library  Efficiency  DH5α  Competent  Cells  (Invitrogen):  F-  φ80lacZΔM15 
Δ(lacZYA-argF)U169 recA1 endA1 hsdR17(rk-, mk+) phoAsupE44 thi-1 gyrA96 
relA1 λ- strain used for maintenance and propagation of DNA; the manufacturer’s 
transformation protocol was followed; 
3.  Library  Efficiency  DB3.1  Competent  Cells  (Invitrogen):  F-  gyrA462  endA1 
Δ(sr1-recA)  mcrB  mrr  hsdS20(rB-,  mB-)  supE44  ara-14  galK2  lacY1  proA2 
rpsL20(SmR) xyl-5 λ- leu mtl1, ccdB-resistant strain used to propagate entry vectors 
and destination vectors; manufacturer’s transformation protocol was followed; 
 
The transformants were maintained on LB agar/broth, with antibiotic selection according 
to the genotype of the vector. The final antibiotic concentrations were as follows: 
-  ampicillin (Sigma) 100µg/ml; 
-  chloramphenicol (Sigma) 170µg/ml; 
-  kanamicin (Sigma) 50µg/ml; 
-  zeocin (Invitrogen, InvivoGen) 30µg/ml. 
 
2.4.2  Yeast Host Strain 
S.cerevisiae PJ69-4A strain (James et al., 1996) was a gift from Dr R. Roepman, and 
used for all the yeast two-hybrid procedures. 
-  PJ69-4A: MATα ura3-52 his3-Δ200 leu2-3,112 lys2-801 trp1-901 gal4Δ gal80Δ 
GAL2- ADE2 LYS2::GAL1-HIS3 met2::GAL7-lacZ 
-  PJ69-4A: MATa ura3-52 his3-Δ200 leu2-3,112 lys2-801 trp1-901 gal4Δ gal80Δ 
GAL2- ADE2 LYS2::GAL1-HIS3 met2::GAL7-lacZ 
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2.4.3  Mammalian Cell Lines 
(for culturing methods, see section 2.12.1)  
1.  HEK293 (personal communication): used for immunoprecipitation study; 
2.  MDCK (personal communication): used for protein localisation study. 
3.  SK-N-SH (personal communication): used for protein localisation study. 
 
2.5  Antibodies 
2.5.1  Primary Antibodies 
1.  Anti-GAL4 DNA-AD: mouse monoclonal antibody, against the activation domain of 
the yeast GAL4 protein (Clontech); 
2.  Anti-GAL4  DNA-BD:  mouse  monoclonal  antibody,  against  the  DNA-binding 
domain of the yeast GAL4 protein (Clontech); 
3.  Anti-6x His tag: rabbit polyclonal antibody, against 6x His tag (Abcam); 
4.  Anti-6x  His  tag:  mouse  monoclonal  antibody,  against  6x  His  tag  (clone  HIS-1, 
ascites fluid; Sigma); 
5.  Anti-V5: mouse monoclonal antibody, against the V5 epitope (Invitrogen). 
6.  Anti-PRPF31484-497:  rabbit  polyclonal  antibody  raised  against  peptide  484-497 
(AEFLKVKGEKSGLM)  of  human  PRPF31  protein;  kindly  donated  by  Prof  R. 
Lührmann (Makarova et al., 2002); 
7.  Anti-PRPF31140-154:  goat  polyclonal  antibody  raised  against  peptide 
KELGNSLDKCKNNEN, corresponding to internal sequence amino acids 140-154 
of Human PRPF31 (Abcam); 
8.  Anti-PRPF6:  goat  polyclonal  antibody,  against  a  peptide  mapping  near  the 
N-terminus of PRP6 of human origin (Santa Cruz Biotechnology); 
9.  Anti-GRIF18-633: rabbit polyclonal antibody, against peptide 8-633 of the rat GRIF1 
protein, orthologue to human TRAK2 (Beck et al., 2002); kindly donated by Prof A. 
Stephenson; 
10. Anti-MAGI3:  purified  mouse  anti-MAGI3,  clone  46/MAGI3  (immunogen: 
recombinant protein human MAGI3 aa 194-298; BD Transduction Laboratories); 
11. Anti-E-Cadherin: mouse monoclonal antibody against Human E-Cadherin, clone 36 
(immunogen: C-terminal recombinant protein; BD Transduction Laboratories);     2. Materials and Methods 
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12. Anti-PNA:  biotinylated  anti-peanut  agglutinin  (Vector  Laboratories,  Burlingame, 
CA); 
13. Anti-Rhodopsin: mouse  monoclonal antibody  1D4  (National Cell Culture Center, 
Minneapolis, MN); 
14. Anti-SC-35:  mouse  monoclonal  antibody  to  SC-35,  nuclear  speckle  marker 
(immunogen: partially purified mammalian spliceosomes; Abcam); 
15. Anti-TOPORS:  Mouse  monoclonal  antibody  raised  against  a  partial  recombinant 
TOPORS (M01, clone 5G11; Abnova); 
16. Anti-TRAK2:  goat  anti  ALS2CR3/GRIF1  antibody,  raised  against  the  peptide 
CTSSPKMGVLKED (Everest Biotech); 
 
2.5.2  Secondary Antibodies 
Secondary antibodies were purchased from Jackson ImmunoResearch, except for Cy2-
conjugated streptavidin (Molecular Probes). HRP-conjugated anti-rabbit and anti-mouse 
were raised in goat; HRP-conjugated anti-goat was raised in rabbit. Cy3-conjugated anti-
goat,  FITC-conjugated  anti-rabbit  and  anti-mouse  were  raised  in  donkey.  HRP-
conjugated antibodies were diluted 1:10000 in TBS-T; FITC-, Cy3- and Cy2-conjugated 
antibodies were diluted 1:800 in blocking solution (for recipe of immunocytochemistry 
blocking solution and immunohistochemistry blocking solution II, see Table 2.1). 
 
2.6  Retina cDNA Libraries 
The bovine and human retinal cDNA libraries used for the yeast two-hybrid screening 
were a gift from Dr R. Roepman. Each cDNA library was custom-made (Roepman et 
al.,  2000b),  constructed  to  be  fused  to  the  yeast  GAL4  activation  domain  (AD,  N-
terminal) and transformed in the S.cerevisiae PJ69-4A strain, MATα. The human library 
(titre: 5.2x10
9 cells/ml) is oligo-dT primed, with 1.9x10
6 independent clones; the bovine 
library (titre: 4.6x10
9 cells/ml) is randomly primed and has 4.5x10
6 independent clones. 
 
2.7  Full Length cDNA Clones 
Full length cDNA of human wild type PRPF6, TRAK2 and ZNF143 were purchased 
from RZPD, sequence verified by the company (image IDs respectively: 2988165 in     2. Materials and Methods 
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pOTB7  vector;  4814594 in pBluescriptR vector;  4902668 in pOTB7 vector);  human 
wild type PRPF31 cDNA was obtained from previous work (Deery et al., 2002); human 
wild type MAGI3 cDNA was cloned in our lab (see section 2.9.7.2 of this chapter and 
section 3.8.1 of Chapter 3). 
 
2.8  Patients 
Mutation  screening  was  carried out on  a  panel of  95  unrelated  autosomal dominant 
retinitis pigmentosa (adRP) patients. Informed consent was obtained from each patient, 
in  accordance  with  guidelines  established  by  the  Declaration  of  Helsinki  and  was 
approved  by  the  Moorfields’  Eye  Hospital  Ethics  Committee.  Genomic  DNA  was 
provided to by Naushin Waseem and Beverley Scott. 
Allele frequencies were calculated as follows: if the population consists of x individuals, 
then the alleles (A and a) for a given locus are 2x (x individuals × 2 alleles at that locus 
per individual); AA homozygous individuals are multiplied by 2 to calculate the number 
of A alleles, so the total of A alleles is = (Aa heterozygotes + 2AA homozygotes), the A 
allele frequency is  = (total of  A  alleles  /  total number of alleles in population);  the 
frequency of the a allele is = (1- frequency of A allele). 
Genotype frequencies were calculated as follows: the number of individuals with each 
genotype is determined; then to determine the frequencies, the number of individuals for 
each  genotype  is  divided  by  the  total  number  of  individuals  in  the  population  (for 
example: frequency of AA genotype = total of AA individuals / population size). 
Assuming  absence  of  selection,  the  genotype  frequencies  can  also  be  calculated 
according to the Hardy-Weinberg equilibrium:  
(p + q)
2 = 1 
where  p =  frequency  of  allele  A  and  q =  frequency  of  allele  a.  From  the  binomial 
expansion of the above equation, 
p
2 +q
2 + 2pq = 1 
one can derive the genotype frequencies: p
2 = frequency of genotype AA, q
2 = frequency 
of genotype aa, 2pq = frequency of genotype Aa. If the genotype frequencies calculated 
from a real population do not meet those predicted by the Hardy-Weinberg equilibrium, 
then evolution changes are in operation.     2. Materials and Methods 
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2.9  General Methods 
2.9.1  Polymerase Chain Reaction (PCR) 
Polymerase Chain Reaction was used in several steps along the project, using different 
polymerases,  according  to  the  purpose.  Oligonucleotides  for  PCR  reactions  and 
sequencing were designed manually and purchased from Sigma. They were designed to 
be 20-30 bp long, with a 40-60 % GC content; the melting temperature was calculated 
according to the formula: Tm = 2(A + T) + 4(G + C). Biotaq polymerase (Bioline), 
supplemented with Pfu polymerase (Promega) when needed, was used to amplify small 
fragments (up to 1kb usually); KOD Hot Start DNA Polymerase (Novagen) and Expand 
Long Template PCR System polymerase (for ELTPS PCRs, of which only buffer #2 was 
used, a buffer 10x concentration, with 22.5mM MgCl2 –datasheet May 2000) were used 
to amplify longer fragments and for high fidelity. The Tables below show the PCR mix 
(Table 2.3) and the cycling conditions (Tables 2.4, 2.5 and 2.6) of each enzyme used; 
PCRs were normally carried out in a volume of 25µl, using ~1µg of DNA. 
 
 
 
 
Table 2.3. PCR parameters for each of the polymerases used throughout this project. 
  Biotaq  KOD  ELTPS 
dNTPs  0.2mM  0.2mM  0.7mM 
Mg  2-2.5mM  1mM  2.25mM 
Buffer 10x  1x  1x  1x  
Primer F  0.25µM  0.3µM  0.25µM 
Primer R  0.25µM  0.3µM  0.25µM 
Enzyme  0.016 U/µl (0.4U)  0.02 U/µl (0.5U)  0.08 U/µl (4U) 
DNA  1µl  0.5µl  2µl 
Water  up to final volume  up to final volume  up to final volume 
Final volume  25µl  25µl  50µl 
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Table 2.4. Thermocycling conditions for BIOTAQ Polymerase. 
BIOTAQ polymerase  Temperature  Time  Cycles 
Initial Denaturation  95°C  5 minutes  - 
Denaturation  95°C  15-30 seconds 
Annealing  Ta °C  30-60 seconds 
Elongation  72°C  up to 4 minutes 
30-40 
Final Elongation  72°C  5-10 minutes  - 
Hold  4°C   - 
 
Table 2.5. Thermocycling conditions for KOD Polymerase. 
KOD polymerase  Temperature  Time  Cycles 
Initial Denaturation  95°C  2 minutes  - 
Denaturation  95°C  15 seconds 
Annealing  60°C  30 seconds 
Elongation  72°C  up to 2 minutes 
35-40 
Final Elongation  72°C  10 minutes  - 
Hold  4°C   - 
 
Table 2.6. Thermocycling conditions for ELTPS polymerase. 
ELTPS polymerase  Temperature  Time  Cycles 
Initial Denaturation  94°C  2 minutes  - 
Denaturation  94°C  10 seconds 
Annealing  59°C  30 seconds 
Elongation  68°C  up to 2 minutes 
35 
Final Elongation  68°C  7 minutes  - 
Hold  4°C   - 
 
 
2.9.2  Agarose Gel Electrophoresis 
DNA molecules of various molecular weights were separated on agarose gels, for either 
visualisation,  quantification  or  for  subsequent  gel extraction.  Gels  were  prepared  by 
dissolving 0.8-2% agarose (Sigma) in 1x TAE buffer (Eppendorf); DNA was stained 
with 0.5µg/ml ethidium bromide, added directly to the dissolved agarose before pouring 
it into a sealed casting plate containing a comb. Samples (0.5-5 µl of DNA) were loaded 
together  with  a  1x  gel  loading  dye;  a  molecular  weight  marker  (Smart  Ladder,     2. Materials and Methods 
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Eurogentec) was also included to allow the sizing and quantification of samples. The gel 
was  placed  into an electrophoresis  tank  (Biorad),  filled  in with 1x TAE buffer,  and 
electrophoresis was carried at 80-120V until the desired separation was achieved. DNA 
was visualised on a UV transilluminator (UVP). 
 
2.9.3  Restriction Enzyme Digest 
Plasmid DNAs were digested to confirm the expected digestion pattern after cloning. 
Digestion  mixtures  contained  2µl  of  10X  appropriate  buffer,  1µg  of  DNA,  
1.0-2.0 units of the appropriate enzyme and distilled water to a final volume of 20µl. The 
reactions were then incubated for 1 hour at the specified temperature. All enzymes and 
buffers  were  purchased  from  Promega  and  used  according  to  the  manufacturer’s 
instruction. 
 
2.9.4  DNA Purification 
1.  From PCR reactions: PCR products were purified from excess dNTPs and primers 
using ExoSAP-IT (USB); ExoSAP-IT consists of two enzymes, Exonuclease I and 
Shrimp Alkaline Phosphatase. Amplified PCR product (3µl) was mixed with 1µl of 
ExoSAP-IT and made up to a final volume of 25 µl with distilled water. The reaction 
was then incubated at 37°C for 15 minutes, followed by 80°C for 15 minutes to 
deactivate the enzyme. The product was then used for the downstream sequencing 
reactions; 
2.  From agarose gel: the desired DNA samples were excised from the gel, dissolved 
and purified using the Illustra™ GFX™ PCR DNA and Gel Band Purification Kit 
(GE Healthcare), following manufacturer’s instructions; 
3.  From E.coli cultures: single colonies were grown overnight in 5ml  selective LB; 
cells were collected and subjected to a series of steps to isolate the DNA, using 
GenElute  Plasmid  Miniprep  Kit  (Sigma)”,  following  manufacturer’s  instructions. 
Alternatively, 200ml cultures were prepared and the DNA purified using “GenElute 
Plasmid Maxiprep Kit (Sigma). 
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2.9.5  DNA Sequencing 
Samples  underwent  sequencing  reactions,  using  BigDye  Terminator  v3.1  Cycle 
Sequencing Kit (Applied Biosystems). Each reaction was carried out in a final volume 
of 10µl, containing: 0.5-3µl of PCR product (100-300ng), 2.5µl of sequencing buffer, 
0.5µM primers, 0.5µl of Big Dye 3.1; thermocycling conditions are shown in Table 2.7. 
 
Table 2.7. Thermocycling conditions for sequencing reactions. 
BigDye Terminator  Temperature  Time  Cycles 
Initial Denaturation  95°C  3 minutes  - 
Denaturation  96°C  10 seconds 
Annealing  50°C  3 seconds 
Elongation  60°C  4 minutes 
25 
Hold  4°C    - 
 
Unincorporated dye and salt was removed from the sequencing product using Sephadex 
G50  (Sigma).  MultiScreen  HTS  Filter  Plate  (Millipore)  was  first  filled  with  dry 
Sephadex G50; each well was then filled with 350µl water, and left to set for 30 minutes 
at room temperature. A collection plate was placed to the MultiScreen plate, and the 
plate was centrifuged for 5 minutes at 910g; 100µl of deionized water was again added 
to each well, and centrifuged again for 5 minutes at 910g. A fresh 96-well plate was 
placed underneath the MultiScreen plate before loading 20µl sequencing samples. The 
plate was centrifuged again at 910g for 5 min and the eluant was loaded on to ABI Prism 
3730 DNA Analyzer. 
 
2.9.6  Reverse Transcription (RT) PCR 
Total retinal RNA (Clontech) was used as a template to prepare cDNA, using randomly 
primed oligonucleotides (Promega). As a precaution, prior to cDNA synthesis, 1 µg of 
total retina  mRNA was  incubated with DNase  I  Amplification  Grade (Invitrogen)  at 
room temperature, 15 minutes (10µl reaction); the DNase I was inactivated by adding 
1µl of 25 mM EDTA and heated for 10 minutes at 65°C. The RNA sample was ready to 
be reverse transcribed, using Superscript II Reverse Transcriptase (Invitrogen),      2. Materials and Methods 
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following the manufacturer’s instructions. The double stranded cDNA was then either 
used immediately as a template for PCR, or stored at –80
oC.  
 
2.9.7  Cloning 
2.9.7.1 Cloning via Recombination Reactions 
Each  clone  was  plated  on  selective  LB  agar  and  grown  overnight  at  37°C;  single 
colonies were picked and cultured in 5ml selective LB, overnight. DNA was purified 
from  the  saturated  culture.  Oligonucleotides  with  attB  overhangs  were  designed  to 
amplify full length PRPF31 (Table 2.8), TRAK2 (Table 2.9), and ZNF143 (Table 2.10 ) 
sequences, using  the KOD or ELTPS polymerases. The three fragments of  PRPF31 
were generated as follows: F1: 562 bp fragment encompassing the NOSIC domain; F2: 
610 bp fragment encompassing the NOP domain; F3: 629 bp fragment encompassing the 
NLS domain (primers listed in Table 2.8). Purified PCR products were recombined in 
either  pDONR201  or pDONR/Zeo  to  generate  entry  clones,  and  sequenced  (primers 
listed in Table 2.11). The entry clones were then recombined into the desired destination 
vectors.  Each  new  clone  was  first  tested  by  restriction  digestion  followed  by 
confirmation by sequencing (primers listed in Table 2.11) The PRPF6 sequence was 
purchased  already  cloned  into  an  entry  vector,  hence  not  requiring  any  preparatory 
amplification with attB overhung primers. The PRPF6 vector was directly used in a 
recombination reaction, and sequenced (primers listed in Table 2.12). All the cloning 
steps described were done using the Gateway Technology from Invitrogen, using BP and 
LR recombinase mixes, following manufacturer’s instruction. 
The  Gateway  Technology  is  a  rapid  and  efficient  way  to  clone  DNA  sequences 
developed  by  Invitrogen,  allowing  use  of  multiple  vector  systems  but  maintaining 
orientation and  reading frame, with no restriction/ligation of the  DNA.  This cloning 
method is based on site-specific recombination properties of bacteriophage lambda, a 
system  which  facilitates  the  integration  of  lambda  into  E.coli  chromosome;  the 
components of this system have been modified to improve specificity and efficiency. 
They include: the DNA recombination sequences (specific attachment sites, or att sites) 
and  the  proteins  that  mediate  the  recombination  reaction.  The  recombination  occurs  
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Table 2.8. Primers for PRPF31 cloning. 
PRPF31 att  Sequence (5' … 3')  Size bp 
PRPF31-I_F  GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGAGTCTGGCAGATGAGCTC 
PRPF31-I_R  GGGGACCACTTTGTACAAGAAAGCTGGGTGTTAGACCATGATGGTGGCATTGG 
562 
PRPF31-II_F  GGGGACAAGTTTGTACAAAAAAGCAGGCTTCAATGCCACCATCATGGTCGTC 
PRPF31-II_R  GGGGACCACTTTGTACAAGAAAGCTGGGTGTTACGGCTTCACCTGCTTCAC 
610 
PRPF31-III_F  GGGGACAAGTTTGTACAAAAAAGCAGGCTTCGGGAAGGTGGGCTACGAAC 
PRPF31-III_R  GGGGACCACTTTGTACAAGAAAGCTGGGTGTTATGTGGACATAAGGCCACTCTTC 
629 
PRPF31-I_F  GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGAGTCTGGCAGATGAGCTC 
PRPF31-III_R  GGGGACCACTTTGTACAAGAAAGCTGGGTGTTATGTGGACATAAGGCCACTCTTC 
1568 
For all  primer pairs,  the annealing  temperature  is  60°C, and Mg concentration  is 1mM, using  KOD 
polymerase. 
 
Table 2.9. Primers for TRAK2 cloning. 
TRAK2 att  Sequence (5' … 3')  Size bp 
TRAK2_F_full  GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGAGTCAATCCCAGAATGCA  
TRAK2_R_full  GGGGACCACTTTGTACAAGAAAGCTGGGTGTTATCAGTCCTCCTTCAGGACACC  
2809 
The annealing temperature is 59°C, and Mg concentration is 2.25mM, using ELTPS polymerase. 
 
Table 2.10. Primers for ZNF143 cloning. 
ZNF143 att  Sequence (5' … 3')  Size bp 
ZNF143_F_full  GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGACAGAGTTTCCTGGAGGA 
ZNF143_R_full  GGGGACCACTTTGTACAAGAAAGCTGGGTGTTATTAATCATCCAACCCTGGCGT 
1945 
The annealing temperature is 59°C, and Mg concentration is 2.25mM, using ELTPS polymerase. 
 
Table 2.11. Summary of the primers used to sequence the corresponding vectors. 
Vector  Primer name  Sequence 5’... 3’ 
pDONR201_F  TCGCGTTAACGCTAGCATGGATCTC 
pDONR201 
pDONR201_R  GTAACATCAGAGATTTTGAGACAC 
M13F  GTAAACGACGGCCAG 
pDONR/Zeo 
M13R  CAGGAAACAGCTATGAC 
pAD_BRP F  AAACCACTGTCACCTGGTTGG 
pAD-GAL4-Amp-DEST 
pAD_BRP R  GTGCACGATGCACAGTTGAAGT 
pBD-GAL4-Cam-DEST  pBD-Dest_F  GGAGACTGATATGCCTCTAACAT 
pDEST26  pDEST26_F  AGCTCGTTTGTGAACCGTCAG 
pcDNA3.1V5DEST  T7  TAATACGACTCACTATAGGG 
 
Table 2.12. Primers used to sequence PRPF6. 
PRPF6  sequence (5' … 3') 
PRP6 F1  CTCGTCATTGTTCTCGTTCCCT 
PRP6 F2  AACCCACGCTATGAGAAGCTGA 
PRP6 F3  AATGTGACAGGGCTGGGAGTGT 
PRP6 R1  CAATGTCTGACCGCGTGGTGAAG 
PRP6 R2  TAGATGGCTCGTGCACACTCCA     2. Materials and Methods 
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between att sites on the interacting DNA molecules, without gain/loss of nucleotides or 
synthesis of new DNA. The att sites are hybrid sequences made of sequences donated by 
each parental vector (i.e., attL sites consist of sequences from attB and attP sites). The 
proteins mediating this reaction are enzymes binding to the att sequences, which bring 
together  the  target  sites,  cleave  and  attach  the  DNA.  BP  reaction  facilitates 
recombination of an attB substrate (attB-PCR product or a linearised attB expression 
clone) with an attP substrate (donor vector) to create an attL-containing entry clone; LR 
reaction  facilitates  recombination  of  an  attL  substrate  (entry  clone)  with  an  attR 
substrate (destination vector) to create an attB-containing expression clone. Here, one 
example regarding the cloning of PRPF31 sequence into the bait vector pBD-DEST is 
explained: 
-  the full length cDNA of PRPF31 has been amplified, using the appropriate 
primers with matching attB site overhangs; 
-  through  the  BP  reaction,  a  recombination  between  the  attB-
PRPF31_PCR_product  and  the  donor  vector  pDONR201  (which  has  attP 
sites)  occurs;  the pDONR-PRPF31  will  now  have attL  sites  and is  named 
“entry” clone; 
-  through LR reaction, the new entry clone pDONR-PRPF31 undergoes further 
recombination with the desired “destination” vector (for ex. pBD-DEST, the 
bait vector); the new expression clone pBD-PRPF31 contains attB sites. 
 
2.9.7.2 SPLICE Cloning 
To  clone  MAGI3,  we  opted  for  a  technique  called  SPLICE  (Davies  et  al.,  2007), 
adapting it to suit our case. SPLICE is a rapid technique which allows intron removal 
from  genomic  DNA  to  generate  a  continuous  coding  sequence,  and  is  based  on  an 
overlapping  fusion-PCR  strategy  (swift  PCR  for  ligating  in vitro constructed  exons; 
Davies et al., 2007). This technique was adapted to amplify bits of coding region of 
MAGI3. Since MAGI3 presents 21 exons, retinal cDNA was chosen instead of genomic 
DNA, allowing for less rounds of amplification. According to the Ensembl database, 
MAGI3 has four different splice variants and we have generated the variant MAGI3-004 
(transcript ENST00000307546), hence primers were designed according to its sequence,     2. Materials and Methods 
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after  having  decided  which  DNA  segments  were  to  be  amplified.  External 
oligonucleotides  were  designed  with  attB  overhangs  (Table  2.13)  to  allow  the 
downstream Gateway cloning (see previous section 2.9.7.1); and, internal primers were 
designed as follows: for forward primers, the first 15 nucleotides corresponded to the 
last 15 nucleotides of an upstream exon, and the last 15 nucleotides corresponded to the 
first 15 nucleotides of a downstream exon (Table 2.13); the reverse primers were exactly 
the reverse complement sequence of the forward primer. PCRs were performed using 
KOD polymerase; fragments were gel-extracted and purified. From the concentration of 
the amplified products, equimolar quantities were calculated
*  and added together for 
subsequent rounds of PCR to amplify longer fragments, including in the reactions only 
the  outermost  primers  and  increasing  the  quantity  of  polymerase.  The  fragment 
corresponding  to  the  full  length  product  underwent  a  “test”  amplification  with  att 
primers, to make sure it was amplifiable by the flanking primers. Finally the product was 
sequenced (additional primers for sequencing are shown in Table 2.14), and used for 
downstream recombination. 
 
* the mol/µl of each fragment were calculated dividing their mass (using the concentration data) by their 
molecular weight (the bp length); the results are normalised to the lowest and the final number represents 
the number of moles in 1 µl. 
 
 
Table 2.13. Primers for MAGI3 SPLICE cloning. 
MAGI3   sequence (5' … 3')  size 
MAGI3_F_full  GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCGAAGACGCTGAAGAAGA  
MAGI3_ex1-2R  TATTAATGACTTTGCCTGGTTTCACAGTCT 
362 bp 
MAGI3_ex1-2F  AGACTGTGAAACCAGGCAAAGTCATTAATA 
MAGI3_ex7-8R  TTCTGGTTAAGGTGATCAACATAGTATGTC 
790 bp 
MAGI3_ex7-8F  GACATACTATGTTGATCACCTTAACCAGAA 
MAGI3_ex13-14R  AGCCCCAATATATATAGACTGGTCAGGTCC 
1201 bp 
MAGI3_ex13-14F  GGACCTGACCAGTCTATATATATTGGGGCT 
MAGI3_ex20-21R  TAATATCCCAATCACCATGGTCAGGTATCA 
1111 bp 
MAGI3_ex20-21F  TGATACCTGACCATGGTGATTGGGATATTA 
MAGI3_R_full  GGGGACCACTTTGTACAAGAAAGCTGGGTGTTATTACTGCCGTTTCTCAGCCATA  
1166 bp 
MAGI3_F_full  GGGGACAAGTTTGTACAAAAAAGCAGGCTTCATGTCGAAGACGCTGAAGAAGA  
MAGI3_R_full  GGGGACCACTTTGTACAAGAAAGCTGGGTGTTATTACTGCCGTTTCTCAGCCATA  
4510 bp 
For all primer pairs, the annealing temperature is 60°C, and Mg
2+ concentration is 1mM, using KOD 
polymerase. 
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Table 2.14. Additional primers used to sequence the full length of MAGI3. 
MAGI3 (MAGI3-004)   sequence (5' … 3') 
ex2  GATCAGAGATAATCTCTACTT 
ex5  ACTGGGAAATGGCCTACACTG 
ex10  GATGACAGTGAAGATCCTGTT 
ex12  AGGTCTACCTGAAATCTAAGA 
ex16  GAATGGGCAGTCCATTGTTGA 
ex20  CAATTGAGCTCATTCAGGCTG 
ex21-1  AGAGGTAGATCGGTTAGTCCC 
ex21-2  AATGGTTGAGAAATCTCTTCC 
 
2.9.7.3 Preparation of AG1 Competent Cells and Transformation 
A single colony of AG1 cells was inoculated into 2ml of LB medium. Cells were grown 
overnight at 37°C, with shaking; cells were diluted 1:100 dilution in fresh LB medium 
and grown until OD600 reached 0.3-0.6; cells were centrifuged and resuspended in TSB 
medium  (10ml  of  TSB  for  100ml  of  culture).  For  the  transformation,  0.1-10ng  of 
plasmid DNA was diluted in 20µl of 5x KCM Buffer and sterile water was added up to 
100µl; 100µl of competent cells were added, and the mixture was incubated on ice for 
20 min. This was followed by incubation at room temperature for 10 min; after which 
1ml of LB was added and the mixture was incubated a 37°C for 1 hour, with shaking. 
Transformed cells were plated on selective LB agar. 
 
2.10  Yeast Two-Hybrid Methods 
(All yeast liquid cultures were grown with vigorous shaking, 230-250 rpm) 
2.10.1  Yeast Transformation 
PJ69-4A competent cells were prepared by inoculating liquid YPAD medium with one 
yeast colony, and grown (with shaking) at 30°C until OD600 reached 0.8-1.0. Cells were 
split in 50ml tubes and centrifuged at 1000g for 5min; for each tube, cells were washed 
with 30ml sterile distilled water, centrifuged at 1000g for 5min, and finally resuspended 
in 6ml 1.1x TE/LiAc solution. The suspension was split in several tubes and centrifuged 
at maximum speed (13000 rpm) on a tabletop centrifuge; the supernatant was removed 
and each pellet was resuspended in 600µl of 1.1x TE/LiAc. 
Competent cells were transformed as follows: 500ng of plasmid DNA was combined 
with 5µg of herring testes carrier DNA (BD Biosciences) – previously denaturated for 5 
minutes at 95°C - and with 50µl of competent cells, mixing gently. PEG/LiAc solution     2. Materials and Methods 
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(0.5ml) was added to the DNA/competent cell mixture, mixing gently, and the cells were 
then incubated for 30 minutes at 30°C. DMSO (20µl, Sigma) was added with gentle 
mixing, and the tube was placed in a water bath at 42°C for 15 minutes, gently vortexing 
every 5 minutes; cells were pelleted at maximum speed on a tabletop centrifuge; the 
supernatant  was  then  removed  and  cells  were  resuspended  in  0.5ml  of  0.9%  NaCl 
solution; 200µl of the suspension was spread on the appropriate SD agar medium and 
cells were incubated at 30°C until colonies appeared. 
As the yeast two-hybrid requires a step of co-transformation, the procedure described 
above was followed, but two vectors instead of one were transformed into the cell: in 
this case, the total 500ng of plasmid DNA correspond to the combination of two desired 
vectors. 
 
2.10.2  Bait Auto-activation and Toxicity Assays 
To confirm  the designed baits  did not  auto-activate  the  reporter  genes,  single  yeast 
colonies of PJ69-4A MATa were transformed with each of the four constructs and empty 
pBD vector. The transformants were then plated on SD-LW and allowed to grow few 
days until colonies reached 1-1.5mm diameter. The toxicity was assessed by comparing 
the  growth  of  the  bait  transformants  with  the  empty  vector  pBD  transformant.  To 
confirm  that  the  baits  did  not  auto-activate  the  reporter  gene,  one  colony  for  each 
transformant was tested for the assays listed in section 2.10.7. 
 
2.10.3  Bait Protein Expression 
To confirm that each bait construct expressed the recombinant protein, yeast colonies 
transformed  with each bait  construct  were  cultured  and  treated  to  prepare  a  protein 
extract to be assayed by western blot. 
For each transformant, a single colony (not older than four days) was used to inoculate 
5ml of selective SD-W  liquid medium,  and grown overnight; a positive control was 
included,  consisting  of  the  empty  vector  pBD  transformant.  Alongside,  a  negative 
control  was  also  prepared  by  inoculating  10ml  YPAD  liquid  medium  with  an 
untrasformed PJ69-4A MATα colony. The next day,  for each transformant, 50 ml of 
YPAD was inoculated and the culture was grown at 30°C, with shaking, until the OD600     2. Materials and Methods 
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reached 0.4-0.6. The culture was then centrifuged  at 1000g for 5 minutes at 4°C in 
pre-chilled 50 ml tubes. The supernatant was discarded and the pellet resuspended in 
25ml of ice-cold dH2O, and then centrifuged at 1000g for 5 minutes at 4°C. The pellet 
was frozen by placing the tube in liquid nitrogen and stored at -80°C. 
For the preparation of protein extracts, complete cracking buffer was prepared by adding 
to 1ml of cracking buffer stock solution: 10µl of -mercaptoethanol, 50µl of 100mM 
PMSF  (4.5mM  final  concentration),  and  a  cocktail  of  protease  and  phosphatase 
inhibitors (see Table 2.1 of this chapter), to a final volume of 1.1ml. The buffer was 
prewarmed to 60°C and 100µl of buffer per 7.5 OD600 units of cells was added to each 
cell pellet (total number of OD600 units = OD600  [1  ml  sample] multiplied by the culture 
volume). The suspension was transferred to a new tube, containing 80µl of glass beads 
(425-600µm, Sigma) per 7.5 OD600 units and heated to 70°C, for 10 minutes; the sample 
was vortexed vigorously for 1 minute and then centrifuged at maximum speed (13000 
rpm) on a tabletop centrifuge for 5 minutes, at 4°C. The supernatant was transferred to a 
new tube and placed on ice. The remaining pellet was boiled in water for 3-5 minutes 
and vortexed vigorously for 1 minute, and then centrifuged at maximum speed on a 
tabletop centrifuge for 5 minutes, at 4°C. This second supernatant was combined with 
the corresponding first supernatant. Each sample was then boiled briefly and loaded on a 
gel (7.5% and 15% acrylamide), or stored at -80°C until ready to electrophorese it on a 
polyacrylamide gel. 
 
2.10.4  Library Screening by Yeast Mating 
This method is based on the mating of haploid yeast cell of the opposite mating type, to 
generate diploid cells.  PJ69-4A  MATa  was  transformed  with  the bait  constructs  and 
PJ69-4A MATα carried the libraries. The mating protocol of Letteboer and Roepman, 
(2008) was followed and briefly described below. 
 
Three milliliter of SD –W medium was inoculated with one colony of PJ69-4A MATa, 
previously  transformed  with  one  bait  construct,  and  grown  overnight  at  30°C  with 
shaking. Hundred milliliter of SD –W (1:50 / 1:100 / 1:250 dilutions) was inoculated 
with the overnight culture and incubated overnight at 30°C. The OD600 was determined,     2. Materials and Methods 
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and the culture with OD600 = ~1 was used (=2.5 x 10
7 cells/ml). 4 x 10
8 library cells 
were thawed and incubated in 20ml of liquid YPAD, for 10 minutes, at 30°C. 8 x 10
8 
bait cells were added to the library cells and mixed. The cell mixture was centrifuged for 
5 minutes at 900g at room temperature; the pellet was resuspended in 2ml of YPAD and 
plated onto four 15-cm YPAD agar plates, incubating for 4.5 hours, at 30°C. Cells were 
scraped in 10 ml 0.9% NaCl using a cell scraper; plates were rinsed with 10 ml 0.9% 
NaCl; all the fractions were pooled and centrifuged for 5 minutes at 900g. Finally the 
pellet was resuspended in 10 ml 0.9% NaCl (and dilutions for mating efficiency were 
prepared). 
 
For the screening, ~2.5 x 10
5 diploid clones were plated onto ten 15-cm SD–LWHA 
plates, ~1  x  10
6  diploid clones onto  ten 15-cm  SD–LWHA  plates. The  plates  were 
incubated for 3-14 days, at 30°C and subsequently streaked onto fresh SD–LWHA plates 
and clones were assayed for interactions. 
 
For the mating  efficiency  (percentage of diploids), different dilutions (10
1-10
6)  were 
prepared in 0.9% NaCl, making serial dilutions: adding 100 µl of culture to 900 µl of 
0.9% NaCl (10
1 dilution), adding 100 µl of 10
1 dilution to 900 µl of 0.9% NaCl (10
2 
dilution), etc. Each dilution was plated onto a 9-cm SD –LW plate and incubated 2-4 
days,  at  30°C.  The  colonies  were  counted  and  the  mating  efficiency  calculated  as 
follows: number of colonies counted × dilution factor (the 10
1-10
6 dilutions) = number 
of cfu/100µl; × 10 = number of cfu/ml; × 10 (last resuspension volume in the mating 
procedure) = total number of cfu; / 4 x 10
8 (library cells used) × 100% = % of diploids, 
that is the mating efficiency. The expected mating efficiency is around 25% (total of 100 
× 10
6 diploid cells). 
 
2.10.5  Yeast Plasmid Preparation  
A single fresh  yeast  colony was  inoculated into  0.5ml of selective SD  medium  and 
grown overnight, at 30°C. Cells were centrifuged for 5 minutes at full speed (13000 
rpm) on a tabletop centrifuge and then resuspended in 100µl of Buffer S (Table 2.1) and 
incubated at 37°C for 30 minutes. The mixture was then added to 25µl of Lysis Buffer     2. Materials and Methods 
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(Table 2.1) and incubated at 65°C for 30 minutes; 50µl of 3M KAc was added to each 
sample, incubated on ice for 10 minutes and afterwards, centrifuged at maximum speed 
on a tabletop centrifuge at 4°C; 150µl of the suspension was combined with 150µl of 
ethanol and incubated overnight at -20°C  (or 1 hour at  -80°C) and  the  mixture was 
centrifuged at maximum speed on a tabletop centrifuge at 4°C. The  supernatant was 
discarded and the pellet was washed with 70% ethanol, centrifuged at maximum speed 
on a tabletop centrifuge at 4°C, the supernatant was then removed and the pellet was air-
dried and finally dissolved in 50µl of deionised water. 
 
2.10.6  Long-term Storage of Strains 
Liquid  cultures  of  S.cerevisiae  PJ69-4A  strain  and  the  range  of  transformants  were 
prepared and  grown overnight at 30°C.  Cells were collected  and resuspended in the 
appropriate medium (YPAD or selective SD) with 20% glycerol (filter sterilised), and 
finally placed at -80°C for long term storage. 
 
2.10.7  Yeast Two-Hybrid Assays for Identification of Positive Interactors 
Colonies obtained from the mating step and growing on SD-LWHA were re-streaked 
onto fresh SD-LWHA plates, one with X-α-Gal and two without, to assess the following 
reporter genes 
1.  Selective Medium Assay for HIS3 and ADE2 reporter genes: yeast colonies were 
plated on SD-LWHA and allowed to grow at 30°C for 3-4 days. The colonies which 
were growing healthily were considered positive for this assay, as they were able to 
synthesise hystidine and adenine to support their growth. 
2.  α-Galactosidase  Assay  for  MEL1  reporter  gene:  yeast  colonies  were  plated  onto 
SD-LWHA supplemented with 20 mg/l X-α-Gal (20mg/ml in DMF; Glycosynth), 
followed  by  incubation  at  30°C  for  3-4  days.  The  colonies  that  developed  a 
blue-green colour (directly on the solid medium) were considered positive for this 
assay, as they were able to synthesise α-galactosidase; 
3.  β-Galactosidase Assay (or filter lift assay) for LacZ reporter gene:  yeast colonies 
were plated on SD-LWHA, and, after growing at 30°C for 3 days, they were covered 
with Whatman 3M paper and grown for a further 2 days at 30°C. The filter was then     2. Materials and Methods 
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dipped  into  liquid  nitrogen  for  1  minute,  thawed  to  room  temperature  (colonies 
facing  up)  and  finally  placed onto  filter  paper  soaked  with Z-Buffer  (containing 
0.27% β-mercaptoethanol and 0.334mg/ml X-β-gal). The filter was placed on a petri 
dish and sealed with parafilm and incubated at 37°C, for up to 4 hours – the time it 
takes  for  a  blue  colour  to  appear;  produced  by  the  yeast  colonies  due  to 
β-galactosidase activity. 
After these three assays performed on co-transformed clones, the positive clones were 
sequenced  with  pAD-GAL4-Amp-DEST  primer  (see  Table  2.11),  and  with  the 
following primers (Table 2.15), designed according to the clone sequence: 
 
Table 2.15. Primers used to sequence the library clones positive for the yeast two-hybrid assays. 
library clones  sequence (5' … 3') 
3.9 I   
1F  AGAGGCATTCTGAGCCGTCTG 
2F  ACTCGAGATCCATCCCAGCCTTA 
4F  CTAGTGACTATCCCTCTGATC 
3.10 I   
1F  AGAGGATGGGCAAGCAGTGCA 
2F  TTACCAGTGTGAGCATGCAGG 
4F  GATCACATATGTTACAGGTGT 
4.17 I   
1F  TCGATCCAAGGCTTGTCACAT 
2F  GGTATGAACTACTGACTCATGC 
4F  GATGCTGATCATCTAGTCTAC 
 
 
2.10.8  Selection of clones 
After a yeast two-hybrid screening, a number of putative interactors will be isolated. 
Some will be false positives, and they will be eliminated with the co-transformation 
experiment and with the assay described in the previous section 2.10.7. After this initial 
selection, the clones will be analysed according to the goodness of the sequence: the 
vector sequence GAA TTC GGC ACG AGN will be looked for, with the reading frame 
defined by the GAATTC sequence, corresponding to the EcoRI restriction site used to 
clone the library. If the clones match this requisite, they will be included in the putative 
interactants list. As this list may be composed of several candidates, a number of criteria 
will be applied to prioritise certain clones among others:     2. Materials and Methods 
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1) investigation in database and literature about the expression in eye of the putative 
candidate;  
2) investigation in database and literature about domains of the protein which can relate 
to splicing activity; 
3) nuclear localisation; 
4) that there is expression of a protein sequence (no early stop codons) from the prey 
vector and not just a small peptide. 
As many clones may be positive for some criteria and negative for others, this is meant 
to  be  more  a  guideline,  and  hence  these  criteria  will  be  applied  with  flexibility, 
according to the type of putative interacting partner. 
 
2.11  SDS-PAGE and Western Blot 
SDS-Polyacrylamide mini-gels (7.5-15%) were cast using a Biorad kit, following the 
recipe stated in the Table 2.1. Samples were prepared previously with the appropriate 
amount  of  2x  Reducing  Sample  Buffer  and  denatured  at  70°C  for  5  minutes.  The 
samples were then loaded on the gel along with a protein marker (Precision Plus Protein 
Standard, Biorad) and electrophoresed in a Biorad tank (150-200 V) until the desired 
separation was achieved. The proteins were transferred onto a nitrocellulose membrane 
(0.45µm, Biorad) using a Biorad tank (100 V, 350 mA max, 1 hour). To ensure that the 
proteins were transferred onto the membrane, the latter was stained for 2 minutes with 
Amido Black Staining solution and bands corresponding to the proteins were visualised 
after 2 washes of 10 minutes each in destaining solution. The membrane was then briefly 
rinsed with TBS or TBS-T and blocked with Blocking Buffer I for 30 minutes at room 
temperature. If the membrane was incubated with an antibody diluted in Blocking Buffer 
II, then the membrane was washed briefly with TBS-T to eliminate any trace of milk 
prior to incubation with the primary antibody. After the incubation with the primary 
antibody (overnight at 4°C, for dilutions see Table 2.16), the membrane was washed in 
TBS-T  3x10  minutes,  and  incubated  45  minutes  at  room  temperature  with 
HRP-conjugated secondary antibody, diluted 1:10000 in TBS-T. The membrane was 
briefly  rinsed  with  TBS-T  and  washed  twice  for  15  minutes  each  in  TBS-T,  and 
ultimately washed in TBS only, twice for 10 minutes each. For the development, ECL      2. Materials and Methods 
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solution  (GE  Healthcare)  was  put  on  top  of  the  membrane  for  1  minute  and  the 
membrane was exposed to detect any signal; the film (Fuji Super RX) was developed in 
Konica SRX-101A medical film processor. 
 
Table 2.16. Summary of the antibody concentrations and blocking buffers used for western blot. 
Primary Antibody  Blocking buffer  Dilution 
Anti-GAL4 DNA-AD  II  1:2000 
Anti-GAL4 DNA-BD  I  1:2000 
Anti-6xHis (Sigma)  II  1:2000 
Anti-V5  II  1:2000 
Anti-PRPF31484-497  II  1:2000 
Anti-PRPF31140-154  II  1:1000 
Anti-PRPF6  II  1:1000 
Anti-MAGI3  II  1:500 
Anti-TRAK2  II  1:1000 
 
 
2.12  Cell Culture 
2.12.1  Maintenance of Cell Lines 
HEK293, MDCK and SK-N-SH cells were grown either in 6-well, 24-well, or 85mm 
plates according to the experimental requirements. Cells used for immunocytochemistry 
(MDCK, SK-N-SH), were seeded on sterile glass coverslips, placed in each well of a 
24-well plate. In each case, cells were fed with D-MEM medium (4.5 g/l D-glucose) 
supplemented with 100 units of penicillin and 100µg of streptomycin and 10% fetal calf 
serum;  the  cells  were  grown  in  a  humidified  incubator  at  37°C  in  5%  CO2.  For 
transfection, cells were cultured in the same medium but lacking the antibiotics. Cells 
were passaged when a high confluence was reached, and hence were seeded at a lower 
cell concentration: cells were washed briefly with sterile PBS to eliminate any trace of 
medium,  and  a solution  of  Trypsin-EDTA  (0.025%-0.01%)  was  added,  ensuring  the 
entire surface was covered by it; cells were incubated 5-10 minutes at 37°C to allow the 
detachament from the surface of the well/plate, and afterwards they were resuspended in 
medium and centrifuged for 3 minutes at 700 rpm; the supernatant was discarded and the 
cells  were  resuspended  in  the  desired  amount  of  medium  and  dispensed  into  new 
wells/plates. 
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2.12.2  Cell Transfection 
Mammalian  cell  transfection  was  performed  using  Lipofectamine  2000  reagent 
(Invitrogen). The protocol involves the formation of complexes between the DNA and 
lipofectamine  reagent.  Prior  to  this  step,  the  DNA  and  lipofectamine  were  both 
incubated  with  OptiMEM  medium  separately,  the  latter  for  5  minutes  at  room 
temperature.  Afterwards,  the  lipofectamine-OptiMEM  complex  was  mixed  with  the 
DNA-OptiMEM complex  and the suspension  was incubated for 20 minutes at  room 
temperature before adding it to the cells. 
One day before transfection, cells were plated in medium without antibiotics (for final 
volume, see Table 2.17); once the lipofectamine-DNA suspension was ready to use, it 
was added to the cells, rocking the plate back and forth to allow even dispersion. Cells 
were incubated at 37°C, and after 4h the medium was replaced with fresh medium. Cells 
were incubated for a total of 24 hours prior to testing for transgene expression.  
HEK293 cells used for co-immunoprecipitation experiments were transfected on 85mm 
plates (~75% confluency), whereas MDCK cells used for immunocytochemistry were 
transfected on 24-well plates (~50-75% confluency); the quantities of reagents used per 
well are summarised in Table 2.17.  
 
Table 2.17. DNA/Lipofectamine ratio for the cell lines used for transfection. 
Cell line  DNA  Lipofectamine  OptiMEM  plating medium 
HEK293  24 µg  60µl  2 x 1.5ml  15ml 
MDCK  0.6µg  2µl  2 x 50µl  0.5ml 
 
 
2.12.3  Preparation of Cell Extracts 
Wild type and transfected HEK293 cells, wild type and transfected MDCK cells and 
wild type SK-N-SH cells were grown in 85mm plates until ~75% confluent; the plates 
were  washed  twice  with  cold  1x  PBS,  and  then  scraped  in  1ml  of  cold  PBS-0.5% 
TX100, supplemented with a cocktail of protease and phosphatase inhibitors (see Table 
2.1).  The  suspension  was  collected  in  1.5ml  tubes  and  kept  on  ice  throughout  the 
procedures to minimise protein degradation. The extracts were syringed at least 10 times 
(or more, until  the suspension did not clump  the needle),  to homogenise the sample 
using a 25G needle. The extracts were either placed in -80°C for long term storage or     2. Materials and Methods 
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used  in  the  downstream  application  (immunoprecipitation),  or  treated  with  reducing 
sample buffer (Table 2.1) for SDS-PAGE. 
 
2.12.4  Methanol Fixation of Cells 
After 24 hours post-transfection (if implied by  the experiment), cells to be used for 
immunocytochemistry  were  fixed  with  methanol.  Cells  were  initially  incubated  in 
ice-cold methanol for 5 minutes, at -20°C; cells were then rehydrated with PBS for 5 
minutes, at room temperature, followed by incubation in blocking solution for at least 15 
minutes before proceeding to staining. At this stage, cells were either stained or stored at 
4°C in blocking solution. 
 
2.12.5  CDK Inhibitors Treatment 
MDCK cells were cultured on sterile glass coverslips, in 24 well plates, until 50-60% 
confluent  (growing  in  islands).  Medium  was  then  replaced  with  fresh  medium 
supplemented with either one of CDK inhibitors, Olomoucine (CDK2 inhibitor, diluted 
1:1000; Calbiochem) and CDK4 inhibitor (Calbiochem, diluted 1:1000), and the cells 
left at 37°C, for 24 hours before fixing them with methanol.  
 
2.12.6  Temperature Stress Treatment 
MDCK cells were cultured on sterile glass coverslips, in 24 well plates, until ~50% 
confluent (growing in islands). Cells were washed and medium replaced with normal 
medium supplemented with 10mM HEPES pH 7.4, and cells were placed at 43°C for 
two hours, after which the cells were immediately fixed in methanol. HEPES buffer was 
added, as the incubator used for the higher temperature was not buffered with CO2. 
 
2.12.7  Osmolarity Stress Treatment 
MDCK cells were cultured on sterile glass coverslips, in 24 well plates, until ~50% 
confluent (growing in islands). The physiological osmolarity of the media used for cell 
culture  is  300  mOsm  and  with  these  treatments,  we  achieved  hyper-  and 
hypo-osmolarity  of  the  medium  by  the  addition  of  salt  or  water  respectively.  For 
hyper-osmolarity stress, 150mM NaCl was added to the medium, for a final osmolarity      2. Materials and Methods 
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of 600 mOsm; hypo-osmotic stress was achieved by adding water to the medium, for a 
final 100 mOsm (10 ml of medium + 20 ml of water). Cells were cultured with these 
media accordingly for 2 hours, before fixing them in methanol. 
 
2.13  Co-immunoprecipitation 
40µl of a 30% suspension of Protein-G Sepharose beads (Pharmacia) were mixed with 
2mg of antibody and 500µl of PBS-0.5% TX100; the mixture was gently shaken for 2 
hours at room temperature to allow the antibody to bind to the beads; afterwards, beads 
were briefly spun at maximum speed (13000 rpm) on a tabletop centrifuge and washed 
once  with  PBS-0.5%  TX100.  HEK293  cell  extracts  were  thawed  on  ice  and 
supplemented with the protease/phosphatase inhibitors cocktail, and finally incubated 
with  the  equivalent  of  50µl  of  Protein-G  Sepharose  beads  for  30  minutes  on  ice, 
inverting the tubes every now and then. Extracts were then centrifuged for 10 minutes at 
maximum speed on a tabletop centrifuge, at 4°C, and the supernatant was distributed to 
each immunobead reaction previously prepared and each tube was rocked for 4 hours, at 
4°C. Beads were finally centrifuged at maximum speed on a tabletop centrifuge at 4°C, 
for 2 minutes, and washed twice with PBS-0.5% TX100 and once with PBS. Finally, 
40µl of sample buffer were added and the beads were heated at 75°C, for 10 minutes. 
The samples were then ready for SDS-PAGE and immunoblot analysis, otherwise were 
stored at -20°C until required. 
 
2.14  Immunofluorescence 
The  immunofluorescence  images  were  processed  using  the  Adobe  Photoshop  7.0 
software. The colour was removed to facilitate the examination on paper after printing; 
therefore the panel for a single signal is shown in black and white throughout the thesis. 
The type of visualised channel is indicated by the colour of the legend on the top-left on 
each panel (for example: PRPF31 detected with Cy3 and identified by a red signal is 
written in RED). The colours composing the final picture (red, green and blue) were 
then restored on one panel, termed “merged”. 
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2.14.1  Immunocytochemistry 
Coverslips of MDCK cells, fixed in methanol and blocked with blocking solution (for 
ICC, see Table 2.1), were stained as follows: 20µl of primary antibody dilutions (Table 
2.18) were prepared in blocking solution and were placed on a piece of parafilm and the 
coverslip was placed on top of it, cells facing down. The cells were incubated for 1h at 
room temperature, placing the parafilm on blotting paper soaked in water to prevent 
evaporation.  Afterwards,  the coverslips  were  placed  back  into  a  24-well plate,  cells 
facing  up,  and  were  washed  three  times  in  blocking  solution;  ~300µl  of  secondary 
antibody dilution together with Hoechst 33258 (0.25ug/ml) (Table 2.17) were added to 
each coverslip directly on the well, and incubated for 45 minutes at room temperature in 
the dark. Subsequently, coverslips were washed twice with blocking solution, and once 
with PBS only. For each coverslip, a drop of ProLong Gold anti-fade reagent was placed 
on a clean glass slide, and the coverslip (after removal of any excess liquid) was lowered 
carefully onto the drop, avoiding air bubbles; the samples were left to set overnight at 
room temperature before examining them on fluorescence (Leica DM-IRB) or confocal 
(Zeiss LSM510UV; Leica TCS-SP2) microscopes. 
 
 
 
Table 2.18. Summary of the concentration of antibody used for immunocytochemistry (for 
antibody reference, see section 2.5). 
Antibody  Dilution in Blocking Solution (ICC) 
Anti-PRPF31484-497  1:200 
Anti-V5  1:500 
Anti-PRPF31140-154  1:100 
Anti-TRAK2  1:50 
Anti-MAGI3  1:50 
Anti-E-cadherin  1:500 
Anti-SC35  1:200 
Donkey FITC anti-mouse  1:800 
Donkey Cy3 anti-rabbit  1:800 
Donkey Cy3 anti-goat  1:800 
Hoechst 33258  1:2000 (from 0.5mg/ml stock solution) 
 
 
     2. Materials and Methods 
 
  83 
2.14.2  Immunohistochemistry 
Adult mice (C57Bl/6J strain, six-month old) were maintained in 12-hour light/dark cycle 
(lights on at 7 am). At 10 am, the animals were euthanised by asphyxiation (carbon 
dioxide) followed by cervical dislocation; dark adapted-mice were sacrificed at 10 am 
maintaining them in darkness from 7 am. Eyes were enucleated with 2-3 mm of the optic 
nerve; the cornea and the lens were removed. The eyes were then incubated in 4% PFA 
at 4°C overnight. The second day, the eyes were washed three times with PBS, for 15 
minutes each, at room temperature with agitation. Subsequently, the eyes were incubated 
in  sucrose-PBS four  times for 30 minutes each, increasing the  sucrose concentration 
each time: 5%, 10%, 12.5% and 15% sucrose respectively (at room temperature with 
agitation).  The  eyes  were  then  left  in  20%  sucrose-PBS  overnight  at  4°C  without 
shaking.  On  the  third  day,  the  eyes  are  shaken  slowly  for  30  minutes  at  room 
temperature in 13% sucrose-PBS and 1/3 of OCT freezing medium (Thermos Biolabs 
UK). The final wash of 30 minutes at room temperature was in OCT only. Each eye was 
then placed in a cryo-tube, filled with OCT and snap-frozen by immersion in a freezing 
medium: 2-methylbutane was frozen in liquid nitrogen and the cylinder was dipped into 
the  2-methylbutane  to  freeze.  The  eyes  were  stored  at  -80°C,  until  ready  for 
cryosectioning; sections were prepared at 10 µm using a cryotome. The mouse retina 
sections were collected on glass slides and were stored at -80°C until ready for use. The 
above procedure was performed by Dr C. Chakarova. 
Once a section was at room temperature, the blocking procedure was done rapidly: a 
hydrophobic pen was used to define a well around the section, and a drop (~30µl) of 
blocking solution I was added gently onto the section, and incubated for 1 hour at room 
temperature. Each slide was placed on a case fitted with blotting paper soaked in water 
to prevent evaporation. After the blocking step, each slide was washed 10 minutes three 
times in PBS-0.1% TX100; the sections were then incubated with the primary antibody, 
diluted in blocking solution II (see Table 2.19), for 1 hour at room temperature. Next, 
the slides were washed for 10 minutes three times in PBS-0.1% TX100 and sections 
were  incubated  for  45  minutes  at  room  temperature  with  FITC/Cy3  conjugated 
secondary antibodies (diluted in blocking solution II, 1:400), in the dark. The slides were 
then washed twice in PBS-0.1% TX100 for 10 minutes each, and once in PBS only for     2. Materials and Methods 
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10 minutes, adding Hoechst 33258. Finally, slides were wiped from excess liquid and a 
drop of ProLong Gold anti-fade reagent was placed on top of each section and a glass 
coverslip was lowered carefully onto the drop, avoiding air bubbles. The sections were 
left to dry overnight at 4°C before examining them on an epifluorescent microscope 
(Leica DM-IRB). 
 
 
Table  2.19.  Summary  of  the  antibody  dilutions  used  for  immunohistochemistry  (for 
antibody reference, see section 2.5). 
Antibody  Dilution in Blocking Solution II (IHC) 
Anti-PRPF31484-497  1:200 
Anti-GRIF18-633  1:50 
Anti-MAGI3  1:10 
Anti-PRPF3  1:200 
Anti-PRPF8  1:200 
Anti-PRPF16  1:200 
Anti-Rhodopsin  1:200 
Anti-TOPORS  1:50 
Anti-PNA  1:200 
Donkey FITC anti-mouse  1:800 
Donkey Cy3 anti-rabbit  1:800 
Cy2 streptavidin  1:800 
Hoechst 33258  1:2000 (from 0.5mg/ml stock solution) 
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3.  Identification of Interactants of PRPF31 
 
 
A powerful approach to study protein interactions in vivo is the yeast two-hybrid system. 
This technique was developed by Fields and Song (1989), and since then has become a 
popular  tool  in  the  examination  of  protein  associations.  Since  its  development,  the 
technique has undergone many improvements hence it is highly standardised. Moreover 
the yeast  two-hybrid technique has the advantage of getting physiologically relevant 
information  by  manipulating  DNA  only:  when  it  comes  to  the  identification  of  the 
protein  interactor,  its  corresponding  cDNA  sequence  can  be  identified  through 
sequencing. Since the aim of this project was to test the hypothesis of a retina-specific 
partner for PRPF31 (see section 1.6), this method was therefore chosen as it allows the 
detection of potential interactants of PRPF31. Furthermore, the selection of candidates 
was restricted to the variety of proteins present in retina by choosing two retina libraries. 
Hence,  the  yeast  two-hybrid  and  the  retina  libraries  will  allow  for  the  discovery  of 
PRPF31 associations in retina, if retina-specific proteins are isolated. 
 
3.1  The Yeast Two-Hybrid System 
The yeast two-hybrid system takes advantage of eukaryotic gene transcription, relying 
on unique properties of the yeast GAL4 transcription factor (TF). A TF is composed of 
two domains: a DNA-Binding Domain (BD), which binds to the upstream activation 
sequence  (UAS)  of  a  promoter,  and  an  Activation  Domain  (AD)  which  elicits  the 
transcription of the gene, recruiting the transcription apparatus. When the domains are 
separated, they are unable to activate the transcription, but the function can be restored if 
they are brought close enough. So if a test protein is attached to one domain, e.g. BD, its 
binding  with  an  interactant  will  bring  AD  closer,  resulting  in  the  increase  of 
transcription of particular genes. This is the essence of the technique, as it depends on 
the production of two hybrid proteins: one is the fusion between BD and a “bait” protein 
(PRPF31 in this study), the second is the fusion between AD and a “prey” sequence (a 
cDNA sequence from retina libraries in this study).     3. Identification of Interactants of PRPF31 
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The fusion proteins BD-bait and AD-prey carry a nuclear localisation sequence to be 
transported into the nucleus, and their expression is regulated by the ADH1 promoter. 
BD-bait initially binds to the UAS upstream a reporter gene; only when there is a direct 
interaction between bait and prey, and the AD is close to the BD will it initiate the 
transcription of the reporter gene (Figure 3.1 D). 
Along  with  the  two  hybrid  proteins,  reporter  genes  are  the  third  component  of  the 
system. Reporter genes are used to detect any occurring interaction, as they are under the 
control of a promoter which has BD binding sites (the UAS). Reporter genes can be 
either integrated in the yeast genome (as in this case) or carried by a plasmid, and are of 
two types: nutritional selection markers (coding for a gene involved in the biosynthesis 
of  a  particular  organic  compound),  and  genes  coding  for  α-galactosidase  and  
β-galactosidase enzymes. 
The approach consists of an initial mating of yeast cells, where BD-bait vector is carried 
by  a  mating  type  yeast  cell  and  the  AD-prey  vector  by  the  opposite  mating  type. 
Following mating, the new diploid yeast cells harbour the two vectors together and the 
interaction is assessed through the transcription of reporter genes. Finally the vectors are 
isolated and sequenced to determine each interacting cDNA. 
The  steps  characterising the yeast  two-hybrid screening  for  the isolation of PRPF31 
interactants described in this chapter are as follows:  
1.  Cloning and characterisation of a suitable bait; 
2.  Transformation of yeast mating type A with a bait construct; 
3.  Mating of strains A and α bringing bait and library respectively; 
4.  Plating and identification of positives; 
5.  DNA extraction of putative positive prey constructs from yeast and transformation in 
bacteria; 
6.  Co-transformation into yeast cells of prey construct and bait construct; 
7.  Plating and identification of positive clones (and elimination of false positives); 
8.  Sequencing of positive clones’ constructs; 
9.  Exchanging of bait sequence into prey vector and human ORF cDNA corresponding 
to prey sequence into bait vector;     3. Identification of Interactants of PRPF31 
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Figure 3.1. Overview of the yeast two-hybrid system. 
In A, the transcription factor GAL4 induces the transcription of a reporter gene, as it would normally. In 
B, the fusion protein formed by the binding domain of GAL4 and the bait is able to bind a DNA sequence, 
but it is not sufficient to start the transcription of the downstream reporter gene. In C, the fusion protein 
formed by the activation domain of GAL4 and the prey does not bind the UAS sequence, nor does it start 
the transcription. In D, the presence of BD-bait bound to the UAS sequence, and the AD-prey interacting 
with the bait is sufficient to restore the GAL4 function, which in turn sets off the transcription of the 
reporter gene. Image adapted from http://en.wikipedia.org/wiki/Two-hybrid_screening. 
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10. Co-transformation into yeast cells; 
11. Plating and identification of positives. 
Before I joined the project, Dr C. Maubaret had already cloned the bait constructs and 
was about to perform the screening of the human and bovine libraries, in collaboration 
with Dr R. Roepman. After I took over the project, I characterised the bait constructs 
used for the screening (point one) and continued the project from point five onwards, 
collaborating again with Dr R. Roepman. Due to time constraints, the yeast two-hybrid 
screening and the characterisation of the bait constructs were carried out in parallel by 
Dr C. Maubaret and myself, respectively.  
As a matter of completeness and clarity, I have included also Dr C. Maubaret’s initial 
results. 
 
 
3.2  Construction of PRPF31 Baits 
The  pBD-GAL4-Cam-DEST  vector  was  used  to  generate  BD-PRPF31  recombinant 
proteins, under the control of the ADH1 promoter. Each bait protein was a hybrid of the 
DNA-Binding Domain (BD) of the transcription factor GAL4 (at the N-terminus) and 
PRPF31. We decided to create not just full length PRPF31 as the bait, but also specific 
fragments  encompassing  the  single  domains,  in  order  to  increases  the  chances  of 
identifying potential interactants. 
From the human  wild type  sequence of  PRPF31, four different bait constructs  were 
generated  (Figure  3.2),  following  the  protocol  described  in  the  section  2.9.7.1  of 
Materials and Methods (Chapter 2): 
1.  F1: 166 amino acid fragment encompassing the NOSIC domain, corresponding to 
exon 2-5 and part of exon 6; the predicted molecular weight of the fusion protein is 
~37 kDa; 
2.  F2: 182 amino acid fragment encompassing the NOP domain, corresponding to part 
of exon 6, exons 7-9 and part of exon 10; the expected molecular weight of the 
fusion protein is ~39 kDa; 
3.  F3: 186 amino acid fragment encompassing the NLS domain, and corresponding to 
exons 10-14; the expected molecular weight of the fusion protein is ~40 kDa;     3. Identification of Interactants of PRPF31 
 
  89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2. Illustration of the various fragments of PRPF31 used as baits for the yeast two-hybrid 
system. 
The  coloured  boxes  highlight  the  protein  domains  and  their  amino  acid  position  along  the  protein 
sequence.  The  arrows  illustrate  the  fragments  (named  F1-F4),  reporting  the  length  in  bp  and  the 
corresponding exons. The upper brackets group the mutations according to the bait fragment; mutation 
numbers correspond to those in table 1.2 (section 1.6.1 of the Introduction). 
 
F3: 558 nt – exons 10-14 
NOP 186-334  NOSIC 92-144   NLS 
351-364 
F1 : 498 nt – exons 2-6  F2: 546 nt – exons 6-10 
F4: 1497 nt – exons 2-14 
499 aa 
Mutations 4-8; 11-15  Mutations 16-34  Mutations 34-41     3. Identification of Interactants of PRPF31 
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4.  F4: 499 amino acid fragment corresponding to the full length sequence of human 
PRPF31; the predicted molecular weight of the fusion protein is ~76 kDa. 
Each  clone  was  restricted  and  sequence  verified  (primer  pBD-Dest_F,  Table  2.11, 
section 2.9.7.1). 
 
3.3  Characterisation of the Baits 
Ideally, a bait to be used in a yeast two-hybrid screening should: 
1.  Not activate the transcription of the reporter genes (auto-activation test); 
2.  Not be toxic to the yeast cell; 
3.  Be expressed in the yeast cell; 
The  characterisation  of  the  bait  constructs  consists  in  verifying  these  three 
characteristics. 
 
3.3.1  Bait Auto-activation Assay 
To confirm each bait did not activate the transcription of any reporter gene, PJ69-4A  
MATa yeast strain was transformed with each bait construct, and the activation of the 
reporter genes was assessed through the selective medium assay (yeast two-hybrid assay 
#1, paragraph 2.10.7). A suitable bait should not activate any reporter gene without the 
presence of an interacting prey, therefore one should not expect growth of the yeast 
transformant in this type of assay. As shown in Figure 3.3, clones were not able to grow 
on SD-WHA medium, as HIS3 and/or ADE2 genes were not expressed, therefore not 
permitting any growth due to the lack of histidine and adenine. 
In  parallel,  an  analogous  test  was  carried  out:  PJ69-4A  MATα  yeast  cells  were  
co-transformed (as described in paragraph 2.10.1) with the bait constructs and with the 
(empty) pAD-GAL4-Amp-DEST vector; and also with empty vectors pBD-GAL4-Cam-
DEST and pAD-GAL4-Amp-DEST vectors. Co-transformed yeast cells were plated on 
SD-LW, and then plated onto SD-LWHA medium carrying out the three tests, observing 
no activation of the reporter genes (Figure 3.4, panels A-E; note that the α-galactosidase 
assay was such that any picture taken was not representative of the result, hence only  
β-galactosidase is presented herein).  
     3. Identification of Interactants of PRPF31 
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Figure 3.3. Selective medium assay for PRPF31 baits. 
Panels A-D represent snapshots of SD-WHA plates: A: BD-F1; B: BD-F2; C: BD-F3; D: BD-F4. None of 
the baits is able to grow on the selective medium lacking Histidine and Adenine. Panel E is an example of 
a patch of healthily growing yeast. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. -galactosidase assay. 
Assay for bait auto-activation: pAD-GAL4-Amp-DEST + (A) pBD-GAL4-Cam-DEST, (B) BD-F1, (C) 
BD-F2, (D) BD-F3, (E) BD-F4. 
Assay of the control plasmids: (F) pAD-WT and pBD-WT, (G) pAD-MUT + pBD-MUT, (H) pAD-WT + 
pBD-pLC. 
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In  conclusion,  all  the  four  baits  were  suitable  for  use  in  a  library  screening  as  no 
activation of the reporter genes was observed: as shown by both Figures 3.3 and 3.4 (A-
E panels), no HIS3, ADE2 or LacZ activity was observed. 
For comparison, a set of control vectors were separately co-transformed: the pBD-WT 
control plasmid expresses the BD of GAL4 and amino acids (aa) 132–236 of wild type 
lambda cI, fragment C. The pAD-WT control plasmid expresses the AD of GAL4 and aa 
132–236 of  wild  type  lambda cI,  fragment  C.  (The  lambda cI  gene product  (cI-wt) 
naturally  forms  homodimers).  The  pAD-MUT  control  plasmid  expresses  the  AD  of 
GAL4 and aa 132–236 of E233K mutant lambda cI, fragment C. The pBD-MUT control 
plasmid  expresses  the  BD  of  GAL4  and  aa  132–236  of  E233K  mutant  lambda  cI, 
fragment C. The cI-E233K  mutation encodes a substitution  in  the  gene product that 
interferes with the interaction between the homodimers, resulting in a weaker protein–
protein interaction (from HybriZAP-2.1 Two-Hybrid Libraries, manual #838401-13). 
The combination pAD-WT + pBD-WT gives a bright blue colour on assays #2 and #3, a 
sign for strong interaction; the combination pAD-MUT + pBD-MUT gives a pale blue 
colour on assays #2 and #3, for a weak interaction; the combination pAD-WT + pBD-
pLC  does  not  show  any  colour,  a  sign  of  no  interaction  (Figure  3.4,  panels  F-H 
respectively). Hence, it is possible to compare the panels A-E for the auto-activation, to 
panel  H  (corresponding  to pAD-WT  +  pBD-pLC),  indicating no  activation of  LacZ 
reporter gene. 
 
3.3.2  Bait Toxicity Assay 
The toxicity of pBD-F1, pBD-F2, pBD-F3 and pBD-F4 was analysed by transforming 
PJ69-4A MATa yeast strain with the four bait constructs. The bait growth was compared 
to the empty vector pBD-GAL4-Cam-DEST as described in section 2.10.2 (Figure 3.5). 
Colonies per quarter section of plate were counted, and estimated for a full 15cm plate 
(Table 3.1); they were, approximately: 
 
Table 3.1. Number of colonies estimated for a 15cm plate. 
  PBD-GAL4-CAM-DEST  PBD-F1  PBD-F2  PBD-F3  PBD-F4 
COLONIES  3036  2972  3264  1136  1648     3. Identification of Interactants of PRPF31 
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Figure 3.5. Bait toxicity assay. 
A-E panels represent snapshots of plates of yeast colonies growing on SD-W medium. A: pBD-GAL4-
Cam-DEST. B: BD-F1. C: BD-F2. D: BD-F3. E: BD-F4. 
     3. Identification of Interactants of PRPF31 
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From the number of colonies, it was observed that pBD-GAL4-Cam-DEST and F1 and 
F2 transformants are similar (panels A, B and C respectively); on the other hand, F3 and 
F4 show less than half the colonies of the pBD-GAL4-Cam-DEST transformant, which 
could be due to a slight toxicity of the recombinant protein to the yeast cell. To the eye, 
the growth and the dimensions of the colonies were comparable for all of them, except 
for F3, which showed slightly larger colonies. Smaller number of colonies in the F3 and 
F4 baits could be due to less number of cells plated after the transformation than that of 
the pBD-GAL4-Cam-DEST, hence explaining the lower number of colonies. 
Nevertheless, as all the baits looked generally healthy compared to the control, each was 
considered suitable to be used in a yeast two-hybrid screening. 
 
3.3.3  Bait Expression 
The  expression  of  the  recombinant  baits  was  assessed  by  western  blot  analysis,  as 
described  in section 2.10.3. Figure 3.6 shows the bands corresponding to the fusion 
proteins,  expressed  in  PJ69-4A  MATa.  The  anti-GAL4  DNA-BD  antibody  (used  to 
detect the bait fusion proteins) revealed two bands corresponding to bait BD-F1 and the 
BD  alone  (in panel  A,  lanes  pBD-F1  and pBD-GAL4-Cam-DEST  respectively).  On 
closer inspection of the blot, the remaining three baits also presented a weak band each 
(indicated by a red arrow in panel A). The presence of bait BD-F4 was confirmed also 
with the anti-PRPF31484-497 antibody (detecting the C-terminal of the prpf31 protein): its 
corresponding band is indicated by the red arrow, lying below the 75kDa as expected. 
Considering the band corresponding to BD-F4 (full PRPF31 protein) in panel B is very 
strong, and the one in panel A is not, it may be that the anti-GAL4 DNA-BD antibody 
does not bind  as efficiently  as  anti-PRPF31484-497  antibody.  The  epitope of  the  anti-
GAL4 antibody might be masked in the F2, F3 and F4 fragments. 
Although some baits did not show a high level of expression, they were nonetheless used 
to screen the libraries, as this characterisation could not take place at the same time of 
the library screening (due to facilities and knowledge for the yeast two-hybrid method 
not in-house). Based on the western blot data, BD-F1 was considered a high quality bait, 
as  it  was  expressed  and easily  detected on  western  blot;  baits  F2,  F3  and  F4  were 
considered less suitable/desirable  than  F1, since their level of expression  was lower.     3. Identification of Interactants of PRPF31 
 
  95 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6. Expression analysis of PRPF31 baits. 
In A: yeast protein extracts of PJ69-4A strain (lane -), of yeast expressing pBD-F1, pBD-F2, pBD-F3, 
pBD-F4, pBD-GAL4-Cam-DEST (as labelled on bottom of each lane). Extracts were probed using anti-
GAL4 DNA-BD antibody, which revealed bands at ~35-37kDa for BD-F1, and at ~17kDa for BD domain 
(pBD-GAL4-Cam-DEST lane). The comparison between lanes for pBD-F2, pBD-F3, pBD-F4 with the 
negative control (lane -) revealed weak bands at a molecular weight corresponding to BD-F2, BD-F3, BD-
F4 (red arrows). 
In B, yeast protein extracts of PJ69-4A strain (lane -) and of yeast expressing pBD-F4 probed with anti-
PRPF31484-497 antibody: the antibody revealed a band lower than 75kDa, evidencing for expression of 
PRPF31. 
     3. Identification of Interactants of PRPF31 
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The low level of expression may be explained either by low abundance of the constructs 
within the yeast; or the hybrid protein is rapidly degraded although not toxic (see section 
3.2.2). However, since a band was detected for each bait, they were considered adequate 
for the screening. 
 
3.4  Yeast Library Mating and Co-transformation 
A bovine retina cDNA library and a human retina cDNA library were screened with the 
four bait constructs. Both libraries were pre-transformed into the PJ69-4A MATα yeast 
strain. The mating consisted of combining yeast cells of opposite mating types (a and α), 
one type carrying one of the bait vectors, the other one carrying the library; this step was 
carried out  as described  in section 2.10.4. The mating efficiency was calculated  and 
summarised in the following Table 3.2: 
 
Table 3.2. Summary of mating efficiencies per bait and per library. 
  BD-F1  BD-F2  BD-F3  BD-F4 
HUMAN 
LIBRARY  2.8%  2.7%  0.5%  1.3% 
BOVINE 
LIBRARY  4.2%  4.1%  2.6%  2.8% 
 
It appeared that the mating efficiency for the human library was lower compared to the 
bovine library; also, in both screenings, the efficiencies of baits F1 and F2 were higher, 
suggesting that perhaps the yeast cells harbouring these baits were more suitable than F3 
and F4, which instead gave a low mating efficiency in both libraries. However, as the 
initial number of library cells used for the mating was 4 x 10
8, even a 0.5% mating 
efficiency allowed to screen  more than a million clones (~2 x 10
6 clones precisely). 
After the mating procedure, the total number of colonies positive for the three reporter 
genes was 68 for the bovine library and 48 for the human library (assays described in 
section  2.10.7).  The  above  steps  were  carried  out  by  Dr.  Maubaret,  and  from  here 
onwards I took over the project. 
     3. Identification of Interactants of PRPF31 
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As different unrelated multicopy plasmids can be present in the same yeast cell, the prey 
plasmids were isolated from yeast (as described in section 2.10.5) and used to transform 
E.coli (section 2.9.7.3). Yeast prey vector was isolated from each bacterial colony which 
was  then  used  for  co-transformation  with  the  appropriate  bait  (described  in  the  last 
paragraph of section 2.10.1). This was done to determine which of the several plasmids, 
if more than one per yeast cell, triggered the reporter genes. 
Makarova and co-workers (2002) have previously shown interaction between PRPF6 
and  PRPF31  by  yeast  two-hybrid,  so  we  cloned  the  full  length  sequence  of  human 
PRPF6  into  pAD-GAL4-Amp-DEST  and  included  it  in  the  co-transformation 
experiment  as  a  positive  control.  Control  vectors  were  co-transformed  alongside  to 
check for reporter genes activation. Figure 3.7A shows the expression of the AD-PRPF6 
protein: the anti-GAL4-AD antibody reacted with a band between 100 and 150 kDa 
believed to be the recombinant protein (indicated by a green arrow), as the same band 
was  not  visible  on  the  yeast  strain  lysate  nor on  the  yeast  expressing  only  the  AD 
domain  (indicated  by  a  red  arrow).  Figure  3.7B  shows  the -galactosidase  assay  of 
PRPF6 with the four baits, to be compared with the controls in Figure 3.4. As can be 
seen in the figure, the interaction of PRPF6 with fragment F1, F2 and F3 of PRPF31 did 
not  give  any  blue  colour  (panels  A-C),  however  full  length  PRPF31  gave  a  weak 
interaction (D). The presence of mutations in the commercially bought clone of PRPF6 
was excluded, since the entire cDNA was sequenced, using the primers listed in Table 
2.12. 
 
3.5  Sequence Analysis of Positive Clones  
After  the  co-transformation  step,  the number  of  putative  interactants positive  on  the 
three assays was reduced to 11 for the bovine library. All the remaining clones from the 
bovine library and all the clones isolated from the human library appeared to be false 
positives: they did not show either growth on selective medium or colour development 
on the assays, therefore they were not included for further analysis. At this stage, the 
verification of the 11 bovine clones was done by sequencing (as described in section 
2.9.5; primers pAD_BRP F and pAD_BRP R in Table 2.11, section 2.9.7.1). Sequencing  
     3. Identification of Interactants of PRPF31 
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Figure 3.7. Expression of AD-PRPF6 (A) and -galactosidase assay of AD-PRPF6 (B). 
Figure A shows the expression of AD-PRPF6 prey (indicated by green arrow) upon incubation with the 
anti-GAL4-AD antibody; the figure shows also the blot of yeast protein extracts of PJ69-4A strain (lane -) 
and  of  pAD-GAL4-Amp-DEST  (AD  domain  is  indicated  by  red  arrow).  Figure  B  shows  the  -
galactosidase assay between pAD-PRPF6 and pBD-F1, pBD-F2, pBD-F3, pBD-F4 (panels A, B, C, D 
respectively).      3. Identification of Interactants of PRPF31 
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was required to check if the prey cDNA, cloned in the prey vector (pAD-GAL4-Amp-
DEST), was in frame with the AD domain, such that the expression of a recombinant 
protein corresponding to the clone was possible. 
The  identification  of  the  cDNA  sequence  was  possible  by  searching  the  vector 
sequence  for  GAA  TTC  GGC  ACG  AGN,  in  which  the  EcoRI  restriction  site 
(GAATTC)  defined the  reading of the frame. Six  clones out of  11 from  the bovine 
library  appeared  to be  in  frame  and thus  were then  considered  for  further  analyses; 
instead  the  remaining  five  were  considered  artifactual  as  not  leading  to  protein 
expression and  thus  rejected. The six clones  were  fully  sequenced (primers listed in 
Table 2.15 of section 2.10.7), of which three showed early stop codons leading to the 
production of truncated proteins (20-40 aa long). Nonetheless they were also considered 
as  it is known  that yeast  tolerates  translational frameshift, skipping stop codons  and 
continuing the translation (Matchmaker Pretransformed Libraries User Manual PT3183-
1, published 5 February 2007). The clones were analysed performing BLASTn searches: 
one corresponded to the MAGI3 protein, four clones corresponded to TRAK2 (three of 
which were those leading to a truncated protein), and one to ZNF143. The remaining 
five clones were not considered for further analysis, as the cloned sequence was not in 
frame with the AD domain sequence, therefore not leading to the translation of a known 
protein. Considering that the number of isolated clones was little (six only) and that four 
out of six corresponded  to the  same protein species, the criteria  for  the selection of 
clones  listed  in  section  2.10.8  was  not  applied.  We  instead  continued  with  the 
investigation of the putative candidates, even though not retina-specific, as they may 
shed new light into PRPF31 protein network, which may be basis for further speculation 
of RP in the future. 
 
3.6  Putative Positive Interactants 
The yeast two-hybrid method resulted in the identification of three potential interactants 
of PRPF31 and they will be described in the following sections. The corresponding prey 
constructs  were  tested  for  auto-activation  in  PJ69-4A  MATα  (following  the  same 
procedure used for PRPF31 baits, described in section 3.3.1): each hybrid protein did not 
activate the transcription of the reporter genes.     3. Identification of Interactants of PRPF31 
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3.6.1  Membrane-associated Guanylate Kinase, WW and PDZ Domain-containing 
Protein 3, MAGI3 (clone 3.9) 
A 1646bp cDNA fragment (clone 3.9) encoding a protein sequence similar to human 
MAGI3,  variant  Q5TCQ9-4  (Swiss-Prot)  was  found  to  interact  with  bait  F3.  The 
translated sequence of clone 3.9 corresponds to residues 127-678 of Q5TCQ9-4 (which 
is 1481 amino acids long), and this fragment encompasses the guanylate kinase domain, 
WW domains, and PDZ-1 and PDZ-2 domains. Figure 3.8A shows the -galactosidase 
assay, with development of pale blue colour. It is possible that this interaction was weak, 
however, the positive control with PRPF6 also showed for weak interaction. Figure 3.8B 
illustrates  the  alignment  between  clone  3.9,  the  bovine  protein 
(ENSBTAP00000026128) and the human protein Q5TCQ9-4 (Clustal W method). 
MAGI3  belongs  to  a  family  of  scaffolding  proteins  named  MAGUKs,  for 
membrane-associated guanylate kinases. 
Cell polarisation is essential for selective and asymmetrical transport of substrates: thus, 
in epithelial cells, apical and basolateral membrane compartments are separated by tight 
junctions,  which  form  beneath  the  most  apical  part  of  the  lateral  membrane.  Tight 
junctions provide a physical barrier yet allowing permeability, and contribute to cell-cell 
adhesion. 
Scaffolding proteins are involved in cellular adhesion organising and anchoring protein 
complexes  at  cell-cell  contact  sites,  contributing  to  tissue  development  and 
differentiation.  They  organise  macromolecular  protein  complexes,  tether  receptors, 
intracellular signalling enzymes and adhesion molecules. 
Previous studies by various groups have identified MAGUKs as ubiquitous scaffolding 
proteins concentrated at cell-cell contacts. MAGUKs are characterised by a guanylate 
kinase (GK) domain of ~300 amino acids, catalytically inactive. Other features include 
an SH3 domain, usually upstream of the GK domain, or a WW domain following the 
GK domain, and also PDZ domains. MAGIs are MAGUK proteins with an inverted 
arrangement of protein-protein interaction domains (GK domain is N-terminal, and the 
PDZ domains are C-terminal). Three MAGIs  have been identified  to date,  (MAGI1, 
MAGI2, MAGI3),  and all contain  an  N-terminal GK domain followed by two WW     3. Identification of Interactants of PRPF31 
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Figure 3.8. Clone 3.9 interacts with BD-F3. 
A: -galactosidase assay after co-transformation of PJ69-4A MATα with clone 3.9 and bait BD-F3; the 
three panels on the right represent the controls. 
B:  alignment  of  the  amino  acid  sequences  of  clone  3.9  cDNA  (detected  as  BD-F3  interactant),  the 
predicted bovine and the human MAGI3 sequences. In light grey residues that match Q5TCQ9-4 exactly, 
in solid black residues that differ from Q5TCQ9-4. 
     3. Identification of Interactants of PRPF31 
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domains and six PDZ domains (Figure 3.9). WW domains are functionally similar to 
SH3  domains  (they  both  bind  to  proline-rich  regions),  perhaps  explaining  the 
substitution (as reviewed by Funke et al., 2005). 
MAGI3 was first identified (Wu et al., 2000) through a yeast two-hybrid screening in 
search  for  interacting  partners  of  PTEN/MAC,  a  phosphatase  which  quenches  PKB 
activity,  the  latter  implicated  in  the  inhibition  of  apoptosis;  MAGI3  interacts  with 
PTEN/MAC through the PDZ-2 domain. Wu and colleagues documented that MAGI3 is 
expressed in various foetal and adult tissues, such as brain, liver and lung. 
Later  it  was  discovered  that  another  phosphatase,  RPTP  (receptor  protein  tyrosine 
phosphatase ) interacts with rat MAGI3, through its PDZ-3 or PDZ-4 (Adamsky et al., 
2003): RPTP is implicated in cell-cell and cell-matrix interactions, and in cell adhesion 
and migration; however, MAGI3 was not found to be tyrosine-phosphorylated. 
Adamsky and colleagues performed western blot analysis on rat cell and tissue samples, 
revealing a major band at 140 kDa, and two minor bands at 170 kDa and 130 kDa, 
suggesting that MAGI3 has multiple isoforms. In epithelial cells, MAGI3 co-localises 
with ZO-1 (Wu et al., 2000) and cingulin to tight junctions, and it partially overlaps with 
-catenin  and  desmoplakin  (proteins  found  in  adherens  junctions  and  desmosoms 
respectively;  Adamsky  et  al.,  2003).  Adamsky  and  colleagues  also  showed  that  in 
transfected MDCK cells, MAGI3 was found at cell-cell contacts, with a strong punctate 
nuclear staining, and a weakly labelled cytoplasm.  In rat primary astrocytes, MAGI3 
was  localised to  the nucleus  and at  adherens junctions and cellular protrusions with 
-catenin.  The  authors concluded that  MAGI3  is found  in the cell nucleus  (MAGI3 
contains two putative nuclear localisation signals) and in specific structures along the 
plasma membrane, and, according to cell type and culture conditions, it could be present 
in tight and adherens junctions, cellular protrusions and focal adhesion sites (Adamsky 
et al., 2003). 
Other interacting partners of MAGI3 include: the oncogenic HPV E6 protein (with the 
PDZ-1 domain of MAGI3), which targets MAGI3  (and  MAGIs 1  and 2 as well) to 
degradation (Thomas et al., 2002); the terminus of the ATEV motif (with PDZ-4) found 
in Delta proteins (interacting also with MAGI1 and MAGI2; Wright et al., 2004); the 
cytoplasmic region of proTGFα (transforming growth factor-α precursor; with PDZ-1;     3. Identification of Interactants of PRPF31 
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Figure 3.9. Domain structure of the MAGI family of proteins. (Image taken from Wright et al., 2004).     3. Identification of Interactants of PRPF31 
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Franklin et al., 2005); the C-terminal region of 1-Adrenergic Receptor (with PDZ-1), a 
G protein-coupled receptor (1AR; He et al., 2006); and the G protein-coupled receptor 
LPA2  (which  mediates signaling  by  lysophospahtidic  acids;  with PDZ-5),  and  when 
MAGI3 was over-expressed, a clear increase in RhoA activation was observed (Zhang et 
al., 2007). 
 
3.6.2  Zinc Finger Protein 143, ZNF143 (clone 3.10) 
A 1960bp cDNA fragment (clone 3.10) encoding a protein sequence similar to human 
ZNF143, P52747 (Swiss-Prot), was detected with bait F3. The translated sequence of 
clone 3.10 matches the complete sequence of P52747 (626 amino acids). According to 
Pfam, the protein contains seven central Zn finger (zf_C2H2) domains. 
Figure 3.10A shows the -galactosidase assay: also in this case, as the colour is a pale 
blue, the interaction between BD-F3 and clone 3.10 was a weak one, in accordance with 
the α-galactosidase assay, which was comparable to the control for weak interaction. 
Figure  3.10B  shows  the  alignment  between  clone  3.10,  the  bovine  protein 
(ENSBTAP0000001394) and the human protein P52747 (Clustal W method). 
ZNF143  encodes  a  zinc  finger  protein  that  is  expressed  in  all  normal  adult  tissues. 
ZNF143,  or  hStaf,  is  the  human  ortholog  of  Xenopus  laevis  Staf  (sharing  84%  of 
identity) and it is a seven-zinc finger transcription factor of 638 amino acids, and the 
zinc finger domains are repeated in tandem. Staf was originally identified in X.laevis as 
a  transcription  factor,  involved  in  the  transcriptional  activation  of  snRNA  and  
snRNA-type genes transcribed by RNA polymerase II and III. It was reported to target 
several  human  snRNA  genes  (U2,  U4,  U6,  U11  and  others)  for  transcription.  As 
Myslinski  and  co-workers  (1998)  identified  the  human  ZNF143  to  be  functionally 
equivalent to Xenopus Staf, it appears that the transcriptional activation of these genes 
relies on ZNF143. 
Recently, it was reported a region on the human U6 snRNA promoter is able to recruit 
the ZNF143 (Yuan et al., 2007): the authors showed that ZNF143 activates transcription 
from  a  U6  gene  template  assembled  into  chromatin  and  identified  CHD8  as  a 
ZNF143-associated protein required for efficient U6 transcription in vivo.     3. Identification of Interactants of PRPF31 
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Figure 3.10. Clone 3.10 interacts with BD-F3. 
A: -galactosidase assay after co-transformation of PJ69-4A MATα with clone 3.10 and bait BD-F3; the 
three panels on the right represent the controls. 
B: alignment of the amino acid sequences of 3.10 cDNA detected as BD-F3 interactant, the predicted 
bovine and the human ZNF143 sequences. In solid light grey residues that match P52747 exactly, in solid 
black residues that differ from P52747.     3. Identification of Interactants of PRPF31 
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Also, ZNF143  regulates the transcription of genes  involved in  DNA repair  (through 
association  with  tumor  suppressor  p73;  Wakasugi  et  al.,  2007),  cell  survival  (TAL; 
Grossman et al., 2004), cell cycle (BUB1B; Myslinski et al., 2007), and mitochondrial 
transcription (TFAM; Gerard et al., 2007). 
 
3.6.3  Trafficking Kinesin-binding Protein 2, TRAK2 (clone 4.17) 
A 580bp cDNA fragment (clone 4.17) encoding a protein sequence similar to human 
TRAK2, O60296 (Swiss-Prot), interacted with bait F4. The translated sequence of the 
clone  corresponds  to  residues  107-299  of  O60296  (914  amino  acids).  According  to 
Pfam, this sequence shows a HAP1_N domain. 
Figure  3.11A  shows  the  -galactosidase  assay:  considering  the  vivid  blue  colour 
developed on the filter-lift assay, the interaction between clone 4.17 and BD-F4 was 
strong – confirmed by the α-galactosidase assay, comparable to the control for strong 
interaction  (not  shown).  Figure 3.11B  shows  the  alignment between clone  4.17,  the 
bovine protein  (ENSBTAP00000019878) and the human protein  O60296 (Clustal W 
method). 
The rat orthologue GRIF1 was firstly isolated from rat brain through a yeast two-hybrid 
screening,  and  was  among  the  partners  interacting  with  the  intracellular  loop of  the 
GABAA  2  subunit.  The  screen  took  place  in  order  to  identify  the  proteins  which 
influence the receptor localisation, which shows different localisations according to its 
subunit composition. GRIF1 is highly expressed in excitable tissues, mostly brain and 
heart.  The  protein  contains  a  coiled-coil  region  (HAPN)  homologous  to  HAP1A, 
HAP1B; GRIF1 also contains a weak leucine zipper motif. The expression of GRIF1 in 
HEK293  cells  revealed  a  punctate,  plasma  membrane  localisation,  along  with 
cytoplasmic localisation (Beck et al., 2002). 
The human GRIF1, also called TRAK2 or OIP98, is a 98 kDa protein, and was found 
both  an  interactor  and  a  substrate  of  OGT,  which  is  responsible  for  the  O-GlcNAc 
(acetylglucosamine) post-translational modification (OGT transfers the saccharide to the 
proteins;  Iyer  et  al.,  2003):  in  fact  TRAK2  is  modified  by  GlcNAc.  Brickley  and  
co-workers  (2005)  proposed  a  role  for  TRAK2  in  membrane  trafficking  of  vesicles 
and/or organelles, via motor proteins, demonstrating that TRAK2 interacts with kinesin.      3. Identification of Interactants of PRPF31 
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Figure 3.11. Clone 4.17 interacts with BD-F4. 
A: -galactosidase assay after co-transformation of PJ69-4A MATα with clone 4.17 and BD-F4; the three 
panels on the right represent the controls. 
B: alignment of the amino acid sequences of 4.17 cDNA detected as BD-F4 interactant, the predicted 
bovine and the human TRAK2 sequences. In solid light grey residues that match O60296 exactly, in solid 
black residues that differ from O60296.     3. Identification of Interactants of PRPF31 
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Further experiments reinforce the hypothesis of TRAK2 being involved in trafficking: 
TRAK2 interacts with K
+ channel Kir2.1, facilitating its trafficking to the cells surface 
(Grishin  et  al.,  2006).  GRIF1  also  interacts  with  Hrs,  and  may  regulate  endosomal 
trafficking since Hrs is a component of the endosome-to-lysosome trafficking (Kirk et 
al., 2006). 
Given these experimental data, TRAK2 was proposed as an adaptor protein involved in 
motor-dependent trafficking of proteins to synapses (Brickley et al., 2005). 
As TRAK2 displays  a HAPN domain, it is of  interest describing the HAP1 protein. 
HAP1  (huntingtin-associated  protein  1)  is  expressed  primarily  in  neurons,  it  is  a 
cytoplasmic protein with no transmembrane domains or nuclear localisation signals; it 
contains several coiled-coil domains, which may regulate or mediate its interaction with 
a  number  of  proteins.  Scientific  evidence  supports  the  hypothesis  of  HAP1  being 
involved in intracellular trafficking and as a scaffold protein in the assembly of protein 
complexes: in fact, it interacts with a subunit (p150
Glued) of dynactin (a component of the 
dynein motor complex), and also interacts with kinesin light chain 2 (KLC2 – a subunit 
of  kinesin  motor),  suggesting  that  HAP1  is  involved  in  both  the  retrograde  and 
anterograde  transport  respectively.  Moreover,  HAP1  interacts  with  Hrs,  involved  in 
endosome-to-lysosome  trafficking,  and  it  also  interacts  with  GABAA  receptor, 
modulating  the  inhibitory  synaptic  transmission.  Still,  it  is  not  clear  how  HAP1 
participates  in  those  diverse  processes:  it  may  act  as  a  scaffold  to  stabilise  protein 
complexes  for  trafficking,  or  it  could  also  be  an  adaptor  to  link  microtubules  with 
different cargoes (as reviewed by Rong et al., 2007). 
The Drosophila orthologue of GRIF1 protein is Milton, which is responsible for the 
transport of mitochondria in the drosophila retina (Stowers et al., 2002). There is also 
evidence that Drosophila photoreceptors lacking Milton, fail to target mitochondria to 
their terminals, remaining abundant and present throughout the soma (Gorska-Andrzejak 
et al., 2003). 
TRAK2, together with its homologous TRAK1 (or OIP106), define a new family of 
kinesin-associated  coiled-coil  proteins,  proposed  to  function  as  adaptors  in  the 
anterograde trafficking of organelles to synapses. It is also interesting to note that  
     3. Identification of Interactants of PRPF31 
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TRAK1 localises to distinct punctate regions in the nucleus, and co-localises with RNA 
polymerase II in vivo (Iyer et al., 2003). 
Clones 4.6, 4.12, 4.31 also correspond to TRAK2, but showed early stop codons after 
the EcoRI site, producing 20-40 amino acid long peptides. It has been reported that yeast 
is capable of skipping stop codons (Matchmaker Pretransformed Libraries User Manual 
PT3183-1, published 5 February 2007), and continuing the translation process. These 
clones were not characterised further but were taken as a further confirmation of TRAK2 
as an interactant of PRPF31. 
 
 
3.7  Expression Profiles on Interactants 
The MAGI3, TRAK2, and ZNF143 genes are ubiquitously expressed, according to their 
UniGene  expression  profiles.  However,  the  proteins  were  identified  as  PRPF31 
interactants from a bovine library. In order to make sure they are all present in human 
retina, the three transcripts were amplified by RT-PCR from human retina cDNA (total 
RNA from Clontech). Along with retina, other human tissues were tested: brain, heart, 
liver,  lung,  pancreas,  placenta  and  skeletal  muscle.  Oligonucleotides  (Table  A.1  in 
appendix)  were  designed  to  amplify  a  region  spanning  two  adjacent  exons  (MAGI3 
exons  17-18,  TRAK2  exons  11-12,  ZNF143  exons  4-5),  using  Biotaq  polymerase. 
Results are shown in Figure 3.12, indicating that all three genes are expressed in the 
human retina, since bands of the expected sizes were amplified (264 bp for MAGI3, 247 
bp for TRAK2, 157 bp for ZNF143). Genomic DNA was also included in the reaction, 
and its amplification showed a band for each gene at a higher molecular weight due to 
inclusion  of  one  intron  separating  the  amplified  exons  (expected  sizes  for  genomic 
DNA: 844 bp, 544 bp, 682 bp, for MAGI3, TRAK2, ZNF143 respectively). 
The RT-PCR amplification also showed that each gene is expressed in other tissues, and 
with the abundance in retina comparable to the rest of the tested tissues. I would point 
out that this result is only indicative, as no quantification was performed.     3. Identification of Interactants of PRPF31 
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Figure 3.12. Expression profiles of interacting partners. 
cDNA types are specified on top of panel A and refer to panels B and C. “-“ lanes for negative control. 
For each gene, the cDNA lanes show a band of the size of the predicted transcript fragment. 
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3.8  Co-transformation of Human Wild Type Sequences 
To further validate the positive interactions, the human wild type cDNA corresponding 
to each of the isolated clones was used in a co-transformation step. Full length MAGI3, 
TRAK2, and ZNF143 cDNAs were cloned into pBD-GAL4-Cam-DEST as described in 
section  2.9.7.1,  to  generate  BD-fused  proteins.  For  the  generation  of  the  wild  type 
MAGI3 sequence (corresponding to isoform MAGI3-004, Ensembl database), refer to 
section 2.9.7.2  and the following section 3.8.1. Full  length  PRPF31  was cloned into 
pAD-GAL4-Amp-DEST, using the gateway cloning system. 
The bait constructs were transformed in PJ69-4A MATα to verify they did not activate 
the reporter genes: the selective medium assay is shown in Figure 3.13A, and as no 
colonies were observed, the baits were considered suitable for the further experiments. 
Figure  3.13  B  shows  the  expression  of  baits  and  prey  in  yeast:  pBD-MAGI3  and 
pBD-TRAK2 (green and yellow arrows respectively) were not as expressed as pBD-
ZNF143 (blue arrow); incubation with the anti-GAL4-AD antibody showed a band at 
~75 kDa compatible with AD-PRPF31 (red arrow). As the expression was confirmed by 
the western blot, we decided to proceed with the experiments. 
Each new bait construct was co-transformed in PJ69-4A MATα with the pAD vector 
expressing PRPF31. Selective medium assay and α-galactosidase assay were positive for 
each combination (not shown). However, as shown in Figure 3.14, the -galactosidase 
assay confirmed the interactions previously observed between PRPF31 and MAGI3, and 
PRPF31 and TRAK2 (panels A and B respectively, showing a vivid blue colouration), 
whereas PRPF31 and ZNF143 interaction was weak. 
As  the  experiment  described  above  partially  supported  the  outcome  of  the  original 
screening (confirming the interaction with PRPF31 of two out of three partners), it was 
decided to continue the characterisation of those showing a strong interaction (MAGI3 
and  TRAK2).  However,  the  fact  that  in  this  experiment  ZNF143  failed  to  interact 
strongly with PRPF31 does not exclude it as a partner: in fact, it is possible that the 
DNA-BD tag affects ZNF143, for example by changing its folding, thus preventing a 
strong contact with PRPF31.     3. Identification of Interactants of PRPF31 
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Figure 3.13. Selective medium assay for human baits (A) and expression of new baits and prey (B). 
In A, selective medium assay for pBD-MAGI3 (panel A), pBD-TRAK2 (panel B), pBD-ZNF143 (panel 
C): no growth was observed after streaking a colony of yeast bearing the respective construct. Panel D 
illustrates a healthily growing patch of yeast. 
In  B,  expression  of  BD-MAGI3,  BD-TRAK2  and  BD-ZNF143  (green,  yellow  and  blue  arrows 
respectively; left-hand  sided  blots)  and  AD-PRPF31  (red arrow,  right-hand  side blot).  BD  domain  is 
indicated by the purple arrow; AD domain is indicated by a pink arrow. 
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Figure 3.14. Co-transformation -galactosidase assay. 
pAD-F4 + (A) pBD-MAGI3, (B) pBD-TRAK2, (C) pBD-ZNF143. The comparison between these panels 
and the three panels on the right for control plasmids suggests a strong interaction for both MAGI3 and 
TRAK2 with PRPF31, whereas ZNF143 represents a weaker interaction.     3. Identification of Interactants of PRPF31 
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3.8.1  Generation of Human Wild Type MAGI3, MAGI3-004 Isoform 
As described in section 2.9.7.2 of the cloning procedures, SPLICE approach was used to 
generate the full coding sequence of MAGI3. According to the alignment of the bovine 
sequences  of  MAGI3  (prey  and  database  sequences),  it  was  decided  to  amplify 
MAGI3-004  (transcript  ENST00000307546  in  Ensembl;  Q5TCQ9-4  protein  in  
Swiss-Prot), from human retinal cDNA. 
Figure 3.15A and 3.15B show the bands corresponding to exons 1, 2-7 and exons 8-13, 
14-20, 21  respectively,  after  the  first  round of  PCR;  Figure 3.15C shows  the bands 
corresponding to exons 1-13 and 14-21, after the second round of PCR, and finally, 
Figure 3.15D shows the band corresponding to the full length sequence. The last was 
verified by sequencing (primers listed in Tables 2.13 and 2.14, Chapter 2). The final 
sequence was then used to generate BD-MAGI3 and V5-MAGI3 constructs as described 
in section 2.9.7.1. 
Oligonucleotides (Table 2.12) were designed for the MAGI3 transcript sequence (~4.5 
kb)  which  generates  protein  Q5TCQ9-4;  each  oligonucleotide  had  15  nucleotides 
overhangs  at  the  5’  and  3’  ends,  pairing  the  upstream  and  downstream  exons,  and 
designed to amplify portions of cDNA of ~1 kb each. KOD Hot Start polymerase was 
used for the purposes of this experiment. 
Exons 1, 2-7, 8-13, 14-20 and 21 were amplified using the following thermocycling 
settings: 40 cycles, 22 sec of elongation (Figure 3.15 A and B). The amplicons were gel-
purified,  mixed  in  an  equal  molar  ratio  and  two  greater  fragments  were  amplified 
(corresponding  to exons 1-13 and  exons 14-21; Figure 3.15 C),  using the following 
conditions:  8  initial  cycles,  50  seconds  of  elongation,  without  addition  of 
oligonucleotides (the products have base-pairing sequences); secondly, 32 cycles, 50 
seconds of elongation with the addition of the flanking primers. As the PCR resulted in 
several amplification products, the fragments for exons 1-13 and 14-21 were identified 
in the gel according to their size (expected to be 2353 bp and 2277 respectively); they 
were purified and mixed in equal molar ratio, and then underwent a third round of PCR 
to amplify the whole 4.5 kb transcript, using conditions as stated before (8 + 32 cycles), 
but with longer elongation time (92 seconds). 
     3. Identification of Interactants of PRPF31 
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Figure 3.15. Generation of human wild type MAGI3 using the SPLICE method. 
In A, amplification of exon 1 (lane 1), exons 2-7 (lane 2). In B, amplification of exons 8-13 (lane 3), exons 
14-20 (lane 4), exon 21 (lane 5). In C, amplification of exons 1-13 (lane 6, red arrow), exons 14-21 (lane 
7, red arrow). In D, amplification of exons 1-21 (lane 8, red arrow). L is for ladder, - is for negative 
control.     3. Identification of Interactants of PRPF31 
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The amplicon (Figure 3.15 D) corresponding to the expected size was gel-extracted and 
purified,  recombined  in  pDONR/Zeo  and  fully  sequenced  to  ensure  the  accuracy 
(oligonucleotides  for  sequencing  listed  in  Table  2.13,  Chapter  2).  The  full  length 
sequence was then recombined in pBD-GAL4-Cam-DEST vector. 
 
3.9  Amplification of PRPF6 from Bovine and Human Libraries 
As PRPF6 is known to interact with PRPF31 (see section 1.6 of the Introduction), it was 
expected  to be  among  the positive  interacting  partners  from  the  library  screens.  As 
described in the previous paragraph 3.6, PRPF6 does not appear among the positive 
interactants. Hence, we decided to amplify it from the retina libraries used for the yeast 
two-hybrid.  Plasmid  DNA  aliquots  of  the  libraries  were  kindly  donated  to  us  from  
Dr R. Roepman. The concentration of the human library aliquot was 150ng/µl, whereas 
the bovine was 4.5ng/µl. One microliter of the human library was sufficient to transform 
AG1  cells  for  amplification,  whereas  10µl  of  the  bovine  library  was  used  for  the 
transformation in the same  E.coli strain. Transformed cells  were plated onto  several 
plates and the following day all the colonies were collected into 5 ml, of which 2.5 ml 
was used to inoculate a 250 ml culture, for subsequent DNA extraction. The amplified 
library  was  then  used  for  a  PCR,  using  three  different  pairs  of  PRPF6  primers  (to 
amplify two adjacent exons, listed in Table A.2 in Appendix), using an equal amount of 
template  DNA  from  each  library,  and  applying  identical  thermocycling  conditions. 
Figure 3.16 shows the amplification  of  PRPF6 in both  libraries:  panel A  shows  the 
results for the human library where lanes 1-3 show the expected fragments (sizes 415 bp, 
582 bp, 622 bp respectively); panel B represents the bovine library, and only lanes 1 and 
3  show  a  weak  band  each,  of  the  expected  size  (415  bp  and  622  respectively,  red 
arrows). 
Several reasons may explain the different levels of amplification of PRPF6 in the two 
libraries: firstly, the process of amplification is likely to have affected the presence of 
the various transcripts constituting the libraries; secondly, the human library might be 
more abundant in PRPF6 transcript than the bovine one. The reason why PRPF6 was not 
picked up among the partners in both screenings may be: 1) the human library screening 
failed  for  some  reasons,  not  allowing  PRPF6  to  be  detected  together  with  other     3. Identification of Interactants of PRPF31 
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Figure 3.16. PRPF6 amplification on retina libraries. 
In A, the human library: lanes 1, 2 and 3 show amplicons at the expected molecular weight. 
In  B,  the  bovine  library:  only  lanes  1  and  3  showed  the  expected  bands,  whereas  no  fragment  was 
detectable on lane 2. L is for ladder, - is for negative control.     3. Identification of Interactants of PRPF31 
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interactants, and 2) regarding the bovine library screening which was successful, the 
interaction with PRPF31 could be weak and hence not detectable by the system used. On 
the other hand, it is to note that the primers used to amplify were designed on a human 
sequence,  hence  the  paucity  of  product  in  the  bovine  library  may  be  due  to  the 
oligonucleotides failing to anneal to the template. 
 
 
3.10  Conclusion 
From the analysis of the results presented in this chapter, only the bovine retina library 
screen was successful in identifying interacting partners for PRPF31. Despite the use of 
four different baits, the screen of the human library was not as successful and did not 
yield any positive interactants. Three novel partners of PRPF31 were isolated from the 
bovine library, corresponding to the following human proteins: TRAK2 (cytoplasmic 
protein  involved  in  trafficking),  MAGI3  (both  nuclear  and  cytoplasmic/junctional 
protein),  and  ZNF143  (a  zinc  finger,  nuclear  protein);  none  of  which  being  
retina-specific.  As  the  yeast  two-hybrid  system  allows  the  detection  of  direct 
interactions,  these partners  are  to be  considered  potential  direct  interactants.  Results 
from  co-transformation  experiments  using  human  MAGI3,  TRAK2  and  ZNF143 
sequences  alongside  PRPF31  (section  3.8),  indicated  the  former  were  both  strong 
interactors, whereas ZNF143 appeared to be quite weak. Therefore we selected MAGI3 
and  TRAK2  for  further  experiments  to  confirm  these  findings.  However, 
notwithstanding the co-transformation experiments (sections 3.4 and 3.8), performed to 
exclude  any  false  positives,  still  care  must  be  taken  when  considering  MAGI3  and 
TRAK2 as good candidates. In fact, both proteins MAGI3 and TRAK2 present domains 
which are protein-protein interaction platforms, hence it may be that they are “sticky” 
proteins that can be isolated in another, unrelated screen with a different bait other than 
PRPF31. The results need a cautious interpretation also because the clones were isolated 
either only once (MAGI3), or with apparent artifactual clones (TRAK2, clones 4.6, 4.12 
and 4.31, see section 3.6.3). Hence, the results presented in this chapter need further 
validations to test their genuinity as PRPF31 interactors, especially because, if they are 
genuine, they may be very interesting and suggestive.  
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4.  Confirmation of Novel PRPF31 Interactants, 
MAGI3 and TRAK2 
 
 
 
Having  identified  new  interacting  partners  of  PRPF31  through  the  yeast  two-hybrid 
system, a validation of these interactions with a different method is necessary. Though 
the isolated partners came from a retinal library but none appeared to be retina-specific, 
we still pursued the validation experiments as they may enrich the knowledge regarding 
network of interactions of PRPF31. We chose to co-immunoprecipitate the proteins to 
verify  the  interactions  illustrated  in  Chapter  3,  using  transfected  mammalian  cells 
expressing  the  proteins  of  interest.  We  followed  up  MAGI3  and  TRAK2  as  they 
appeared  to  be  the  strongest  interacting  partners  of  PRPF31  in  the  direct  yeast  
two-hybrid experiments, as demonstrated in section 3.8 of Chapter 3. 
 
 
Immunoprecipitation (IP) is a technique which allows the precipitation of an antigen 
(protein) using a specific antibody directed against the antigen. Thereby, the specific 
protein can be isolated from a mixture of many other proteins, simply by incubating the 
protein solution with the specific antibody. However, the antibody must be coupled to a 
solid substrate, commonly beads coated with immunoglobulin-binding protein, which 
binds the Fc region of an immunoglobulin (i.e. the tail region of an antibody). 
The term co-immunoprecipitation (co-IP) describes the application of the IP procedure 
to precipitate  protein complexes.  In  this case, the  antibody  of choice  will target  the 
desired protein, and the entire complex will be extracted from the solution, making it 
possible to identify the various components of the complex (Figure 4.1). For successful 
pull-down, the known protein must have the epitope exposed, and not masked by any 
other member of the complex.  Thus any  partner  binding on  the epitope will not be 
identified.                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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Figure 4.1. Illustration of a traditional co-immunoprecipitation. 
Panel A is a depiction of a protein mixture, combined together with beads coupled to antibodies, in a tube. 
Panel B represents the situation after a washing step: the final product bead+antibody+complex is cleared 
from the unbound proteins, and ready for SDS-PAGE and western blot as pictured in C.                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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For this study, the co-IP approach involved the over-expression of the desired proteins in 
the HEK293 cell line. We chose to over-express tagged proteins as antibodies directed 
against the tags are commercially available. These will also facilitate the pull down of 
the complex and its detection on western blot. However this method presents a drawback 
in  that  it  raises  the  likelihood  of  formation  of  inclusion  bodies,  in  which  case  the 
over-expressed  protein  aggregates  and  is  less  accessible.  Also,  the  over-expressed 
protein may interfere with the cellular pathway  in  which  the equivalent endogenous 
protein is involved. 
For  the  purpose,  the proteins  were expressed  as  N-terminally  6xHis  tagged  and  V5 
tagged proteins. This procedure was also used to detect association between wild type 
PRPF31 and V5-MAGI3, and V5-TRAK2. In addition, the reverse approach was also 
performed. 
 
4.1  Generation of N-terminally Tagged Proteins 
The  pDEST26  vector  was  used  to  generate  construct  6xHis-PRPF31; 
pcDNA3.1V5DEST  vector  was  used  to  generate  constructs  V5-MAGI3,  V5-PRPF6, 
V5-TRAK2. All hybrid proteins were expressed in HEK293 cells, under the control of 
the CMV promoter. Full-length open reading frames, listed in section 2.7, were used for 
this purpose. All the clones were checked first by restriction digestion followed by direct 
DNA sequencing (primers listed in Table 2.11). 
 
4.2  Expression of Tagged Proteins in HEK293 Cell Line 
HEK293 cells were cultured in 85 mm plates, and when ~75% confluent, they were 
transfected with Lipofectamine 2000 reagent (as described in section 2.12.2) with the 
following combinations of DNA constructs (ratio 1:1): 
1.  pDEST26-PRPF31 + pcDNA3.1V5-MAGI3; 
2.  pDEST26-PRPF31 + pcDNA3.1V5-PRPF6; 
3.  pDEST26-PRPF31 + pcDNA3.1V5-TRAK2; 
After 24 hours, cells were scraped and  lysed  into PBS-0.5% TX100 as described  in 
section 2.12.3. In order to see whether these proteins are expressed in the transfected                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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cells, each cell extract was treated with sample buffer and loaded on an acrylamide gel 
for immunoblot analysis. Figure 4.2 shows the bands corresponding to the various fusion 
proteins: 6xHis-PRPF31 is shown on blot A, as a band migrating at ~65kDa as expected; 
untransfected cells were also blotted with anti-6xHis antibody (lane “-” in blot A), and 
the antibody revealed a weak band at the same molecular weight of 6xHis-PRPF31. V5-
tagged proteins are shown in blots B and C: V5-MAGI3 migrates at a ~150 kDa (lane 
“V5-MAGI3”), and V5-TRAK2 is detected at ~120 kDa; V5-PRPF6 is shown in blot C, 
and as expected, migrates at ~100 kDa; untransfected cells (lane “-”, blot B) were also 
probed, revealing no significant background. As MAGI3 is 1481 amino acids long, its 
corresponding band was expected to be at ~165 kDa; however, the actual band lies at a 
lower molecular weight. This may be caused by incomplete denaturation of the protein; 
formation of secondary structures; presence of detergents. However, it is also important 
to consider that protein size in Daltons is estimated as an average for all the amino acids 
whereas each actually contributes a different amount according to the type of amino 
acid.  Therefore  proteins  of  similar  length  in  amino  acids  may  migrate  differently 
depending on the combination amino acids they contain, and as such cannot be predicted 
accurately. 
The backgrounds from the two antibodies were different: the α-V5 antibody gave a clean 
blot  even  after  long  exposure  time,  whereas  the  background  from  α-6xHis  antibody 
(Sigma) showed extra bands, among which a non-specific band at ~65kDa. 
 
 
4.3  Co-immunoprecipitation  of  6xHis-PRPF31  and  Interactants, 
Using anti-6xHis Antibody (Abcam) 
The method for validating the yeast two-hybrid data was the co-immunoprecipitation of 
PRPF31 with the said proteins. Having shown that the fusion proteins were successfully 
expressed (according to section 4.2), the first step was to precipitate PRPF31 and the 
splicing factor PRPF6. The same procedure was then applied to validate MAGI3 and 
TRAK2 with PRPF31.                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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Figure 4.2. Expression analysis of tagged proteins in HEK293 cells. 
A, expression of 6xHis-PRPF31: anti-6xHis antibody (Sigma) revealed a band at ~65 kDa, corresponding 
to the tagged protein; however, a faint band was observed in wt cells (lane -). B and C: expression of V5-
MAGI3,  V5-TRAK2,  V5-PRPF6:  anti-V5  antibody  revealed  bands  at  the  corresponding  sizes  of  the 
fusion proteins (~150 kDa, ~120 kDa, ~110 kDa respectively); the incubation of the wt cell lysate (lane -) 
did not reveal any significant band. The positions of molecular mass standards (kDa) are shown on the 
right.                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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4.3.1  Co-immunoprecipitation of 6xHis-PRPF31 and V5-PRPF6 
For this assay, HEK293 cells were co-transfected with the following combinations of 
DNA constructs (ratio 1:1): 
1.  pDEST26-PRPF31 + pcDNA3.1V5-PRPF6; 
2.  pDEST26-PRPF31 + pcDNA3.1V5DEST; (control: PRPF31 and empty V5 vector); 
3.  pDEST26 + pcDNA3.1V5-PRPF6; (control: empty 6xHis vector and PRPF6); 
4.  pDEST26 + pcDNA3.1V5DEST; (control: empty 6xHis and V5 vectors). 
 
Protein-G  beads  were  coupled  with  anti-6xHis  (Abcam)  and  crude cell  lysates  were 
incubated with the immunobeads, according to the protocol described in section 2.13. 
The samples were then electrophoresed on SDS-polyacrylamide gel, and probed with the 
antibodies directed against the tags. 
Figure 4.3 (panel A) shows the co-IP of PRPF31 and PRPF6 expressed in HEK293 cells, 
pulled  down  with  the  anti-6xHis  antibody  and  probed  with  the  anti-6xHis  and  the 
anti-V5  antibodies. The  complex 6xHis-PRPF31  + V5-PRPF6 shows strong positive 
interaction. In fact, panel A confirms the interaction between the two protein species, 
when construct combination #1 was used for immunoprecipitation: the 6xHis blot shows 
a band for 6xHis-PRPF31 in both IP (immune pellet) and input (transfected cell lysate) 
lanes (6xHis-PRPF31 is marked by a green asterisk, and represents the lower band at 
~65 kDa); the V5 blot shows V5-PRPF6 in both IP and input lanes (immunoreactive 
band observed at ~100 kDa, marked by a red asterisk). 
Panels B, C and D show all the possible controls run alongside to exclude the possibility 
of nonspecific interactions (construct combinations #2, #3, and #4 respectively). Panel B 
shows anti-6xHis antibody immunoreactive bands at ~65 kDa (6xHis-PRPF31) in both 
the IP and input lanes. Panel C demonstrates that V5-PRPF6 does not precipitate in the 
absence of 6xHis-PRPF31, as an anti-V5 antibody immunoreactive band is detected at 
~110 kDa in the input lane (indicated by the red asterisk) but not in the IP lane. A 
comparison between the 6xHis blots of panel B and panels C and D, illustrates that 
6xHis-PRPF31 is represented by the lower band (panel B, green asterisks), as only the 
upper band is present in C and D (yellow asterisks).                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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Figure 4.3. PRPF31 associates with PRPF6, as shown by immunoprecipitation. 
Gel  lanes  are:  IP,  anti-6xHis  immune  pellet;  input:  transfected  cell  homogenate;  -:  non-immune 
pellet/negative control. Pellets and cell homogenates were analysed by immunoblotting with the antibody 
specificities as indicated under each blot, “antibodies” (anti-6xHis antibody is from Sigma); the type of 
homogenate analysed is stated under the “constructs”. Coloured asterisks highlight relevant bands (green 
for  6xHis-PRPF31,  red  for  V5-PRPF6,  yellow  for  the  un-specific  band,  as  explained  in  text).  The 
positions of molecular mass standards are indicated in kDa.                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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A  mock  immunoprecipitation  for  construct  combination  #1  was  also  performed,  as 
illustrated in panel E: the anti-6xHis immunoreactive band at ~65 kDa is still observed 
on the non-immune pellet lane (“-“, negative control). However the upper band observed  
in the previous panels (A, B, marked by the yellow asterisks) is not detected. The anti-
V5 immunoreactive band at ~100 kDa is detected only in the input lane, although a faint 
band is present also in the negative control (red asterisks). These results may indicate a 
modest binding of 6xHis-PRPF31 to the beads, which did not strongly affect the result 
shown in panel A (care was taken to ensure all the gels -blots A and E- were equally 
loaded). 
Panel F is dedicated to lysates of mock transfected cells, which were used to produce 
immune-pellets and non-immune pellets: anti-6His immunoreactivity is observed at ~65 
kDa in both the IP and input lanes, but not in the negative control; this allowed us to 
conclude that the upper band observed in panels A and B is due to a protein species 
other than 6xHis-PRPF31, but which binds to the anti-6xHis antibody. No significant 
V5-immunoreactivity was observed. 
 
As the membranes incubated with the anti-6xHis antibody revealed an extra band close 
the molecular weight of 6xHis-PRPF31 (see Figure 4.3, yellow asterisks), the samples 
were re-electrophoresed on a gel and probed with an anti-PRPF31 antibody (Abcam) 
and anti-PRPF6 antibodies, for which the blots are shown in Figure 4.4. 
Using  the anti-PRPF31140-154 antibody  (Abcam), an immunoreactive band  at ~65kDa 
(6xHis-PRPF31)  was  detected  in  the  immune  pellets  corresponding  to  construct 
combinations #1 and #2 (panels A and B respectively, green asterisks). The anti-PRPF6 
immunoreactivity  with  ~110  kDa  (V5-PRPF6)  was  detected  in  the  immune  pellets 
corresponding  to  construct combinations #1  (panel  A,  red  asterisks),  confirming  the 
interaction observed in the previous experiment, but not in the IP lane of panel B (where 
only the empty V5 vector was transfected), or panel C (construct combination #3) where 
6xHis-PRPF31  is  not  expressed.  Panel  D  shows  only  the  endogenous  PRPF31  and 
PRPF6, as only empty vectors were transfected. 
In panel E, a very faint band at ~65 kDa (green asterisk) is visible in the IP lane of 
PRPF31  blot,  validating  what  was  previously  observed  (panel  E,  Figure  4.3),  that:                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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Figure 4.4. PRPF31 associates with PRPF6, as shown by immunoprecipitation. 
Gel  lanes  are:  IP,  anti-6xHis  immune  pellet;  input:  transfected  cell  homogenate;  -:  non-immune 
pellet/negative control. Pellets and cell homogenates were analysed by immunoblotting with the antibody 
specificities as indicated under each blot, “antibodies”; and the type of homogenate analysed is stated 
under “constructs”. Coloured asterisks highlight relevant bands (green for 6xHis-PRPF31, red for V5-
PRPF6, as explained in text). The positions of molecular mass standards are indicated in kDa.                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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6xHis-PRPF31 is able to bind the beads. 
No immunoreactivity for the anti-PRPF31140-154 antibody (Abcam) is detected on either 
the  immune-beads  or  the  non-immune  beads,  as  shown  on  panel  F  (PRPF31  blot), 
therefore concluding the un-specific nature of the band observed at ~65kDa in panel F 
(6xHis blot) of Figure 4.3. In panel F of Figure 4.4, the only band visible on the input 
(green arrow, PRPF31 blot) is the band corresponding to the PRPF31 protein, confirmed 
by its position at ~61 kDa (as indicated by the green arrow). 
 
The experiments shown in this section proved that the anti-6xHis antibody (Abcam) was 
unsuitable for immunoprecipitation, and a different, perhaps monoclonal antibody could 
have been more suitable for the purpose, avoiding un-specificity. 
 
4.3.2  Co-immunoprecipitation of 6xHis-PRPF31 and V5-MAGI3, 6xHis-PRPF31 
and V5-TRAK2 
Once the conditions were optimised for successful co-IP in detecting the 6xHis-PRPF31 
+  V5-PRPF6  interaction,  they  were  applied  to  investigate  any  association  between 
6xHis-PRPF31 + V5-MAGI3, and 6xHis-PRPF31 + V5-TRAK2. As in section 4.3.1, 
HEK293 cells were co-transfected with the following combinations of DNA constructs 
(ratio 1:1): 
1.  pDEST26-PRPF31 + pcDNA3.1V5-MAGI3; 
2.  pDEST26-PRPF31 + pcDNA3.1V5-TRAK2; 
3.  pDEST26-PRPF31 + pcDNA3.1V5DEST; (control: PRPF31 and empty V5 vector); 
4.  pDEST26 + pcDNA3.1V5-MAGI3; (control: empty 6xHis vector and MAGI3); 
5.  pDEST26 + pcDNA3.1V5-TRAK2; (control: empty 6xHis vector and TRAK2); 
6.  pDEST26 + pcDNA3.1V5DEST; (control: empty 6xHis and V5 vectors). 
 
Figure 4.5 shows association between PRPF31 and MAGI3, and between PRPF31 and 
TRAK2, upon probing with anti-tag antibodies. An anti-6xHis immunoreactive band at 
~65  kDa  (6xHis-PRPF31)  was  detected  in  the  immune  pellets  corresponding  to 
constructs PRPF31 and MAG13 co-transfection (combination 1), PRPF31 and TRAK2 
(combination 2) and PRPF31 and empty V5 vector (combination 3), as shown in Figure                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
 
  129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. PRPF31 associates with MAGI3 and with TRAK2. 
Gel  lanes  are:  IP,  anti-6xHis  immune  pellet;  input:  transfected  cell  homogenate.  Pellets  and  cell 
homogenates were analysed by immunoblotting with the antibody specificities as indicated under each 
blot, “antibodies”; the type of homogenate analysed is stated under the “constructs”. Red asterisks point 
out  V5-MAGI3;  blue  asterisks  point  out  V5-TRAK2;  green  asterisks  point  out  6xHis-PRPF31.  The 
positions of molecular mass standards (kDa) are shown on the centre.                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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4.5, panels A, B and C respectively (green asterisks). An anti-V5 immunoreactive band 
at  ~150  kDa  (V5-MAGI3)  was  detected  in  the  immune  pellets  corresponding  to 
constructs PRPF31 and MAG13,  but not constructs empty-6xHis-vector  and MAGI3 
(combinations 1 and 4, panels A and D respectively, marked by red asterisks). The anti-
V5 immunoreactive band at ~120 kDa (V5-TRAK2) was detected in the immune pellets 
corresponding  to  construct  PRPF31  and  TRAK2,  but  not  empty-6xHis-vector  and 
TRAK2  (combinations  #2  and  #5,  panels  B  and  E  respectively,  indicated  by  blue 
asterisks). 
As previously observed, also this experiment confirms the presence of an extra band 
around the molecular weight of 6xHis-PRPF31 (see Figure 4.5, 6xHis blot in panel C as 
an example), but it does not affect the outcome of the immunoprecipitation between 
6xHis-PRPF31 and the interactants. 
 
Table 4.1 summarises the protein combinations and the outcome (interaction or non-
interaction), when the anti-6xHis antibody (Abcam) was coupled to the beads. 
 
Table  4.1.  Summary  of  co-immunoprecipitations  coupling  anti-6xHis  antibody  (Abcam)  to  the 
beads. 
V5-PRPF6  V5-MAGI3  V5-TRAK2  V5 
 
Section 4.3.1  Section 4.3.2 
6xHis-PRPF31  +  +  +  - 
6xHis  -  -  -  - 
The  table  provides  an  overview  of  the  various  combinations  between  6xHis-PRPF31/6xHis  and  V5-
proteins, stating  in which  section each  interaction  is described. It also  provides a  first glance  of the 
immunoprecipitation outcomes, where “+” stands for interaction and “-” for no interaction observed. 
 
 
4.4  Reverse Co-immunoprecipitation 
To further validate these interactions, reverse co-immunoprecipitation was performed. In 
the  previous  section  the  immunoprecipitation  reactions  were  performed  with  the  
anti-6xHis antibody conjugated to  the beads.  On the reverse co-IP, it  is the anti-V5 
antibody coupled to the beads, and therefore the V5-tagged protein that is linked to the 
solid substrate. 
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4.4.1  Co-immunoprecipitation of V5-MAGI3 and 6xHis-PRPF31, V5-TRAK2 and 
6xHis-PRPF31 
This  experiment  was  performed  on  HEK293  cells  transfected  with  the  same 
combinations  of  DNA  constructs  stated  in  section  4.3.2.  Figure  4.6  shows  the 
immunoblots of the  co-immunoprecipitation reactions as well as  inputs,  although on 
separate blots: panels A and B show the immune pellets of the different cell homogenate 
type  stated  on  “constructs”,  whereas panels C  and  D  represent  the  input  blots.  The 
membranes were probed twice: first with the anti-V5 antibody, and subsequently with 
the anti-6xHis antibody (from Sigma), and due to which a background is observed on 
blots B and D. 
Upon incubation with the anti-V5 antibody, protein bands corresponding to V5-MAGI3 
(red asterisks) and V5-TRAK2 (blue asterisks) were detected both in the IP blot (panel 
A) and in the input blot (panel C), confirming that the IP reaction took place in the first 
instance. However, the anti-6xHis reactive band at ~65 kDa (for 6xHis-PRPF31) was 
observed not only where expected (when 6xHis-PRPF31 was expressed together with a 
V5-protein, shown by green asterisks in IP panel B), but also when expressed together 
with the V5 tag alone (indicated by a green arrow in panel B). Hence a cross-reaction 
between the anti-V5 antibody and 6xHis-PRPF31 must have occurred. 
Panel A confirms what is observed in panel B (green arrow): an anti-V5 immunoreactive 
band  at  ~65  kDa  was  detected  in  the  immune  pellets  corresponding  to  construct 
combinations #1, #2 and #3, that is when 6xHis-PRPF31 is expressed (green arrows in 
panel A), but not #4, #5 and #6, that is when only 6xHis tag is produced (in this case, it 
is not possible to see a band corresponding to the 6xHis tag only as it is too small). This 
may be due to a cross reaction between the anti-V5 antibody and the 6xHis tag. 
 
4.4.2  Co-immunoprecipitation  of  V5-MAGI3  and  Wild  Type  PRPF31,  V5-
TRAK2 and Wild Type PRPF31 
To evaluate whether or not the anti-V5 antibody cross-reacted with the 6xHis tag and 
not  with  PRPF31  protein,  and  furthermore  to  prove  that  the  wild  type  protein  also 
co-precipitated with each interactant, a set of immunoreactions prepared corresponding 
to construct combinations #4, #5 and #6 (that is the cells expressing the V5-proteins and                                  4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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Figure  4.6.  Cross  reaction  between  the  anti-V5  antibody  and  6xHis-PRPF31,  as  shown  by 
immunoprecipitation. 
Immune pellets (A and B) and inputs (cell homogenates; C and D) were analysed by immunoblotting with 
the  antibody  specificities  as  shown  (the  membranes  were  probed  first  with  an  anti-V5  antibody  and 
secondly with an anti-6xHis antibody (Sigma), therefore the 6xHis immunoblots have a background from 
the  previous  incubation  with  the  anti-V5  antibody);  the  type  of  homogenate  analysed  is  stated  at 
“constructs”. Red asterisks indicate V5-MAGI3; blue asterisks indicate V5-TRAK2; green asterisks and 
green arrows indicate 6xHis-PRPF31. The positions of molecular mass standards (kDa) are shown on the 
right                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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the empty 6xHis tag vector), were probed with the anti-PRPF31484-497 antibody. 
The  anti-PRPF31484-497  immunoreactive  band  at  ~61  kDa  (wild  type  PRPF31)  was 
detected  in  the  immune  pellets  corresponding  to  construct  combinations  #4  and  #5 
(expressing  V5-MAGI3  and  V5-TRAK2  respectively,  shown  in  panels  A  and  C  of 
Figure 4.7, green asterisks), but no detectable immunoreactivity in the immune pellet for 
combination #6 (cells expressing both tags only; shown in panels B and D), confirming 
there was no cross-reaction between the anti-V5 antibody and wild type PRPF31. 
Therefore,  not  only  was  the  wild  type  splicing  factor  found  complexed  with  the 
V5-interactant, corroborating the previous results, but also it was not implicated in any 
cross-reaction with the anti-V5  antibody, the cross-reaction can then be  attributed to 
only the 6His tag. 
 
Table 4.2 summarises the results of the co-IPs showed in the sections 4.4.1 and 4.4.2: 
 
Table 4.2. Summary of co-immunoprecipitations coupling anti-V5 antibody to the beads. 
    V5-MAGI3  V5-TRAK2  V5 
6xHis-PRPF31  +  +  + 
6xHis 
Section 4.4.1 
-  -  - 
wt PRPF31  Section 4.4.2  +  +  - 
The  table  offers  a  synopsis  of  the  various  combinations  between  the  V5-proteins  and  the  6xHis-
PRPF31/6xHis/wtPRPF31, referring to the section each interaction is described. It also provides a first 
glance of the immunoprecipitation outcomes, where “+” stands for (potential) interaction and “-” for no 
interaction observed. 
 
 
4.5  Conclusion 
Based  on  the  results  presented  so  far,  MAGI3  and  TRAK2  may  be  considered  as 
partners  of  PRPF31  in vitro;  however,  to undoubtedly  consider  them  as part  of  the 
PRPF31 protein complex, the interaction must be further proven in vivo. 
Before attempting any further experiment to confirm or rule out MAGI3 and TRAK2 as 
true interacting partners of PRPF31, conditions were optimised against a known PRPF31 
interactant,  V5-PRPF6  (Makarova  et  al.,  2002).  Results  showed  that  PRPF6  was 
successfully  detected  in  the  immune  pellets.  Similarly,  the  co-immunoprecipitation                                  4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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Figure  4.7.  Wild  type  PRPF31  associates  with  MAGI3  and  with  TRAK2,  as  shown  by 
immunoprecipitation. 
Gel lanes are: IP, anti-V5 immune pellet; input, transfected cell homogenate. Pellets and cell homogenates 
were analysed by immunoblotting with the antibody specificities as shown in the abscissae; the type of 
homogenate analysed is stated at the “constructs” abscissae. The positions of molecular mass standards 
(kDa) are shown on the right.                                   4. Confirmation of Novel PRPF31 Interactants, MAGI3 and TRAK2 
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reactions  between  6xHis-PRPF31  and  V5-MAGI3  and  between  6xHis-PRPF31  and 
V5-TRAK2  were  also  successful,  when  pulled  down  using  the  6xHis  species.  The 
interaction was also proven by the reverse reaction: when the immune pellet was pulled 
down using the V5-species, wild type PRPF31 was detected in the complex.  
These experiments also revealed a cross-reaction between the anti-V5 antibody and the 
6xHis  tag,  which  hindered  detection  of  the  interactants  in  reverse 
co-immunoprecipitation conditions. 
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5.  Co-localisation of PRPF31 with MAGI3 and 
TRAK2 
 
 
In  order  to  validate  in  vivo  the  interaction  of  PRPF31  with  MAGI3  and  TRAK2, 
co-localisation in cells was performed, using both tagged and endogenous proteins. 
For  this purpose,  MDCK  cells  were  transfected  with  the  same  constructs  as  for  the  
co-immunoprecipitation  experiments  (encoding  N-terminally  tagged  proteins),  to 
observe  potential  associations  through  the  immunofluorescence  technique.  As  the 
HEK293 cell line shows a low adhesion to glass coverslips, the MDCK epithelial cell 
line  was  preferred.  MDCK  cells  grow  in  a  monolayer  and  strongly  adhere  to  glass 
coverslips,  rendering  this  cell  line  more  suitable  for  microscopic  analysis  than  the 
HEK293 cell line. As mentioned at the beginning of Chapter 4, experiments were carried 
out even if the interacting candidates were not retina-specific: still, new information can 
be gathered on PRPF31 role. That is also why we selected the MDCK cell line as a 
model:  non-neuronal,  to  identify  whether  the  interactions  are  happening  not  just  in 
particular cell types, since all three proteins (PRPF31, MAGI3, TRAK2) are expressed 
ubiquitously;  differentiated,  to  be  able  to  infer  the  significance  of  any  hypothetical  
co-localisation of PRPF31 with the interactants. 
To ensure results were robust, we performed a test staining in order to ascertain whether 
the cross-reaction between the 6xHis-tag and the anti-V5 antibody occurred also in the 
immunofluorescence  method,  since  it  was  observed  in  western  blot  and  co-IP 
procedures.  The experiment  is  described in  the “Preliminary  Work”  section  (section 
5.2.1). 
The  chapter also  addresses  the  localisation of the endogenous proteins: PRPF31  and 
MAGI3  were  investigated  in  MDCK  cells,  whereas  a  potential  association  between 
PRPF31 and TRAK2 was examined in the SK-N-SH cell line; the choice of the SK-N-
SH cell line was dictated by the fact that TRAK2 is enriched in neuronal tissue, and it 
was not detected at satisfying levels in MDCK cells.  
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5.1  Expression of Tagged Proteins in MDCK Cells 
To verify the expression of the tagged proteins, MDCK cells were cultured in 24-well 
plates, transfected with the combinations of constructs as used for the co-IP experiments 
(see section 4.3.2 of Chapter 4), using the Lipofectamine 2000 reagent (section 2.12.2). 
After 24 hours, the cells were harvested in PBS-0.5% TX100 (according to protocol in 
section 2.12.3). The cell lysates were then treated with sample buffer for SDS-PAGE 
(section 2.11).  
Figure 5.1 shows the expression of the tagged proteins in MDCK cells. The anti-6xHis 
antibody (Sigma)  revealed bands at ~65 kDa  likely  corresponding  to 6xHis-PRPF31 
(indicated by red asterisks on blot A); lanes corresponding to cells transfected with only 
the 6xHis tag, mock transfected cells or wild type cells show an overlapping band, at the 
molecular weight of 6xHis-PRPF31 (~65 kDa), suggestive of non-specificity. Anti-V5 
antibody  incubation  revealed  bands  corresponding  to  V5-MAGI3  (~150kDa),  
V5-TRAK2 (~120kDa) and V5-PRPF31 (~70kDa). 
 
 
5.2  Co-localisation of 6xHis-PRPF31 and V5-MAGI3, 6xHis-PRPF31 
and V5-TRAK2 
MDCK  cells  were  cultured  on  sterile  glass  coverslips placed  in  24-well plates,  and 
transfected with Lipofectamine 2000 reagent according to protocol in section 2.12.2. 
After 24 hours, cells were fixed with methanol and stained  (as described in sections 
2.12.4 and 2.14.1 respectively). Over-expressed proteins were detected upon incubation 
with  the  anti-V5  and  the  anti-PRPF31484-497  antibodies.  We  chose  not  to  use  any 
anti-6xHis  antibody  (Sigma  and  Abcam)  to  detect  the  6xHis-tagged  protein  as  the 
outcoming signals were indistinct (not shown). 
The localisation experiments involving over-expressed protein (paragraphs 5.2 and 5.3) 
were  performed  with  the  following  secondary  antibodies:  a  donkey  Cy3-conjugated 
anti-rabbit secondary antibody to detect the anti-PRPF31484-497 antibody, and a donkey 
FITC-conjugated anti-mouse secondary antibody to detect the anti-V5 antibody.                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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Figure 5.1. Expression of tagged proteins in MDCK cells. 
In A, detection of tagged proteins upon incubation with the anti-6xHis antibody (Sigma): the blot shows 
three strong bands at ~65 kDa corresponding to 6xHis-PRPF31 (red asterisks). In B, the detection of 
tagged proteins upon incubation with the anti-V5 antibody revealed bands at ~150 kDa for V5-MAGI3, at 
~120 kDa corresponding to V5-TRAK2 and at ~70 kDa for V5-PRPF31.                                                          5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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5.2.1  Preliminary Work 
To  rule  out  a  cross  reaction  between  the  anti-V5  antibody  and  the  6xHis  tag,  the 
pcDNA3.1V5DEST vector was used to generate the V5-PRPF31 construct. A staining of 
two  sets of  cells, expressing  6xHis-PRPF31 or  V5-PRPF31 each,  was  performed  to 
ascertain whether the cross-reaction still persisted in immunofluorescence techniques. 
In Figure 5.2, panels A1 and B1 provide two examples of cells expressing V5-PRPF31, 
detected with the anti-V5 antibody: the distribution of the protein was observed to be 
both  nuclear,  in  speckles,  and  in  round  aggregates  resembling  the  nucleoli  -  and 
cytoplasmic too; in each case, the level of expression was high and the protein was 
easily detected. 
Cells expressing 6xHis-PRPF31 were also stained with the anti-V5 antibody, to examine 
the possible occurrence of a cross-reaction in these conditions: the staining revealed no 
cross-reaction, as no fluorescence was detected (Figure 5.2, panel C); if any signal was 
to be seen, it would have resembled the one shown in panels A and B. The fact that no 
fluorescence was detected indicates that the anti-V5  antibody recognised its specific 
epitope,  even  though  6xHis-PRPF31  and  V5-tagged  protein  were  simultaneously 
present. 
Furthermore, the V5 tag was expressed in cells, in order to assess whether an N-terminal 
tag would affect PRPF31 localisation. Although PRPF31 was expressed with the 6xHis 
tag, its detection was not clear using an anti-6xHis antibody in the conditions adopted 
for immunofluorescent staining. We therefore expressed the V5 tag instead, since its 
detection  was  more  feasible.  The  anti-V5  staining  did not show  any  cytoplasmic or 
nuclear staining pattern (panel D of Figure 5.2), thus confirming that the tag does not 
alter  the protein  localisation.  However,  a  small  peptide  such  as  the  V5  tag  may  be 
quickly degraded by the cell, making its detection difficult. 
Panel E illustrates cells which underwent treatment with the transfecting agent alone; 
after methanol fixation, cells were incubated with anti-V5 antibody followed by donkey 
FITC-conjugated anti-mouse secondary antibody. No fluorescence was detected. 
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  140 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2. V5-PRPF31 and 6xHis-PRPF31 localisation in MDCK cells, using anti-V5 antibody. 
V5-PRPF31 (FITC signal) was localised in nuclear speckles (A1) and in the cytoplasm (A1 and B1). In C, 
the presence of 6xHis-PRPF31 is not detected by the anti-V5 antibody. In D, cells expressing only the V5 
peptide  do not show any significant staining upon incubation with  the  anti-V5  antibody.  In  E, mock 
transfected cells  incubated  with the  anti-V5  antibody.  Nuclei were  stained with  Hoechst 33258 (blue 
signal). Scale bars, 10µm. Colour is indicated by legend on each black and white panel.                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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5.2.2  Localisation of 6xHis-PRPF31 in MDCK Cells 
As  no cross  reaction between 6xHis-tag  and  the  anti-V5  antibody  was observed  (as 
described  in  the  previous  section  5.2.1),  we  proceeded  with  the  localisation  of 
6xHis-PRPF31, using the anti-PRPF31484-497 antibody. Figure 5.3 shows that the staining 
of 6xHis-PRPF31 is similar to that observed for V5-PRPF31 (compare with Figure 5.2). 
The transfected cells showed both a nuclear localisation (in small speckles and in round 
aggregates resembling the nucleoli) and a distinct cytoplasmic presence. 
The expression of the tagged protein, and hence the signal intensity of the PRPF31, was 
very high and the exposure time of the image was adjusted in accordance with this; for 
this  reason  no  signal  was  observed  from  the  endogenous  PRPF31  in  the  mock 
transfected cells (panel D).  
 
5.2.3  Localisation of V5-MAGI3 in MDCK Cells 
In  epithelial  cells,  the  distribution  of  the  V5-MAGI3  protein  was  predominantly 
cytoplasmic (Figure 5.4): in fact the expressed protein localised strongly at intercellular 
junctions  -  likely  tight  junctions  as  previously  reported  by  Wu  et  al.  (2000)  and 
Adamsky et al. (2003) - , and around the nucleus, its presence becoming progressively 
weaker towards the distal part of the cytoplasm. A less intense signal was detectable in 
the  nucleus  too.  No  formation  of  aggregates  was  observed.  Figure  5.4  shows  two 
examples of the localisation of the V5-MAGI3 protein. 
 
5.2.4  Localisation of V5-TRAK2 in MDCK Cells 
V5-TRAK2 was localised primarily in the cytoplasm (Figure 5.5): the signal was present 
throughout the entire cell. The signal was also observed in the nucleoplasm, although 
weakly.  In  cells  expressing  less  V5-TRAK2  (judged  by  lower  signal  intensity),  the 
protein was mainly detected in a perinuclear  fashion;  the  signal  also had  a streaked 
pattern. Also for V5-TRAK2, no aggregates were observed. Approximately 50% of the 
cells expressing the protein, exhibited a very intense fluorescence at the end of cellular 
extension, detected as several speckles in a limited area (Figure 5.5, panel A1 upper 
portion of the cell  as  indicated by green  arrows; panel  B1, stronger signal  in upper 
portion of the cell, weaker in the lower, as indicated by green arrows).                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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Figure 5.3. 6xHis-PRPF31 localisation in MDCK cells, using anti-PRPF31484-497 antibody. 
The series of panels represent the same area of MDCK cells, expressing 6xHis-PRPF31, detected with the 
anti-PRPF31484-497 antibody (Cy3 signal). Panels A, B and C are three different z sections, of 0.70 µm 
each. Panel D represents mock transfected cells. Nuclei were stained with Hoechst 33258 (in blue). Scale 
bar, 10µm. Colour is indicated by legend on each black and white panel.                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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Figure 5.4. Localisation of V5-MAGI3 in MDCK cells, using the anti-V5 antibody. 
A,  B: cells  over-expressing V5-MAGI3 (A1,  B1;  FITC)  presented  a  staining  pattern  which  included 
intercellular  junctions (fluorescence at the edge  of  the  cell),  cytoplasm  (stronger  around  the  nucleus, 
progressively fading towards the cytoplasm), and a little the nucleus (visible in A1). Nuclei were stained 
with Hoechst 33258 (blue signal). Scale bars, 10µm. Colour is indicated by legend on each black and 
white panel.                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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Figure 5.5. Localisation of V5-TRAK2 in MDCK cells, using the anti-V5 antibody. 
A,  B:  cells  over-expressing V5-TRAK2 (A1,  B1;  FITC) presented  a  staining  pattern  which  included 
mainly the cytoplasm, and a little the nucleus (right-hand border of the nucleus in both A and B). Nuclei 
were stained with Hoechst 33258 (blue signal). Scale bars, 10µm. Colour is indicated by legend on each 
black and white panel.                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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5.2.5  Co-localisation of 6xHis-PRPF31 and V5-MAGI3 
Figures  5.6,  5.7  and 5.8  show  three  examples  of  the  localisation observed  for  both 
6xHis-PRPF31 and V5-MAGI3, co-expressed in MDCK cells. It was observed that in 
the presence of V5-MAGI3, 6xHis-PRPF31 was expressed mainly in nuclear aggregates, 
with little or no cytoplasmic staining; less frequently, it was also observed dispersed 
throughout  the  nucleus,  again  with  little  cytoplasmic  staining.  On  the  other  hand, 
V5-MAGI3 was detected largely at cell-cell junctions, and faintly in the cytoplasm, but 
also in nuclear aggregates together with 6xHis-PRPF31. According to the observations, 
the two recombinant proteins localised mainly to the nucleus, in large round aggregates, 
in which 6xHis-PRPF31 stained mostly the outer area and V5-MAGI3 was detected on 
the inner side: as the overlay shows, there is a region of overlap (denoted by a yellow 
colour), which suggests that they co-localise. 
To summarise, two staining patterns were observed (100 co-transfected cells counted for 
each of three independent transfections): 
-  cytoplasmic, junctional and nuclear V5-MAGI3 and nuclear 6xHis-PRPF31 (~57% 
of cells co-expressing the proteins); 
-  cytoplasmic and junctional V5-MAGI3, and nuclear 6xHis-PRPF31 (~43% of cells 
co-expressing the recombinant proteins). 
Because the anti-PRPF31484-497 antibody was used for the detection of 6xHis-PRPF31, 
the observed fluorescence is the contribution of two signals, one originating from the 
6xHis-tagged  protein,  and  a  second  from  the  endogenous  PRPF31.  However,  the 
abundance of the over-expressed protein was such that the exposure had to be adjusted, 
therefore  the  visibility  of  the  endogenous  signal  is  very  reduced,  explaining  why  it 
cannot be observed in non-transfected cells. 
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5.2.6  Co-localisation of 6xHis-PRPF31 and V5-TRAK2 
Figures  5.9,  5.10  and  5.11  show  three  examples  of  the  localisation  observed  for 
6xHis-PRPF31  and  V5-TRAK2,  co-expressed  in  MDCK  cells.  In  this  case,  6xHis-
PRPF31  exhibited  a  nuclear  (speckles  and  aggregates)  and  a  cytoplasmic  presence. 
Interestingly, when co-expressed with V5-TRAK2, in a number of cells 6xHis-PRPF31 
was  detected  at  the  tip  of  spike-like  structures  on  cellular  extensions  (Figure  5.11 
provides an example). V5-TRAK2 was detected in the cytoplasm, and it was frequently 
observed that its signal was mainly detected on one side of the cell. Furthermore, the 
V5-TRAK2  protein  was  detected  on  nuclear  aggregates,  co-localising  with  6xHis-
PRPF31 with a pattern similar to V5-MAGI3 (i.e. an inner staining of V5-TRAK2 and 
PRPF31 on the outside). Interestingly, V5-TRAK2 co-stained with 6xHis-PRPF31 on 
the  aforementioned cellular  extension  (as  indicated by  white  arrows  in  panel  A4 of 
Figure 5.11). 
The most prominent pattern of co-localisation observed was (on 100 co-transfected cells 
for each of three independent transfections): 
-  perinuclear  signal  for  V5-TRAK2  with  nuclear  aggregates,  and  6xHis-PRPF31 
detected throughout the entire cell, and more strongly in nuclear aggregates (~58% 
of co-expressing cells counted). 
The rest showed a weak staining to no staining of V5-TRAK2 in the nucleus, and 6xHis-
PRPF31 present especially in nuclear aggregates. 
The presence of 6xHis-PRPF31 in the cellular extensions was unexpected, as the single 
expression of the 6xHis-PRPF31 did not present such localisation. As was discussed in 
the previous section  5.2.4, the  single expression  of V5-TRAK2 showed this type of 
localisation; thus TRAK2 over-expression may alter the localisation of 6xHis-PRPF31, 
or  it  may  enhance  its  presence  in  these  regions  (as  it  may  be  that  there  is  a  basal 
presence of the wild type splicing factor which is not detectable). 
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5.3  Exclusion  of  Cross-reaction  between  anti-PRPF31484-497  and  
anti-V5 Antibodies 
To ensure no cross-reaction between the antibodies and the epitopes was occurring, a set 
of  control  experiments  were  carried  out  for  both  6xHis-PRPF31  +  V5-MAGI3 
transfection and 6xHis-PRPF31 + V5-TRAK2 transfection. Figure 5.12 summarises the 
controls: panels A, B and C are dedicated to 6xHis-PRPF31 + V5-MAGI3 transfection, 
whereas D, E and F are for 6xHis-PRPF31 + V5-TRAK2 transfection: 
1.  A, D: double-transfected cells were incubated with primary anti-PRPF31484-497 only, 
followed by incubation with anti-rabbit-Cy3 and anti-mouse-FITC antibodies; 
2.  B, E: double-transfected cells were incubated with primary anti-V5 antibody only, 
followed by incubation with anti-rabbit-Cy3 and anti-mouse-FITC antibodies; 
3.  C,  F:  double-transfected  cells  were  incubated  with  anti-rabbit-Cy3  and 
anti-mouse-FITC  secondary  antibodies  (performed  following  a  mock  primary 
antibody incubation). 
Any  unexpected  staining  was  not  detected:  the  anti-PRPF31484-497  immunoreactivity 
corresponded to a nuclear/nucleolar staining due to 6xHis-PRPF31 (red signal in A and 
D; due to the image processing, any cytoplasmic staining is not visible on the picture). 
Also,  anti-V5  immunoreactivity  revealed  only  V5-interactants:  as  in  panel  B, 
V5-MAGI3 signal (in green) was detected at the junctions, and in the nucleus (nucleoli-
like  structures)  along  with  cytoplasm;  panel  E  exhibits  the  pattern  of  localisation 
previously observed for V5-TRAK2 (in green), which was weakly nuclear with a strong 
cytoplasmic  signal  (a  faint  signal  from  nuclear  aggregates  was  also  observed).  The 
staining of the double-transfected cells with a combination of the secondary antibodies 
was insignificant, as shown by panels C and F. 
The results described above support the validity of the data presented in sections 5.2.3 
and 5.2.4. Moreover, panels B and E are in accordance with the description provided in 
section 5.2.1:  6xHis-PRPF31  was  not  detected  by  the  anti-V5  antibody  (Figure  5.2, 
panel C; section 5.2.1), nor it was detected this instance.                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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Figure 5.12. Control experiments on MDCK cells expressing 6xHis-PRPF31 and V5-interactant. 
A, B and C: cells transfected with 6xHis-PRPF31 and V5-MAGI3; D, E and F: cells transfected with 
6xHis-PRPF31 and V5-TRAK2. The anti-PRPF31484-497 antibody did not reveal any fluorescence pattern 
resembling the V5 recombinant protein (panels A and D, 6xHis-PRPF31 in red). The anti-V5 antibody did 
not reveal any fluorescence pattern belonging to 6xHis-PRPF31 (panels B and E, V5-tagged proteins in 
green). No signal was detected upon incubation with the two secondary antibodies only (panels C and F) 
Nuclei were stained with Hoechst 33258 (blue signal). Scale bars, 10µm. 
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5.4  Localisation  of  Wild  Type  PRPF31 and Wild  Type MAGI3 in 
MDCK Cells 
As  demonstrated  by  the  yeast  two-hybrid,  immunoprecipitation  and  localisation 
experiments, mounting evidence suggests an association between the two interactants, 
MAGI3  and  TRAK2,  with  PRPF31.  However,  it  is  important  to  validate  the 
co-localisation of the endogenous proteins. The techniques adopted so far have provided 
promising  perspectives;  however  the  use  of  over-expressed  proteins  has  made  them 
considerably artificial,  as  the  amount of protein expressed may not correlate  closely 
enough to the in vivo environment. For specialised cells such as photoreceptor cells it is 
not practical to work in vivo, hence the use of models is preferred which simulate basic 
in  vivo  conditions.  Furthermore,  the  results  shown  thus  far  suggest  a  thorough 
investigation of the role of PRPF31 should be undertaken prior to speculating the role of 
PRPF31  and  interacting  partners  in  the  retina.  That  is  why  we  continued  work  on 
MDCK  cells  to  test  whether  or  not  the  endogenous  PRPF31  and  MAGI3  proteins 
co-localise (for TRAK2, see section 5.5). 
 
 
5.4.1  PRPF31 and MAGI3 Overlap at Cell-cell Junctions 
Wild  type  PRPF31  and  MAGI3  were  detected  with  the  anti-PRPF31484-497  and  the 
anti-MAGI3 antibodies respectively. 
As  shown  by  panel  A1  in  Figure  5.13,  anti-PRPF31484-497  immunoreactivity  was 
predominantly nuclear, in speckles. Cytoplasmic staining for PRPF31 was negligible; 
however, a distinct staining at cell-cell junctions was observed (arrows on panel A1). 
This staining pattern appeared to intensify depending on cell density: when cells were 
sparsely  populated,  the  staining  was  not  as  intense  as  when  the  cells  became  more 
confluent. In the latter case however, the signal strength was exceeded by that of the 
nuclear counterpart, although one could still detect it at a different focus plane. This 
signal  appeared to define  the shape of the cell as  if the protein  was localised  along 
intercellular  junctions;  the  staining  appeared  to  be  very  grainy  and  in  speckles. 
Compared  to  the  nuclear  fluorescence,  the  junctional  signal  was  very  faint,  as  the                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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majority of PRPF31 appeared to localise to the nucleus. The exposure was adjusted to 
compensate for the low junctional staining in order to detect it when recording images. 
MAGI3 (panel A2, Figure 5.13) was observed mainly at intercellular junctions (possibly 
tight  junctions;  Wu  et  al.,  2000;  Adamsky  et  al.,  2003),  where  it  appeared  as  an 
intermittent signal; it also was localised to the cytoplasm, in a perinuclear fashion, and 
very  weakly  to  the  nucleus,  reminiscent  of  the  localisation  pattern  of  V5-MAGI3. 
Generally, anti-MAGI3 immunoreactivity was fainter than that of PRPF31. 
In epithelial cells, the PRPF31 and MAGI3 signals showed no co-localisation. However, 
a partial overlap was seen principally at cell-cell contacts (in panel A4, as indicated by 
white  arrow).  Furthermore,  the  co-staining  of  PRPF31  and  MAGI3  revealed  that 
PRPF31  does  not  localise  to  the  tight  junctions,  as  no  yellow  signal  was  observed 
(indicating co-localisation of the two proteins). Still, the partial overlap indicates that the 
proteins may be recruited to a common site and possibly interact. 
Wild type MDCK cells  were  also subjected to a mock primary antibody  incubation, 
followed by incubation with secondary antibodies. As shown in Figure 5.13, panels B1 
and B2  illustrate an  area of the specimen, laser-excited  to detect any  red and  green 
fluorescence respectively, for donkey anti-rabbit Cy3-conjugated and donkey anti-mouse 
FITC-conjugated antibodies. No significant signal was observed.                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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5.4.2  Detection of PRPF31 with a Second anti-PRPF31 Antibody in MDCK Cells 
The junctional localisation observed for PRPF31, described in the previous section 5.4.1, 
was  unexpected.  PRPF31  is a well-known splicing factor  and therefore presumed to 
localise specifically to the nucleus. To verify that the junctional localisation of PRPF31 
was  consistent  and  not  caused  by  non-specific  binding  of  the  anti-PRPF31484-497 
antibody, the splicing factor was detected with a second antibody. For this purpose, the 
commercial anti-PRPF31140-154 antibody from Abcam was used. 
Anti-PRPF31140-154 immunoreactivity was detected mostly in the nucleus (Figure 5.14); 
a little fluorescence was observed in the cytoplasm, conferring a reddish colour to the 
cells. A junctional localisation pattern was observed (indicated by red arrows in panels 
A1 and B1 in Figure 5.14), therefore implying that PRPF31 localises at intercellular 
junctions in epithelial cells. Also this antibody did not appear to detect PRPF31 in the 
nucleoli, as the comparison with the chromatin staining reveals (compare with panels A2 
and B2, Figure 5.14). 
Figure 5.14 illustrates also wild type MDCK cells fixed with methanol which underwent 
a mock primary antibody incubation (panels C), followed by incubation with donkey 
anti-goat Cy3-conjugated antibody, used to detect PRPF31 with the anti-PRPF31140-154 
antibody.  A  faint  cytoplasmic  fluorescence  was  observed  (panel  C1),  which did  not 
appear to interfere with the detection of the signal from the primary antibody. 
 
 
5.4.3  Western  Blot  Analysis  of  anti-PRPF31484-497,  anti-PRPF31140-154,  anti-
MAGI3 Antibodies on MDCK Cell Extracts 
MDCK cell extracts were electrophoresed, blotted on nitrocellulose, and the membranes 
were probed using the antibodies to detect endogenous PRPF31 and MAGI3. Figure 
5.15 shows the blots for the two antibodies used to detect PRPF31 (blots A and B for 
anti-PRPF31484-497  and  anti-PRPF31140-154  respectively)  and  the  antibody  for  MAGI3                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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Figure 5.14. Nuclear and junctional localisation of PRPF31 in wild type MDCK cells, using the anti-
PRPF31140-154 antibody. 
Panels A  and  B illustrate  two  different areas  of  cells  incubated  with  the anti-PRPF31140-154  antibody 
(Abcam; in Cy3): the antibody revealed a similar localisation pattern as the anti-PRPF31484-497 antibody. 
Red arrows indicate the intercellular junctions.  
The panels C illustrate epithelial cells incubated with the donkey anti-goat secondary antibody used for the 
detection of anti-PRPF31 antibody140-154. No significant fluorescence was observed. 
Colour is indicated by legend on each black and white panel. 
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Figure 5.15. Immunoblots showing expression of PRPF31 and MAGI3 in MDCK cells. 
In blots A and B, PRPF31 is detected using two different antibodies: the anti-PRPF31484-497 antibody 
detects a major band at ~61 kDa (pointed by the green arrow in A), and a minor band at ~75 kDa. The 
anti-PRPF31140-154 antibody detects only the ~61 kDa (green arrow in blot B). Blot C shows MAGI3 
detected by  anti-MAGI3  antibody,  showing  ~140  kDa (red arrow); a second  band at  ~170 kDa  may 
correspond to an isoform (indicated by upper red arrow). The positions of molecular mass standards (kDa) 
are shown on the right of each blot. 
                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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(blot C). Anti-PRPF31484-497 immunoreactivity shows two major bands: one at ~61 kDa, 
which  corresponds  to  the  splicing  factor,  and  another  one  at  ~75  kDa,  termed  as 
non-specific  (Makarova  et  al.,  2002).  The  anti-PRPF31140-154  antibody  from  Abcam 
revealed a band at ~61 kDa, likely corresponding to PRPF31. The anti-MAGI3 antibody 
displayed a major band at ~140 kDa, likely corresponding to MAGI3. Each relevant 
band is indicated by an arrow. 
 
The blots from MDCK cells showed that the anti-PRPF31484-497 antibody displays two 
bands. As Makarova and co-workers (2002) reported a non-specific band at ~75 kDa, a 
correlation  between  this  band  and  the  junctional  staining  may  be  hypothesised. 
However, the second antibody for PRPF31 (anti-PRPF31140-154, Abcam) detects only the 
expected band for  PRPF31  (at  ~65 kDa),  and was also  able to detect  the junctional 
staining, hence supporting the validity of the immunofluorescent signals observed for 
PRPF31 described in the previous section.  
 
 
5.5  Localisation  of  Wild  Type  PRPF31 and Wild  Type TRAK2 in 
SK-N-SH Cells 
TRAK2 has been described as enriched in neuronal tissues (Brickley et al., 2005), hence 
MDCK cells were not suitable for its localisation, since they are a kidney epithelial cell 
line. For this reason, SK-N-SH cell line (a human neuroblastoma cell line) was used for 
this purpose. Cells were fixed with methanol, followed by co-staining with the anti-
PRPF31484-497  and  anti-TRAK2  antibodies.  Figure  5.16  provides  an  example  of  the 
observed localisation. PRPF31 was observed in nucleus and cytosol: in the nucleoplasm, 
the signal was detected in small speckles and approximately one third to half of the cells 
exhibited a weaker signal than MDCK cells; some cells also showed a uniform signal 
throughout nucleus and cytoplasm, forming  a continuum (red arrow  on panel A1 of 
Figure  5.16).  The  cytoplasmic  labelling  was  more  pronounced  than  MDCK  cells, 
and  the  protein  was  observed  to  localise  around  the  nucleus.  TRAK2 
showed  a  localisation  pattern  similar  to  the  over-expressed  protein:                                                        5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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it was detected predominantly in the cytoplasm, in a perinuclear fashion with a mottled 
signal. The  spike-like  structures on cellular  extensions witnessed when MDCK cells 
expressed V5-TRAK2 were not observed. When the signals from the two proteins were 
merged together, no clear-cut co-localisation (indicated by yellow) was observed. 
SK-N-SH  cells  which  contacted  other  cells  showed  localisation  for  PRPF31  which 
resembled  the  one  observed  at  the  junctions  in  MDCK  cells.  However  the 
reproducibility  in  print  was  not  representative  due  to  the  weakness  of  the  signal, 
nonetheless one example is illustrated for completeness (Figure 5.17).  
Methanol-fixed  SK-N-SH  cells  were  also  subjected  to  a  staining  with  secondary 
antibodies only, to ensure no interfering signals were present. Cells were incubated with 
donkey anti-rabbit Cy3-conjugated and donkey anti-goat FITC-conjugated antibodies. 
No significant labelling was present, as shown in panels B in Figure 5.16. 
SK-N-SH crude lysates were electrophoresed and blotted on nitrocellulose to assess the 
anti-TRAK2  antibody;  also  the  anti-PRPF31484-497  antibody  was  tested.  Figure  5.18 
illustrates the immunoblot: an anti-TRAK2 immunoreactive band was detectable at ~100 
kDa,  likely  corresponding  to  TRAK2  (indicated  by  light  blue  arrow  on  panel  A); 
PRPF31 is represented by the band at ~61 kDa (indicated by red arrow in panel B). 
 
5.6  Conclusion 
The data regarding the interactions observed by yeast two-hybrid experiments (Chapter 
3) and co-immunoprecipitation experiments (Chapter 4) is now supported by the data 
generated from localisation in cells. 
V5-MAGI3 localisation and distribution was in accordance with what has been reported 
in previous publications (Wu et al., 2000; Adamsky et al., 2003), i.e. nuclear but mainly 
cytoplasmic, in particular surrounding the nucleus and at the tight junctions. V5-TRAK2 
was present mostly in the cytoplasm, however a little nuclear staining was also detected; 
interestingly,  V5-TRAK2  was  strongly  present  in  punctuate  structures  at  cellular 
extensions. Most significantly, over-expressed 6xHis-PRPF31 appeared to be strongly 
cytoplasmic as well as nuclear, forming large nuclear aggregates which resembled the 
nucleoli.                                                        5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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Figure 5.18. Expression of TRAK2 and PRPF31 in SK-N-SH cells. 
The anti-TRAK2 antibody was used to probe a crude lysate of neuroblastoma SK-N-SH cells, and it 
detected a band at ~100 kDa likely corresponding to TRAK2, indicated by the blue arrow on panel A. 
Panel B shows the immunoblot using the anti-PRPF31484-497 antibody (PRPF31 is pointed out by the red 
arrow). The positions of molecular mass standards (kDa) are shown on the right of each blot.                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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The co-expression of 6xHis-PRPF31 and V5-MAGI3 resulted in the concentration of 
PRPF31 in nuclear aggregates, and the protein co-localised with MAGI3 within these 
aggregates.  No  other  sites  of  co-localisation  were  detected.  The  same  pattern  of 
“nucleolar” co-localisation was  also observed  with  V5-TRAK2: the two proteins co-
localised mostly to nuclear aggregates, and also to the cytoplasm, especially to spike-
like structures. 
The  observations  concerning  the  co-localisation  of  tagged  proteins  were  not 
misinterpreted because no cross-reaction between the anti-V5 antibody and the 6xHis 
tag  was  observed  (as  opposed  to  the  co-IPs,  see  Chapter  4).  The  likelihood  of  a  
cross-reaction  was  ruled  out  by  experiments  which  required  the  use  of  the  anti-V5 
antibody on 6xHis-PRPF31 expressing cells. Also, secondary antibodies did not exhibit 
any cross-reaction. 
However,  experiments  implying  the  overexpression  of  a  protein  may  give  only  an 
approximation of the in vivo situation, since the protein is present with an additional tag 
and at a higher level than the normal levels. 
Endogenous  PRPF31  localised  mainly  to  the  nucleus  in  MDCK  cells,  with  a  faint 
presence  in  the  cytoplasm;  it  appeared not  to be present  in  the  nucleoli.  Wild  type 
MAGI3 displayed the same pattern of localisation as the over-expressed protein: it was 
detected mostly at the tight junctions and around the nucleus, and weakly inside the 
nucleus. The overlays  showed that the signals from  the  two proteins did not  merge, 
suggesting no co-localisation; however, the signals overlapped at the junctions, giving a 
yellow signal in forms of little spots. Interestingly, wild type PRPF31 was found at the 
junctions  (likely  not  tight  junctions  as otherwise  co-localisation  with  MAGI3  would 
have been observed). The intercellular junction staining was also observed when using a 
different antibody against PRPF31. 
Experiments to co-localise wild type PRPF31 and TRAK2 were conducted on SK-N-SH 
cells: SK-N-SH cell line is derived from neuroblastoma cells, thus supposed to express 
TRAK2 in an amount adequate for detection (TRAK2 has been described as enriched in 
neuronal  tissues;  Brickley  et  al.,  2005).  The  staining  revealed  a  pattern  for  TRAK2 
which  resembled  the  localisation  of  the  tagged  TRAK2  protein,  i.e.  it  was  mainly 
cytoplasmic  and  surrounding  the  nucleus.  No  spike-like  structures  were  observed,                                                         5. Co-localisation of PRPF31 with MAGI3 and TRAK2 
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although this may be due to the type of cell used. Regarding PRPF31 localisation, many 
cells did not display an intense fluorescence in the nucleus; conversely they showed 
smaller speckles than in the MDCK cells. It appeared that many cells (30-50%) did not 
exhibit a distinction between the nuclear and the cytoplasmic signal: a poor labelling of 
the nucleoplasm but a distinct labelling of the cytosol around the nucleus.  
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6.  PRPF31 in MDCK Cells and Retina 
 
 
As  PRPF31  appeared  to  localise  to  intercellular  junctions  in  MDCK  cells,  the 
localisation of the splicing factor in this cell line was pursued further, as this may link to 
recent findings of splicing occurring outside the nucleus (Denis et al., 2005; König et 
al.,  2007).  Since  MDCK  cells  show  a  stable  differentiation,  allowing  inferring 
conclusions on observations, we opted to continue with their use in our investigation of 
the role of PRPF31.  As retina  is a highly stressed tissued,  we  wanted to  investigate 
whether stress events elicit any change in the pattern of localisation of PRPF31: for this 
purpose, cells MDCK were cultured under different conditions, altering the levels of 
stress. 
Furthermore, since the junctional localisation posed an interesting question regarding the 
localisation of PRPF31, we performed staining of PRPF31 in wild type murine retina 
sections. 
The results reported in this chapter reveal an interesting scene for PRPF31, however are 
far  from elucidating  the role of PRPF31 in  MDCK cells and in  mouse  retina. More  
in-depth studies addressing PRPF31 in epithelial cells and also studies targeting retina 
have to be pursued. 
 
6.1  PRPF31 Localises to the Adherens Junctions in MDCK Cells 
Chapter 5 (section 5.4) presented an unexpected  localisation of the PRPF31 splicing 
factor  in  MDCK  cells.  The  aforementioned  section,  dedicated  to  the  concomitant 
localisation of PRPF31 and MAGI3, suggested that PRPF31 not only localises to the 
nucleus, but also at intercellular junctions (localisation not previously reported). 
Cells were cultured on glass coverslips, fixed with methanol and then stained with the 
appropriate antibodies (procedures in sections 2.12.4 and 2.14.1 respectively). 
Figure 6.1 illustrates these observations: the splicing factor  was abundant in nuclear 
speckles,  in  a  granular  and  mottled  fashion;  comparing  with  the  chromatin  staining 
(panel  A2),  the nucleoli  appear  to  be  largely unstained  (white  arrows  in  panel  A3).     6. PRPF31 in MDCK Cells and Retina 
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Figure 6.1. PRPF31 localises to the nucleus and at  cell-cell junctions in wild type MDCK cells. 
PRPF31 presence at intercellular junctions is indicated by red arrows in A1. PRPF31 does not appear to 
localise to the nucleoli, as pointed by white arrows in A3. Nuclei were stained with Hoechst 33258 (blue 
signal), panel A2. Colour is indicated by legend on each black and white panel. 
     6. PRPF31 in MDCK Cells and Retina 
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A little fluorescence was detected in the cytoplasm; however, a more abundant PRPF31 
signal was observed at the periphery of the cell, likely corresponding to intercellular 
junctions (Figure 6.1, as indicated by red arrows in A1). 
As already stated, the labelling of the protein was observed at the junctions at certain 
cell densities. When cells were grown sparsely, the signal from the cell membrane was 
almost imperceptible. When the cells were grown to confluence, the signal became more 
prominent (as in Figure 6.1); however, the fluorescence of nuclear PRPF31 was stronger 
than  the  junctional,  therefore  the  exposure  was  adjusted  to  compensate  for  the  low 
junctional staining in order to detect it when recording images  (hence explaining the 
brightness of the nuclei). At higher cell density, the signal was detected on a different 
plane of focus than the nuclear plane, and as its intensity was exceeded by that of the 
nuclear signal, it was difficult to take representative pictures. 
Due to the fact that PRPF31 did not co-localise with MAGI3 (section 5.4.1), it was 
suggested that the splicing factor is not present in the tight junctions of this type of 
epithelial  cell  line,  and  with  the  conditions  employed.  We  then  hypothesised  that 
PRPF31  localised  at  the  adherens  junctions  (AJs):  to  investigate  this  hypothesis, 
PRPF31 was localised with E-cadherin, a protein known to localise to the AJs of MDCK 
cells (Sheibani et al., 2000). As shown in Figure 6.2, PRPF31 and E-cadherin exhibit a 
similar distribution pattern at the AJs (compare panels A1 with A2) and the merge panel 
illustrates the resulting yellow signal (indicated by white arrows in panel A4), suggestive 
of co-localisation. 
Cells were also co-stained for PRPF31 and SC-35. SC-35 is a non-snRNP splicing factor
 
of the SR family of proteins, and it is known to be part of the splicing complex and 
hence it can be used as a marker for splicing nuclear speckles (as in Comitato et al., 
2007). In panel A4 of Figure 6.3, the yellow signal in the nucleus illustrates that the 
mottled pattern  shown by  PRPF31 (Cy3)  merges with the dotted presence of SC-35 
(FITC). However, SC-35 appears to be less abundant, having fewer speckles, whereas 
PRPF31 is observed throughout the nucleoplasm, likely representing PRPF31 associated 
with snRNPs, but not with the spliceosomes. PRPF31 also appears to be absent from the 
nucleoli,  as  SC-35  protein  is  not  present  in  these  structures,  supporting  the  results 
reported  by  Makarova  and  co-workers  (2002).  However,  it  would  be  desirable  to     6. PRPF31 in MDCK Cells and Retina 
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perform a co-labelling with a nucleolar marker (fibrillarin for example). In Figure 6.3 
the adherens junction staining of PRPF31 is also visible. 
 
6.2  PRPF31 Localisation in G0/G1 Arrested Cells 
To  investigate  PRPF31  localisation  in  epithelial  cells  according  to  the  normal 
proliferative state of mammalian cells, MDCK cells were arrested at the G0/G1 phase. 
To specifically target cell proliferation, cells were treated with CDK inhibitors (protocol 
described in section 2.12.5) to arrest the cell cycle. 
Two  inhibitors  were  used:  olomoucine,  which  is  specific  for  CDK2,  and  “CDK4 
inhibitor”, which is specific for CDK4. After 24 hours of treatment, cells were fixed 
with  methanol,  stained  for  PRPF31  using  the  anti-PRPF31484-497  antibody  (for 
procedures, see sections 2.12.4 and 2.14.1) and examined at the microscope. Results are 
shown in Figure 6.4. 
Olomoucine-treated cells grew in islands; they presented round nuclei, similar to the the 
untreated cells  (compare panel  A2  with C2);  PRPF31  was detected at the junctions, 
although its signal was more attenuated and weaker than the wild type (signal indicated 
by  the  red  arrows  in  panel  A1),  nonetheless  it  still  delineated  the  cell  borders. 
Olomoucine-treated cells appeared to be sparser and more separated than the untreated 
cells. 
Cells  treated  with  CDK4  inhibitor  (panels  B)  were  sparser,  compared  to  both  the 
olomoucine-treated  cells  and  the  untreated.  They  also  appeared  to  grow  in  smaller 
patches  compared  to  the  untreated  cells,  and  the  nuclei  were  not  as  round  as  the 
untreated control. PRPF31 localised both to the nucleus and to the intercellular junctions 
(red arrow in panel B1), and the junctional signal appeared to be more prominent than 
the olomoucine-treated cells. 
In both cases, the protein did not appear to be present in the nucleoli, according to the 
chromatin staining with Hoechst (white arrows in panels A3 and B3).     6. PRPF31 in MDCK Cells and Retina 
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Figure 6.4. PRPF31 localises to the nucleus and to intercellular junctions during G0/G1 phase in 
MDCK cells. 
Panels A refer to Olomoucine-treated cells; panels B to CDK4-inhibitor-treated cells; panels C to the 
untreated cells. PRPF31 localisation is illustrated in panels A1, B1 and C1 (Cy3); Hoechst 33258 in A2, 
B2 and C2 (blue signal); A3, B3 and C3 represent the overlays. Red arrows in A1 and B1 indicate the 
junctional staining  for PRPF31 in treated  cells; white arrows in the overlays A3 and B3 indicate the 
nucleoli of the treated cells, according to the Hoechst chromatin stain. Colour is indicated by legend on 
each black and white panel. 
     6. PRPF31 in MDCK Cells and Retina 
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6.3  PRPF31 Localisation under Stress Conditions 
To investigate whether the distribution of the splicing factor is affected during stress 
conditions, PRPF31 localisation in MDCK cells was examined after stress treatments of 
the cells. Two different methods were applied to insult the cells: a temperature stress, 
heat-shocking  the cells  at  43°C  for  two hours  (procedure  in  section 2.12.6),  and  an 
osmotic stress, varying the concentration of salts in the medium (section 2.12.7). Cells 
were  then  fixed  with  methanol  and  incubated  with  the  anti-PRPF31484-497  antibody 
(procedures  2.12.4  and  2.14.1  respectively),  together  with  the  anti-SC-35,  
anti-E-cadherin (AJs marker) and anti-MAGI3 (one interacting partner) antibodies. The 
results are described in the next two sections. 
 
 
6.3.1  Heat Shock 
PRPF31 localisation on cells subjected to heat-shock treatment appeared to be similar to 
the untreated cells: as shown in Figures 6.5, 6.6 and 6.7, PRPF31 immunoreactivity is 
detected at the AJs and in the nucleus, predominantly in speckles (panels A1 of the 
aforementioned figures). However, it appeared that the intensity of the signal from the 
AJs due to PRPF31 was stronger than the untreated sample (compare panels A1 and B1 
of Figures 6.5, 6.6 and 6.7, where panels A1 illustrate the treated sample and panels B1 
illustrate the untreated sample). 
Antibody  against  SC-35  was  used  to  localise  the  spliceosomes,  and  its  signal  was 
detected  mainly  in nuclear  speckles,  along  with  a  faint  halo  throughout  the nucleus 
(panel A2 of Figure 6.5), resembling the untreated cells (panel B2). The simultaneous 
localisation of PRPF31 and SC-35 revealed co-localisation (yellow signal in A4 and B4) 
of the two proteins in splicing nuclear speckles, in both treated and untreated cells. 
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As shown on Figure 6.6 (panel A4), the signal from the anti-PRPF31484-497 antibody 
poorly localises with the signal from the anti-E-cadherin antibody in the heat-shocked 
cells.  Nonetheless  it  appears  that  the  junctional  pattern  of  PRPF31  is similar  to  the 
pattern of E-cadherin. It may be that the procedures were inadvertently altered while 
processing the cells, hence the poorer localisation of PRPF31 to the junctions compared 
to different samples of treated cells. 
A third set of coverslips were incubated with the anti-PRPF31484-497 and the anti-MAGI3 
antibodies (Figure 6.7): in heat-shocked cells, PRPF31 localised to the nucleus and to 
the AJs (panel A1), and MAGI3 localised mainly to the TJs (panel A2 of Figure 6.7). 
The localisation pattern given by the anti-PRPF31484-497 antibody appeared towards the 
inward part of the membrane, whereas the pattern for MAGI3 delineated the outer part 
of the plasma membrane. The overlay from PRPF31 and MAGI3 signal does not appear 
yellow, however  a partial overlap on the  lower left part of  the plasma membrane  is 
observed (as indicated by the white arrow in panel A4). 
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6.3.2  Osmotic Stress 
Cells  were  put  under  osmotic  stress  by  altering  the  physiological  osmolarity  (300 
mOsm; procedure in section 2.12.7) of the culturing medium to: 
-  600 mOsm for a hyperosmotic stress; 
-  150 mOsm for a hypoosmotic stress. 
Two sets of cells were treated separately with the two media for 2 hours. Cells were then 
fixed with methanol and stained with the anti-PRPF31484-497 antibody, together with the 
anti-SC-35  antibody  for  detection  of  splicing  nuclear  speckles,  the  anti-E-cadherin 
antibody for the adherens junctions and the anti-MAGI3 antibody for the interacting 
partner MAGI3 (protocols described in sections 2.12.4 and 2.14.1). 
As the heat-shock and osmotic stress experiments were conducted on the same batch of 
cells and at the same time, the images of the untreated cells reported in this section 
correspond to the images of the untreated cells of the heat-shock experiment. 
Figures  6.8,  6.9  and  6.10  show  the  cells  stained  for  PRPF31,  together  with  SC-35 
(Figure 6.8), E-cadherin (Figure 6.9), and MAGI3 (Figure 6.10). Each figure illustrates 
cells treated with hyperosmotic- and hypoosmotic-medium and the untreated control. 
In cells which underwent treatment with hyperosmotic medium, PRPF31 (all panels A1 
of Figures 6.8, 6.9 and 6.10) appeared to be in the nucleus and also at the AJs, as in the 
untreated cells. PRPF31 presence appeared to be more granular than the untreated cells 
in both the nucleus and the junctions; SC-35 signal was also observed in larger granules 
(panel A2, Figure 6.8). In addition, PRPF31 appeared to be present in the nucleoli, a 
localisation  which  was not observed  in the untreated cells. The nucleolar  staining is 
visible in Figure 6.8, and is indicated by a red arrow in panel A1 and a green arrow in 
panel A2 (SC-35), and white arrows in the overlay panel A4. Figure 6.9 shows that the 
anti-E-cadherin fluorescence pattern is shared with the anti-PRPF31484-497 fluorescence 
pattern: PRPF31 appeared to be prominent at the adherens junctions. Panel A4 of Figure 
6.9 shows the merge image, with an intense yellow signal along the adherens junctions, 
indicative of co-localisation of the two proteins. MAGI3 was present at the TJs (Figure 
6.10, panel A2), and in the nucleus; in the latter the fluorescence was diffuse, resembling 
a halo, and showed increased intensity towards the centre (green arrow, panel B2), likely      6. PRPF31 in MDCK Cells and Retina 
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a nucleolus, as identified by the Hoechst staining (Figure 6.10, panel A3). The nuclear 
and  nucleolar  signals  for  MAGI3  were  more  prominent  in  the  cells  treated  for 
hyperosmotic stress than for the hypoosmotic stress. Furthermore, the pattern resembled 
the one observed when V5-tagged MAGI3 was expressed in MDCK cells (compare with 
Figures 5.6 and 5.7 in section 5.2.5 of Chapter 5). Merging the three signals together –
PRPF31,  MAGI3  and  Hoechst,  (red,  green  and  blue  respectively)  –  reveals  a  co-
localisation  of  PRPF31  and  MAGI3  to  the  nucleolus  and  partially  to  the  junctions 
(yellow signal in panel A4, indicated by white arrows). 
In cells treated with hypoosmotic-medium, PRPF31 presence was detected mainly in the 
nucleus, and did not appear to be in the nucleoli as the co-staining for the SC-35 protein 
revealed (Figure 6.8, panels B1 and B2, to be compared with the nuclear staining B3). 
Also, the fluorescence appeared to be more evenly distributed in the nucleoplasm, with 
smaller speckles than the hyperosmotic stressed cells. The junctional staining was weak 
and barely visible, almost absent in places. Also, the faint cytoplasmic staining usually 
seen for PRPF31 in wild type cells, was not detectable, leaving the cytoplasm almost 
unlabelled in comparison. 
The markers SC-35 (Figure 6.8, panel B2) and E-cadherin (Figure 6.9, panel B2) also 
produced  a  fainter  signal  compared  to  untreated  cells  and  to  hyperosmotic-medium 
treated cells, however co-localisation with PRPF31 was still observed. 
The hyperosmotic stress generally appeared to affect cell morphology, as proteins and 
chromatin detection revealed grainy patterns. However, PRPF31 still localised to the 
adherens junctions, as well as to the nucleus, and strongly to structures resembling the 
nucleoli (as revealed by co-localisation with SC-35). 
The co-localisation between PRPF31 and MAGI3 reinforces what was observed in the 
co-localisation experiments performed using the tagged proteins (compare with section 
5.2.5 and Figures 5.6 and 5.7 of Chapter 5). However, the “nucleolar” co-localisation 
observed between MAGI3 and PRPF31 under stress conditions may be considered either 
an  artefact  due  to  abnormal  conditions,  such  as  transfecting  reagents  and change  in 
medium composition, or may be considered a “normal response” which occurs in cells 
under certain physiological stresses (exemplified by a transfecting reagent and an altered 
medium in this case).     6. PRPF31 in MDCK Cells and Retina 
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6.4  Localisation of PRPF31 in Murine Retina 
We performed immunohistochemistry using the anti-PRPF31484-497 antibody on sections 
of retina from a light-adapted mouse. Sections from this type of retina were extensively 
used  for  following  labellings;  however  dark-adapted  mouse  retina  was  also  used, 
although only to detect PRPF31. 
In  retina  from  a  light-adapted  mouse,  anti-PRPF31484-497  immunoreactivity  was  not 
extensively observed in the photoreceptor nuclei. As Figure 6.11 shows, the signal from 
PRPF31 was detected mostly in the inner segment of photoreceptors and in the outer 
plexiform layer. Also, PRPF31 was detected in, but mostly around, the nuclei of the 
cells composing the inner nuclear layer, just below the signal from the outer plexiform 
layer in panel A1. Anti-PRPF31484-497 also weakly labelled the inner plexiform layer and 
ganglion cell layer. As mentioned, the splicing factor was observed to localise in strips 
bordering the nuclei of both the inner and the outer nuclear layers. This signal was more 
prominent  in  the  inner  nuclear  layer.  A  retina  section  incubated  with  a  secondary 
antibody (Cy3-conjugated, used to detect the anti-PRPF31484-497 antibody) did not show 
any significant staining  that may influence  the  interpretation  of PRPF31 localisation 
(panel B1 of Figure 6.11). 
To ascertain whether PRPF31 translocates in response to light, similar to arrestin and 
transducin (arrestin found in outer segments in light adapted retinas and proximal to the 
connecting cilium in dark adapted retina, the opposite is true for transducin; Reidel et 
al., 2008), a retina section from a dark-adapted mouse was labelled for PRPF31. Figure 
6.12 illustrates that the distribution of PRPF31 is similar to the light-adapted retina: in 
fact, fluorescence due to anti-PRPF31484-497 immunoreactivity is strongly detected in the 
photoreceptor inner segment and in the outer plexiform layer. The signal appeared to be 
stronger in the IS than in the OPL as compared to the light-adapted retina (in which the 
opposite was observed, i.e. weaker in the IS and stronger in the OPL), however, this is a 
qualitative assessment and a detailed investigation may be required. Furthermore, this 
observation  may  be  an artefact produced  by the  procedure of the preparation of  the 
retina. The signal was also detected in the inner nuclear layer and in the inner plexiform 
layer  to  a  lesser  extent.  Dark-adapted  mouse  retina  incubated  with  Cy3-conjugated 
secondary antibody did not show any significant staining (panel B1 of Figure 6.12).     6. PRPF31 in MDCK Cells and Retina 
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Figure 6.11. PRPF31 localisation in light-adapted mouse retina. 
PRPF31 (A1; Cy3) localises to the inner segment, to the outer plexiform layer and to the inner nuclear 
layer but not within the nuclei of the outer nuclear layer in light-adapted murine retina. A2: Hoechst 33258 
stain; A3: overlay. B1: section incubated with Cy3-conjugated secondary antibody and Hoechst 33258. 
Colour is indicated by legend on each black and white panel. 
(OS: outer segment; IS: inner segment; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner 
nuclear layer; IPL: inner plexiform layer; GCL; ganglion cell layer).     6. PRPF31 in MDCK Cells and Retina 
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Figure 6.12. PRPF31 localisation in dark-adapted mouse retina. 
PRPF31 (in A1; Cy3) localises to the inner segment, to the outer plexiform layer and to the inner nuclear 
layer but not within the nuclei of the outer nuclear layer in dark-adapted murine retina. A2: Hoechst 33258 
stain;  A3:  overlay.  B1:  section  from  dark-adapted  mouse  incubated  with  Cy3-conjugated  secondary 
antibody and Hoechst 33258. Colour is indicated by legend on each black and white panel. 
(OS: outer segment; IS: inner segment; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner 
nuclear layer; IPL: inner plexiform layer).     6. PRPF31 in MDCK Cells and Retina 
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An anti-Rhodopsin antibody, a marker of the rod photoreceptor outer segments, was 
used to ascertain whether PRPF31 was present in the rod outer segment. Figure 6.13 
illustrates  that  PRPF31  does  not  appear  to  localise  to  the  outer  segments  of  rod 
photoreceptors,  as  no  yellow  signal  (indicative of co-localisation) is  observed in  the 
merge image with Rhodopsin (panel A4 of Figure 6.13). 
From the previous observation, we proceeded to investigate the localisation of PRPF31, 
using the anti-TOPORS antibody. The TOPORS protein has been detected at the base of 
the  connecting  cilium  of  the  rod  photoreceptors  (Dr  C.  Chakarova  personal 
communication),  hence  the  anti-TOPORS  antibody  was  used  to  evaluate  PRPF31 
presence in the connecting cilium. Figure 6.14 illustrates the localisation of PRPF31 and 
TOPORS, showing that PRPF31 does not appear to localise to the connecting cilia, as no 
distinct yellow signal is present. The partial overlap in panel A4 may be due to a cutting 
plane not parallel to the plane of the retina; however no co-localisation is observed, as 
shown by the overlay B4 (from confocal microscopy). 
Figure 6.15 shows a murine retina section stained with the anti-PRPF31484-497 antibody 
and  peanut  agglutinin  (PNA),  which  is  a  marker  for  cone  cells.  PNA  detects 
carbohydrates found only in the extra cellular matrix sheaths of cone photoreceptors, 
allowing the rod and cone photoreceptors to be distinguished (van der Spuy et al., 2002).  
This  staining  should  highlight  cone  photoreceptors  and  may  provide  a  better 
appreciation of PRPF31 presence in the retina. It is expected that PRPF31 is present in 
both rods and cones, as it is a ubiquitous protein; however, if localisation is limited to 
only the rod photoreceptors, it may be indicative of a disease mechanism underlying 
retinal degeneration, such as RP. The overlay A4 did not show a distinct yellow signal as 
the fluorescence from the cone marker was much higher than that of PRPF31. However, 
on  closer  inspection  (Figure  6.15,  overlay  B4;  from  confocal  microscopy),  PRPF31 
appears to be present in cone photoreceptors inner segments.     6. PRPF31 in MDCK Cells and Retina 
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Figure 6.14. PRPF31 and Topors do not co-localise to the connecting cilium in murine retina. 
Panels A illustrate the localisation of PRPF31 (Cy3; in A1 and B1) and TOPORS (FITC; in A2 and B2) in 
respect  to  the  entire  retina.  Panels  B  (from  confocal  microscope)  show  an  enlargement  of  the  inner 
segment and connecting cilium area. A3, B3: Hoechst 33258 stain; A4, B4: overlays. Colour is indicated 
by legend on each black and white panel. 
(OS: outer segment; CC: connecting cilium; IS: inner segment; ONL: outer nuclear layer; OPL: outer 
plexiform layer; INL: inner nuclear layer).     6. PRPF31 in MDCK Cells and Retina 
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Figure 6.15. PRPF31 localises in cone photoreceptors in mouse retina. 
Panels A illustrate the co-localisation of PRPF31 (Cy3; in A1 and B1) and PNA (Cy2; in A2 and B2). 
Panels B (from confocal microscopy) show an enlargement of the inner segment area, evidencing overlay 
between red and green signals. A3, B3: Hoechst 33258; A4, B4: overlays. Colour is indicated by legend 
on each black and white panel. 
(OS: outer segment; IS: inner segment; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner 
nuclear layer).     6. PRPF31 in MDCK Cells and Retina 
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A double labelling with the anti-PRPF31484-497 and the anti-MAGI3 antibodies was also 
performed, to ascertain whether PRPF31 and MAGI3 co-localise in retina. Figure 6.16 
illustrates what has been previously shown for PRPF31, which localised to the inner 
segment, to the inner and outer plexiform layer, and the inner nuclear layer (panel A1 of 
Figure  6.16).  Anti-MAGI3  immunoreactive  fluorescence  was  detected  in  the  outer 
segment, marking the photoreceptor outer segments; a weaker signal was also present in 
the inner segment. The signal also labelled the outer and inner plexiform layers (Figure, 
6.16;  panel  A2).  Therefore,  it  is  possible  that  PRPF31  and  MAGI3  overlap  in  the 
plexiform layers and partly to the inner segment (overlay shown in panel A4 of Figure 
6.16). Panels B show a magnification of a cell from the inner nuclear layer which was 
observed to be labelled around the edge by both antibodies. A number of inner nuclear 
layer  cells,  bordering  the  inner  plexiform  layer  and  presenting  this  pattern  were 
observed; however they were not abundant and hence may be a particular type of cell. 
We were also interested in the second interacting partner, TRAK2, for which we had 
available two antibodies: the anti-TRAK2 antibody used for staining the SK-N-SH cells 
did  not  give  a  significant  signal  in  retina.  We  therefore  performed 
immunohistochemistry using the second antibody, anti-GRIF18-633, which was raised in 
rabbit, and hence could not be coupled with the anti-PRPF31484-497 antibody.  
Both the goat anti-TRAK2 and the commercial antibody goat anti-PRPF31140-154 did not 
give a significant signal in retina, which may be due to the type of fixation used for the 
mouse tissue. 
Nonetheless,  a  single  staining  with  the  anti-GRIF18-633  antibody  was  performed  to 
investigate TRAK2 localisation and infer whether or not it co-localised with PRPF31.  
From Figure 6.17, it appears that TRAK2 was detected strongly amid the nuclei of the 
photoreceptor cells (outer nuclear layer), in the upper portion of the outer plexiform 
layer  and  in the  ganglion  cell  layer.  The  antibody  also  labelled  the  inner  and  outer 
segments, however the signal was weak. The TRAK2 localisation pattern suggests that if 
TRAK2  and  PRPF31  interact,  this  may  happen  at  the  edges  of  their  respective 
expression domains,  such  as  the  outer  plexiform  layer  and  the  inner  segment  layer; 
however this speculation should be corroborated by performing the experiment using    6. PRPF31 in MDCK Cells and Retina 
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Figure 6.16. PRPF31 and MAGI3 signals overlap at the inner segment, outer plexiform layer and 
inner plexiform layer in mouse retina. 
A1, B1: PRPF31 (Cy3); A2, B2: MAGI3 (FITC); A3, B3: Hoechst 33258; A4, B4: overlays. Colour is 
indicated by legend on each black and white panel. 
(OS: outer segment; IS: inner segment; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner 
nuclear layer; IPL: inner plexiform layer).     6. PRPF31 in MDCK Cells and Retina 
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Figure 6.17. Localisation of TRAK2 in murine retina. 
TRAK2 (in A1; Cy3) is predominantly detected in the outer nuclear layer, in the outer plexiform layer and 
in the ganglion cell layer. A2: Hoechst 33258; A3: overlay. Colour is indicated by legend on each black 
and white panel. 
(OS: outer segment; IS: inner segment; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner 
nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer).     6. PRPF31 in MDCK Cells and Retina 
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antibodies raised in different species in order to achieve a simultaneous detection of the 
proteins. 
The localisation of three other splicing factors was investigated in retina: PRPF3, PRPF8 
and PRPF16. PRPF3 and PRPF8 genes are involved in tri-snRNP assembly (Liu et al., 
2006) and known to be mutated in RP (Chakarova et al., 2002; McKie et al., 2001). 
PRPF16  is  involved  in  the  later  stages  of  splicing,  in  structural  remodeling  of  the 
spliceosome (Wahl et al., 2009); to date, no mutations causing retinal degeneration have 
been reported in PRPF16. 
Co-staining with PRPF31 was not possible as the antibodies were raised in the same 
species (rabbit). 
Figures 6.18 and 6.19 show the labelling of PRPF3 and PRPF8 respectively. The two 
splicing factors shared a similar pattern of localisation as PRPF31: PRPF3 and PRPF8 
were localised to the inner segment and outer plexiform layer; they were observed to 
weakly surround the nuclei of the photoreceptors, in streaks amid the nuclei as PRPF31; 
also, they did not appear to be present within the photoreceptor nuclei. Interestingly, 
both PRPF3 and PRPF8 antibodies showed a stronger signal from the inner nuclear layer 
than PRPF31. However, to ascertain whether there is any difference among the splicing 
factor distributions, a co-staining on the same retina section would be of great value, 
allowing  a  direct  comparison  of  the  localisation  signals.  All  three  splicing  factors, 
PRPF31, PRPF3 and PRPF8, weakly labelled the ganglion cell layer. 
Conversely, PRPF16 localisation appeared to be different to that of PRPF31, PRPF3 and 
PRPF8. The PRPF16 splicing factor localised to some photoreceptor nuclei and also 
around  them,  in  a  circular  pattern  (ONL  layer  in  panel  A1  of  Figure  6.20).  The 
anti-PRPF16 antibody also weakly labelled the outer plexiform layer, the inner nuclear 
layer with a granular signal, more prominent in the nucleoplasm than the other splicing 
factors tested. PRPF16 also appears to be present in the nuclei of the ganglion cell layer, 
and in the nuclei of the RPE cells. The inner segment of photoreceptor cells appeared 
weakly labelled.     6. PRPF31 in MDCK Cells and Retina 
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Figure 6.18. PRPF3 shows a similar pattern of localisation to PRPF31 in mouse retina. 
PRPF3 (A1; Cy3) is prominently found in the inner segment, the outer plexiform layer and in the inner 
nuclear layer. A2: Hoechst 33258; A4: overlay. Colour is indicated by legend on each black and white 
panel. 
(OS: outer segment; IS: inner segment; ONL: outer nuclear layer; OPL: outer plexiform layer; INL: inner 
nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer).     6. PRPF31 in MDCK Cells and Retina 
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Figure 6.19. PRPF8 shows a localisation pattern comparable to PRPF31 in mouse retina. 
Also  PRPF8  (Cy3;  in  A1)  localises  to  inner  segment,  outer  plexiform  layer  and  inner  nuclear  layer 
predominantly. A2: Hoechst 33258; A4: overlay. Colour is indicated by legend on each black and white 
panel. 
(RPE: retinal pigment epithelium; OS: outer segment; IS: inner segment; ONL: outer nuclear layer; OPL: 
outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer).     6. PRPF31 in MDCK Cells and Retina 
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Figure 6.20. PRPF16 localisation in murine retina differs from the tri-snRNP associated splicing 
factors PRPF31, PRPF3 and PRPF8. 
PRPF16 (Cy3; in A1) localises mostly to the inner nuclear layer and the ganglion cell layer, and weakly to 
the outer nuclear layer and the outer plexiform layer. It is also detected in the RPE nuclei. A2: Hoechst 
33258; A4: overlay. Colour is indicated by legend on each black and white panel. 
(RPE: retinal pigment epithelium; OS: outer segment; IS: inner segment; ONL: outer nuclear layer; OPL: 
outer plexiform layer; INL: inner nuclear layer; IPL: inner plexiform layer; GCL: ganglion cell layer).     6. PRPF31 in MDCK Cells and Retina 
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6.5  Conclusion 
As observed in Chapter 5, PRPF31 had a significant presence at the junctions in MDCK 
cells.  In  this  chapter  we  proceeded  with  additional  labellings  to  ascertain  whether 
PRPF31 presence at intercellular junctions was affected by changes in the physiological 
conditions of the cells. 
In wild type MDCK cells, PRPF31 was localised to the adherens junctions as the co-
staining  with  E-cadherin  revealed.  PRPF31  was  also  shown  to  be  absent  from  the 
nucleoli (from SC-35 co-staining), as was previously described (Makarova et al., 2002), 
but strongly present  in the  rest of  the nucleus  as expected. However,  the pattern of 
localisation at the junctions appeared to be grainy and mottled and not as uniform as that 
of E-cadherin. At times it was interrupted, appearing in different planes of the cell, thus 
suggesting a fluctuation of the proteins’ localisation (however, it may be also due to the 
cells not being completely horizontal). 
Treatment with CDK inhibitors to arrest cells in G0/G1 phase moderately altered the 
distribution of PRPF31: olomoucine treatment retained the PRPF31 signal mostly in the 
nucleus, and the junctions were not as intensely labelled as the untreated cells. There 
were fewer cells for which PRPF31 was present at the junctions and the observed signal 
was much weaker. On the other hand, cells treated with the CDK4 Inhibitor, still showed 
nuclear and junctional staining, although the latter was quite intermittent. 
Heat-shocked cells and cells treated with hyperosmotic-medium showed PRPF31 at the 
junctions, but interestingly, its presence was more prominent than in the untreated cells. 
Furthermore, hyperosmotic-stressed cells showed a peculiar localisation of PRPF31 in 
the nucleoli, which was not observed in untreated samples. The hypoosmotic-stressed 
cells showed a weaker, almost imperceptible staining at the junctions for PRPF31. 
Concerning the murine retina, PRPF31 would be expected to be found mostly in the 
nucleus of retina cells, however, not all the nuclei showed this localisation: in fact, only 
the inner nuclear layer and the ganglion cells (although weakly) show PRPF31 in the 
nucleus. The splicing factor was then observed in the inner and outer plexiform layers 
(layers  of  neuronal  synapses  from  ganglion  cells  and  bipolar  cells,  and  from 
photoreceptor  cells  and  horizontal  and  bipolar  cells  respectively),  and  in  the 
photoreceptor inner segments, of both rods and cones. Interestingly, PRPF31 was found     6. PRPF31 in MDCK Cells and Retina 
 
  199 
at the borders of the cells on inner and outer nuclear layer. PRPF31 localisation did not 
appear to be greatly affected by light and dark adaptation. 
MAGI3 signal in retina was predominantly observed in the outer segment, delineating 
the outer segments of photoreceptors; in the remaining layers of the tissue MAGI3 signal 
was generally faint, labelling weakly the inner segment and the outer plexiform layer. 
Interestingly, its presence was observed in few cells along the lower section of the inner 
nuclear layer, overlapping with the signal from PRPF31. From the localisation sites of 
MAGI3, it is possible to reason that the signals for the splicing factor and MAGI3 may 
overlap in the outer plexiform layer and in the region between the inner nuclear layer 
and the inner plexiform layer. 
Results from  the PRPF3 and  PRPF8 labellings supported  the observations regarding 
PRPF31:  these  splicing  factors  were  also  detected  in  the  inner  segments,  the  outer 
plexiform layer, the inner nuclear layer and ganglion cell layer, in a similar manner as 
PRPF31, with streaks lining the nuclei of photoreceptors cells and inner nuclear layer, 
and in the ganglion cells with a weak signal from the nuclei. 
PRPF16 showed a different distribution in retina: the splicing factor was observed in the 
nuclei of the inner nuclear layer, and also in some nuclei of the photoreceptor cells, and 
in that same layer also it surrounded the nuclei in a circular fashion. Opposed to PRPF31 
(and PRPF3 and PRPF8), PRPF16 was observed in some nuclei of the retinal pigment  
epithelium.  
200 
7.  Retina Isoforms and Mutation Screening 
 
 
The results discussed in the previous chapters suggested MAGI3 and TRAK2 as novel 
interacting  partners  of  PRPF31.  However,  MAGI3  and  TRAK2  genes  are  not 
retina-specific but are instead expressed in a wide range of tissues. It may be that a 
retina-specific transcript is produced, whose protein interacts with PRPF31: Part I of this 
chapter is dedicated to the study conducted on human retina RNA to verify the possible 
existence of retina-specific transcripts, for both MAGI3 and TRAK2. 
If the two interactants are involved in PRPF31 pathway, it is possible that a mutation in 
their genes may lead to retinal degeneration. Therefore the genes may be considered 
candidates  for  screening  of  mutations  in  patients  affected  by  RP.  Part  II  addresses 
screening of patients, affected by autosomal dominant RP, in order to find mutations in 
MAGI3, potentially linked to retinal degeneration. 
 
 
 
Part I  Isoform Study on Retina for MAGI3 and TRAK2 
 
PRPF31 is a splicing factor and ubiquitously expressed protein, however mutations in 
PRPF31 only result in retinal degeneration. As described in Chapter 3, the interacting 
proteins found from the bovine library corresponded to human MAGI3 and TRAK2, 
later  proven  to  be  associated  with  PRPF31  by  co-immunoprecipitation  and 
co-localisation studies (Chapters 4 and 5). Both MAGI3 and TRAK2 are expressed in a 
wide range of tissues, (see Chapter 3, sections 3.6.1, 3.6.3 and 3.7). It was proposed that 
these proteins may have a retina-specific transcript, which interacts with PRPF31 and 
produces  eye  specific  function.  Therefore,  the  amplification  of  the  transcripts  as 
predicted by the Ensembl database was performed, using human retina RNA. PRPF31 
transcript  was  not  included  in  the  experiments,  since  the  presence  of  alternative,  
retina-specific isoforms of PRPF31 was recently excluded by Tanackovic and Rivolta     7. Retina Isoforms and Mutation Screening 
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(2009): the authors have analyzed PRPF31 transcripts by PCR on cDNA derived from 
human retina, a whole eye as a positive control, and HeLa cells as a negative control. 
The detected changes affected the 5’ UTR region, but not the coding region. This was 
also proven by western blot, showing the presence of a single band, corresponding to the 
full-length protein. 
 
7.1  Amplification  of  MAGI3  and  TRAK2  Coding  Sequences  from 
Human Retina Total RNA 
Human retina total RNA was used to prepare retina cDNA, following the procedure 
described in section 2.9.6. Oligonucleotides (listed in section A.3 and A.4 for MAGI3 
and TRAK2 respectively, in Appendix) were designed to allow the amplification of DNA 
fragments of approximately ~1kb in length, using KOD Hot Start DNA polymerase. The 
aim was to investigate whether a different protein isoform was expressed in retina. 
 
7.1.1  MAGI3 
Figure  7.1  is  a  representation  of  the  four  transcripts  of  MAGI3  (Ensembl  database, 
accessed January 2009). 
MAGI3-001 is considered the reference sequence in Ensembl: it shows the longest 5’ 
UTR and 3’ UTR (see Figure 7.2 A and B), and comprises 21 exons. MAGI3-002 differs 
from MAGI3-001 by an extra exon (exon 7a, 75 bp long), in between exons 7 and 8 of 
the reference transcript. MAGI3-003 shares the same exon architecture as MAGI3-001, 
although it presents a shorter 5’ UTR and a portion of the 3’ UTR is missing, generating 
an extra exon, 21a. MAGI3-004  shows  a shorter 5’  UTR and shares the  same exon 
architecture as MAGI3-001, but displays a shorter exon 21. 
Intron 1 is almost 160 kb, intron 2 is ~31 kb. Also introns 6, 9 and 16 are long (~19, kb, 
~20 kb and ~12 kb respectively). The gene spans ~295 kb. 
The  experimental  design  was  aimed  to  verify  which  isoform(s)  is(are)  expressed  in 
retina, and if there are new, alternatively-spliced retina-specific transcripts. 
The lower part of Figure 7.1 provides a schematic view of the portions of transcripts 
designed  to  be  amplified.  The  approach  implied  the  design  of  eight  overlapping 
fragments: in the figure, a black bar is assigned to each of them (eight bars in total,    7. Retina Isoforms and Mutation Screening 
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Figure 7.2. Diagram to show MAGI3 UTRs. 
In  A:  MAGI3  5’UTR;  in  B:  MAGI3  3’UTR.  Rectangles  represent  exons  (light  blue:  UTR;  white: 
translated; connecting lines: introns - not to scale). Numbers 1, 2, 3 and 4 on the right of the transcripts 
represent the variant (1 is for MAGI3-001, and forth). Numbers inside the exons represent the length in 
base pairs. Red arrows denote the position of primers, marked by capital letters. 
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numbered 1 to 8), spanning several adjacent exons, and overlapping by two exons (for 
further details on the length, see Table 7.1). 
Although our interest was mainly focused on the coding region of the transcripts, the 
UTRs were included in the experiments to ensure that any potential exons lying within 
these regions were not excluded. 
Figure 7.2 provides a diagrammatic representation of the 5’ and 3’ untranslated regions 
of MAGI3. For the 5’ region, the approach consisted of amplifying regions which were 
assumed to be transcribed (hybrids of translated and untranslated regions), and regions 
which were assumed not to be transcribed (according to Ensembl): hence, a set of three 
forward primers (A, B and C in Figure 7.2 A) were designed on the upstream intronic 
region of the 5’ UTR, encompassing <600 bp; a unique forward primer was designed to 
anneal on the UTR region (primer D in Figure 7.2 A, position -89). The four forward 
primers were coupled with a unique reverse oligonucleotide (E) pairing to the translated 
sequence, after the ATG start site. 
For the 3’ region, the approach involved the generation of amplicons spanning part of 
the penultimate exon and part of the last exon (forward primers F and H respectively, 
Figure 7.2 B), using different 3’ end points (reverse primers G and I, Figure 7.2 B). 
Following  are  three  tables,  which  summarise  the  oligonucleotide  pairs  used,  the 
expected length of the corresponding products, and the transcript versions of the gene. 
Table 7.1 is for the coding region of the MAGI3 mRNAs. Tables 7.2 and 7.3 are for the 
UTR region. Table 7.2 and 7.3 also feature small drawings of the expected products, 
based on the drawing of Figure 7.2.     7. Retina Isoforms and Mutation Screening 
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Table 7.1. Expected fragment sizes for MAGI3 mRNA sequence (translated region). 
#  1  2  3  4  5  6  7  8 
Exons  1-4  2-8  6-10  8-12  10-14  12-17  15-21  20-21 
Length  763 
855 / 930 
(vv 1,3,4 
/ 2) 
1028 /  
1103 (vv 
1,3,4 / 2) 
1079  980  920  938 
1057 (vv 1,2) / 
463 (v 3) / 
372 (v 4) 
Summary  of  the  fragments to be amplified:  the  exon  interval,  the  length  in bp  is indicated  for each 
fragment (1 to 8 as in Figure 7.1); for  fragments 2, 3 and 8, the sizes  according to the isoforms are 
reported (for example, “v1” is for variant MAGI3-001). 
 
 
 
 
Table 7.2. Expected fragments for MAGI3 5’ UTR. 
Primers 5'  MAGI3-001  MAGI3-002  MAGI3-003  MAGI3-004  Genomic 
A + E (9)  n.e.  n.e.  n.e.  n.e.  607 
B + E (10)  n.e.  n.e.  n.e.  n.e.  413 
C + E (11)  n.e.  n.e.  n.e.  n.e.  281 
D + E (12)  142     142     n.e.  n.e.  142 
The  oligonucleotides  refer  to  the  Figure  7.2  A.  The  table  provides  the  expected  product  sizes  (bp) 
according to the pair of oligonucleotides used and the transcript version, plus genomic DNA. N.e. stands 
for “not expected”, as no amplicons is expected. The rectangles depict the expected products, referring to 
Figure 7.2 A (light blue: UTR; white: translated - not to scale). 
 
 
 
 
Table 7.3. Expected fragments for MAGI3 3’ UTR. 
Primers 3’  MAGI3-001  MAGI3-002  MAGI3-003  MAGI3-004  Genomic 
F + G (13)  138     138     138     n.e.  1013 
F + I (14)  1024     1024     430     339     1899 
H + I (15)  883     883     289     n.e.  883 
Primer pairs according to Figure 7.2 B. The table presents the expected product sizes (bp) according to the 
primer pair, the transcript and genomic DNA. N.e. stands for “not expected”. The rectangles illustrate the 
expected products, referring to Figure 7.2 B (light blue: UTR; white: translated - not to scale). 
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Figure 7.3 shows  the  products  of  the  amplification of  MAGI3  coding  sequence:  the 
primers were designed to amplify the fragments listed in Table 7.1. Genomic DNA (g 
lanes)  was  included  in  the  amplification.  Lanes  corresponding  to  the  fragments  are 
marked by progressive numbers 1-8 (see Table 7.1 for expected sizes): 
- lane 1: exons 1-4 generated a fragment lower than 800 bp (expected size: 763 bp); 
- lane 2: exons 2-8 produced a ~800 bp fragment (expected 855 or 930 bp), whose 
sequence matched  to the 855 bp version.  A higher size product  (~1000 bp) was 
observed, suspected to correspond to MAGI3-002 (which shows an extra exon, 7a, 
of  75  bp):  after  purification  and  sequencing,  it  appeared  to  be  a  non-specific 
amplicon (not corresponding to MAGI3-002 or to any genomic sequence); 
- lane 3: exons 6-10 generated a fragment at ~1000 bp (expected 1028 or 1103 bp). Its 
sequencing revealed that it was the 1028 bp product. The gel did not show any extra 
band suggesting the presence of the extra exon 7a, hence supporting that the upper 
band on lane 2 was an artefact; 
- lane 4: exons 8-12 generated a fragment higher than 1000 bp, corresponding to the 
expected 1079 bp; 
- lane 5: exons 10-14 produced an amplicon higher than 1000 bp, which sequencing 
revealed was the expected 980 bp size. Abnormalities in the agarose gel may have 
compromised a proper sizing. The two lower, weak bands were extracted but their 
sequences  failed  to  align  to  MAGI3,  thus  they  were  considered  non-specific 
products; 
- lane 6: exons 12-17 generated a fragment at ~1000 bp, which corresponded to the 
expected 920 bp product; 
- lane  7:  exons 15-21 product  is  a  band  at  ~1000 bp,  which corresponded  to  the 
expected 938 bp; 
- lane 8: exons 20-21 generated products at 463 bp and 372 bp. Also, a ~2000 bp band 
was present in the genomic DNA lane (red arrow), hence proving that the conditions 
were optimal to allow the synthesis of a high molecular weight product (the 1057 bp 
product for MAGI3-001 and MAGI3-002). 
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Figure 7.3. Agarose gel electrophoresis of MAGI3 CDS amplification products. 
Gel lanes are numbered according to fragments corresponding to Figure 7.1 and to Table 7.1. Lane 1: 
fragment 1 (763 bp); lane 2: fragment 2 (855 bp); lane 3: fragment 3 (1028 bp); lane 4: fragment 4 (1079 
bp); lane 5: fragment 5 (980 bp); lane 6: fragment 6 (920 bp); lane 7: fragment 7 (938 bp); lane 8: 
fragment 8 (463 bp and 372 bp). L is for ladder (bp), g is for genomic DNA, - is for negative control. 
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Figure 7.4 shows the amplification products of the 5’ UTR of MAGI3: 
- lane 9: primer  pair A+E did not generate any  visible  product;  however, the low 
intensity of the product in the corresponding genomic lane may suggest that further 
optimisation of the experimental conditions would be desirable.  
- lanes 10, 11: no amplicon was expected for primer pairs B+E and C+E; however 
bands of molecular size comparable to the genomic DNA product (each indicated by 
a red arrow, in lanes 10 and 11 respectively) were observed; 
- lane 12: primer pair D+E generated a fragment <200 bp which corresponded to the 
expected (142 bp). 
Figure 7.5 shows the amplification products of the 3’UTR of MAGI3 (see Table 7.3 for a 
reference on product sizes): 
- lane 13: for F+G pair, a band of 138 bp was present as expected; 
- lane  14:  F+I  primers  generated  two  amplicons  above  and  below  400  bp,  in 
agreement with the product sizes expected for transcript versions 003 and 004 (430 
bp and 339 bp respectively). No band at ~1000 bp denoting versions 001 and 002 
was  observed.  A  weak  2000  bp  band  is  present  in  the  genomic  DNA  lane,  red 
arrow); 
- lane 15: H+I  pair generated a unique  fragment at ~300 bp, corresponding to  the 
product size expected for transcript 003. 
The products from primer pairs F+I and H+I suggest that the retina transcripts of MAGI3 
do not show the longer UTR described for transcripts 001 and 002. 
Reactions performed using “cDNA” made from RNA withouth the reverse transcriptase 
enzyme did not show any significant band suggestive of genomic DNA contamination 
(panels C in Figures 7.4 and 7.5). 
All products were gel-extracted, sequenced and compared to the deposited MAGI3 UTR 
sequence.     7. Retina Isoforms and Mutation Screening 
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Figure 7.4. Agarose gel electrophoresis of MAGI3 5’UTR amplification products. 
Gel lanes are numbered according to numbers in brackets in Table 7.2. Lanes 10, 11 and 12 show bands at 
~400bp, ~300bp and ~150bp respectively. Panel C shows the reactions using cDNA prepared without 
reverse transcriptase (-RT). L is for ladder (in bp), g is for genomic DNA, - is for negative control. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.5. Agarose gel electrophoresis of MAGI3 3’UTR amplification products. 
Gel lanes are numbered according to numbers in brackets in Table 7.3 (primers’ ordinate). Lane 13 shows 
an expected band at ~138 bp; lane 14 shows two bands at 430 bp and 339 bp, expected for transcripts 003 
and 004; lane 15 shows a band at 289 bp, expected for transcript 003. Panel C shows the reactions using 
cDNA prepared  without  reverse transcriptase  (-RT).  L  is  for ladder,  g  is  for  genomic  DNA,  - is for 
negative control.     7. Retina Isoforms and Mutation Screening 
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The  results  so  far  described  suggest  that  no  new  alternatively  spliced  transcript  for 
MAGI3 is present in retina. However, the findings determined that the retina transcripts 
of MAGI3 may be hybrids between MAGI-001 and MAGI-003/MAGI-004. In fact, the 
retina transcript showed a 5’UTR similar to MAGI-001, but longer; this experimental 
data was also supported by EST data (GenBank accession numbers: CN286170.1 from 
embryonic  stem  cells,  and  BX333323.2  from  neuroblastoma,  394  and  405  bp  long 
upstream the beginning of 5’ UTR respectively; retrieved through human ESTs database 
search using exon 1 and part of the region upstream as a query). Concerning the 3’ 
region,  it  appeared  that  two  isoforms  (MAGI3-003,  MAGI3-004)  out  of  four  are 
expressed in retina (see lane 8, panel D of Figure 7.3), as only the 463 and 372 bp 
products  were  amplified,  and  not  the  longer  1057  bp,  which  would  have  identified 
isoform 001. The accuracy of the amplification was proven by a genomic band at 1932 
bp, which corresponded to the expected genomic DNA amplicon. Additionally, the extra 
exon 7a, which characterises MAGI-002, was not detected in two different reactions, 
likely suggesting that it is not transcribed in the retina. 
In conclusion it appears that the protein MAGI3 is present in two different species in 
retina: they differ at their C-terminal, as one corresponds to the translation of MAGI-003 
and the longer one to the translation of MAGI-004. 
 
 
7.1.2  TRAK2 
According  to  Ensembl  database  (accessed  January  2009),  the  human  TRAK2  gene 
generates one unique transcript, TRAK2-001, shown in Figure 7.6: it encompasses 16 
exons, of which the first exon and part of the second are not translated (UTR); also, most 
of exon 16 represents untranslated region. Introns 1 and 2 are quite large, being ~30 kb 
long and ~12 kb long respectively. 
Figure 7.6 includes also four bars referring to the portions of transcript designed to be 
amplified: as for MAGI3, also in this case the approach implied the design of fragments 
overlapping by two exons, and spanning adjacent exons for a maximum size of ~1kb.     7. Retina Isoforms and Mutation Screening 
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Figure 7.7 provides a schematic view of the untranslated regions of TRAK2. The 5’ UTR 
is <400 bp, and comprises exon 1 (182 bp) and part (199 bp) of exon 2, interrupted by a 
~30kb-long intron. The method consisted of amplifying exons 1 and 2, using forward 
oligonucleotides priming the upstream intronic region and the 5’ sequence of exon 1 
(primers A and B respectively); the reverse primers were designed on the 5’ and 3’ 
regions of exon 2 (primer E and F). Other forward oligonucleotides were designed to 
anneal to the 5’ sequence of exon 2 and the intronic region upstream exon 2 (primers D 
and C respectively). 
Concerning the 3’UTR, exon 16 is ~4kb in length, of which only ~600 bp are translated 
and the remaining ~3.5 kb constitute the UTR. The fragments encompassed exon 15 and 
part  of  exon  16:  forward  primers  were  designed on  the 5’  area  of  exon  15  and 16 
(primers G and H respectively), whereas the reverse primers were designed on the end of 
the translated sequence (primer I, exon 16) and at ~1 kb downstream the start of exon 16 
(primer L). 
The following tables 7.4, 7.5, and 7.6 summarise the characteristics of the fragments to 
be  amplified:  Table  7.4  corresponds  to  the  coding  sequence  of  the  transcript:  each 
number refers to the bars in Figure 7.6, providing the exon interval and the expected 
size. Tables 7.5 and 7.6 are dedicated to the various products of the 5’ and 3’ UTRs 
respectively. 
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Figure 7.7. Drawing of TRAK2 UTRs. 
A: TRAK2 5’UTR; B: TRAK2 3’UTR. Rectangles represent exons (light blue: UTR; white: translated; 
connecting lines: introns - not drawn to scale). Numbers inside the exons represent the length in bp. Red 
arrows denote the position of primers used, marked by capital letters.     7. Retina Isoforms and Mutation Screening 
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Table 7.4. Expected fragment sizes for TRAK2 translated mRNA sequence. 
#  1  2  3  4 
Exons  1-8  6-12  10-15  13-16 (TGA) 
Length  1281  917  1094  1348 
Summary of the characteristics of each fragment to be amplified: for each segment 1 to 4 (to be compared 
with the black bars in Figure 7.6), the exon interval and its length in bp are indicated. 
 
 
 
 
 
Table 7.5. Expected fragments for TRAK2 5’ UTR. 
Primer pairs  A + E (5)  B + E (6)  C + E (7)  B + F (8)  C + F (9)  D + F (10) 
TRAK2-001  n.e.  247     n.e.  465     n.e.  290    
Genomic DNA  n.e.  n.e.  338  n.e.  556  290 
The oligonucleotides refer to the Figure 7.7 A. The table summarises the expected product sizes (in bp) 
according  to  the  pair  of  oligonucleotides,  the  transcript  and  genomic  DNA;  numbers  in  brackets 
correspond to gel lanes in Figure 7.9. N.e. stands for “not expected”, as either the region not transcribed, 
or the size of the amplicon is too large. The rectangles illustrate the expected products, referring to Figure 
7.7 A (light blue: UTR; white: translated - not to scale). 
 
 
 
 
 
Table 7.6. Expected fragments for TRAK2 3’ UTR. 
Primer pairs  G + I (11)  H + I (12)  H + L (13) 
TRAK2-001  729     671     894    
Genomic DNA  n.e.  n.e.  894 
The primer pairs are in accordance with Figure 7.7 B. Expected product sizes (in bp; numbered as gel 
lanes in Figure 7.10) are in relation to transcript and genomic DNA. N.e. stands for “not expected”, as the 
size of the amplicon is too large. The rectangles depict the expected products, referring to Figure 7.7 A 
(light blue: UTR; white: translated - not to scale). 
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Figure  7.8  illustrates  the  products  obtained  from  the  amplification  of  the  coding 
sequence  of  TRAK2.  Lanes  corresponding  to  the  designed  fragments  are  numbered 
according to Table 7.4. The experiment also included amplification of genomic DNA (g 
lanes). The amplified products were comparable to the expected products: 
- lane 1: exons 1-8 product was higher than 1000 bp, and the expected length was 
1281 bp; 
- lane  2:  exons  6-12  generated  a  fragment  lower  than  1000  bp,  and  the  expected 
product was 917 bp; 
- lane 3: exons 10-15 generated a product higher than 1000 bp, corresponding to the 
expected product (1094 bp); 
- lane 4: exons 13-16 presented a band higher than 1000 bp, corresponding to the 
expected 1348 bp. 
All  the  bands  were  extracted  and  purified  from  the  agarose  gel,  sequenced  and 
successfully aligned to TRAK2 reference sequence. 
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Figure 7.8. Agarose gel electrophoresis of TRAK2 CDS amplification products. 
Gel lanes are numbered according to fragments corresponding to black bars of Figure 7.6 and to Table 7.4. 
Lane 1: fragment #1 (1281 bp); lane 2: fragment #2 (917 bp); lane 3: fragment #3 (1094 bp); lane 4: 
fragment #4 (1348 bp). L is for ladder (in bp), g is for genomic DNA, - is for negative control.     7. Retina Isoforms and Mutation Screening 
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Figure 7.9 shows the amplification products for the 5’ UTR of TRAK2: 
- lane 5: primers pair A+E did not generate any product: as the forward primer anneals 
on  a  region  upstream  exon  1,  and  the  reverse  primer  anneals  on  exon  2,  no 
amplification is expected (either the region upstream exon 1 is not present in cDNA, 
or the amplicon is too large to be amplified, >30 kb for genomic DNA); 
- lane 6: one band higher than 200 bp, corresponding to the product generated by B+E 
oligonucleotides (247 bp); 
- lane 7: amplification product of C+E generated a band lower than 400 bp, observed 
in  the  genomic  (g)  lane  as  well  (expected  size:  338  bp).  Both  products  were 
sequenced and corresponded to TRAK2, part intron 1 and part exon 2 (this result 
was not supported by any EST data). The product was not observed in a reaction 
using cDNA prepared without reverse transcriptase (7 –RT lane in panel F); 
- lane 8: B+F generated a band at ~400 bp, corresponding to the expected product 
(465 bp); 
- lane 9: C+F generated a band at ~500 bp, present also in the genomic DNA (g) lane 
(expected size: 556 bp). The sequencing of the two bands revealed it corresponded to 
TRAK2, part intron 1 and part exon 2, as observed for C+E primer pair (lane 7). The 
product  was  not  detected  in  the  reaction  using  cDNA  prepared  without  reverse 
transcriptase (9 –RT lane in panel G); 
- lane 10: primer pair D+F generated a band at ~300 bp, corresponding to the expected 
product size (290 bp, present on both cDNA and genomic DNA as expected). 
Considering the findings from C+E and C+F primer pairs, a new forward primer was 
designed on the 3’ end of exon 1 (primer M in Figure 7.7 A), to be coupled with reverse 
primer E. However, no amplicon was generated (not shown). 
Also  in  this  case,  reactions  using  “cDNA”  made  from  RNA  without  the  reverse 
transcriptase enzyme were performed, not showing bands suggestive of genomic DNA 
contamination (panels F and G in Figure 7.9). 
The amplification of the 3’ UTR of TRAK2 generated three amplicons (Figure 7.10), 
which corresponded to the deposited sequence: 
- lane 11 (panel A): primers pair G+I generated a 729 bp product (band at ~800bp); 
- lane  12:  primers  pair  H+I  generated  a  product  of  671  bp  (band  at  ~600bp);    7. Retina Isoforms and Mutation Screening 
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Figure 7.9. Agarose gel electrophoresis of TRAK2 5’UTR amplification products. 
Gel lanes are numbered according to numbers in brackets in Table 7.5. Lanes 6, 7, 8, 9, 10 show bands at 
~200bp, ~300bp, ~500bp, ~500bp and ~300bp respectively. To note, genomic lanes of C+E (panel B) and 
C+F (panel D) also show bands at ~300bp and ~500bp respectively. Panels F and G show the reactions 
using cDNA prepared without reverse transcriptase (-RT). L is for ladder (in bp), g is for genomic DNA, - 
is for negative control. 
 
 
 
 
 
 
 
 
 
 
 
Figure 7.10. Agarose gel electrophoresis of TRAK2 3’UTR amplification products. 
Gel lanes are numbered according to numbers in brackets in Table 7.6. Lanes 11, 12 and 13 show each a 
band at ~800bp, ~600bp and ~1000bp respectively. Panel C shows the reactions using cDNA prepared 
without reverse transcriptase (-RT). L is for ladder (in bp), g is for genomic DNA, - is for negative control. 
     7. Retina Isoforms and Mutation Screening 
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- lane 13: primers pair H+L generated a product of 894 bp (band at ~1000bp). 
No  significant  bands  were  observed  in  reactions  using  “cDNA”  made  from  RNA 
without reverse transcriptase (panel C of Figure 7.10), as expected. 
 
The amplification and subsequent sequencing of TRAK2 transcript fragments suggested 
the presence of the unique transcript in the human retina, corresponding to the sequence 
deposited in Ensembl database. The amplification of the coding sequence did not reveal 
any  variation,  suggesting  that  the  protein  present  in  retina  may  correspond  to  the 
translation of  the reference  sequence. Also  the amplification of the 3’ UTR did  not 
suggest any diversity from the deposited sequence: however, the entire length of the 
3’UTR was not characterised (~3.5kb), but only ~300bp. Conversely, the study on the 5’ 
UTR  region  revealed  an  extra  portion upstream  exon  2,  adjacent  to  its  5’  end:  this 
experimental data was repeatedly found but was not supported by any EST data. It may 
be  that  the  retinal  TRAK2  transcript  possesses  a  longer  exon  2  (not  excluding  an 
alternative upstream exon 1, or more exons), which could be better investigated with a 
different technique, such as RACE. Furthermore, this result should be examined in a 
range of tissues, to assess whether it is retina-specific or not. The experiments were not 
continued further due to time limitations. 
 
 
Part II  Mutation Screening of adRP Patients for MAGI3 
 
A  human  disease  gene  may  be  identified  in  a  large  multigeneration  family  through 
linkage analysis. This approach relies on genetic markers, which help define a genomic 
region, since their position in the genome is known. Genetic markers lying next to each 
other  tend  to  segregate  during  meiosis,  and  so  they  are  inherited  jointly  (i.e.  the 
likelihood of a crossover taking place within a small DNA fragment is low), allowing 
tracking of the inheritance pattern of an unknown gene. Genetic linkage is feasible when 
several affected and unaffected members of the same family tree are available, as this 
allows  for  mapping  data  to  be  determined.  If  no  relevant  mapping  information  is 
available, a position independent approach may be used. As PRPF31 is the gene known     7. Retina Isoforms and Mutation Screening 
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to  be  mutated  in  RP11,  it  is  conceivable  that  gene  products  involved  in  PRPF31 
pathway(s) can cause retinal degeneration too, such as adRP (RPGRIP is an example; 
Boylan & Wright, 2000; Roepman et al., 2000a; Dryja et al., 2001). This rationale runs 
parallel  of  a  reverse  genetic  approach  applied  to  discover  new  human  RP  genes, 
identifying  mutant  alleles  in  genes  that  are  already  known  but  independent  from 
mapping data. In this case, gene products MAGI3 and TRAK2 are dependent on the 
direct physical interaction with PRPF31. The approach consisted of amplifying selected 
regions of genomic DNA of adRP patients; the regions corresponded to the exons of the 
gene. The genetic sequence of these regions was compared to a reference sequence for 
the  detection  of  mutations.  Due  to  limitation  in  time,  only  the  MAGI3  gene  was 
screened,  selected  because  of  its  localisation  with  PRPF31  (both  nuclear  and 
cytoplasmic in MDCK cells). 
 
7.2  Primer Design 
Primers  (listed  in  section  A.5  of  the  Appendix)  were  designed  to  amplify  genomic 
regions corresponding to each exon, plus 100-250 bp of the upstream and downstream 
intronic regions, to identify any intronic mutation which may interfere with splicing. All 
four isoforms of MAGI3 were included in the analysis. 
 
7.3  Mutation Screening 
A panel of DNAs from 95 patients affected by adRP was used as a sample population 
for the screening of the MAGI3 gene. Each patient was representative of a family, for 
which the most common mutations in adRP genes had already been excluded (such as 
rhodopsin  and  PRPF31).  Biotaq  polymerase  supplemented  with  Pfu  polymerase  (for 
proofreading)  was  used  for  amplification.  A  total  of  23  fragments  were  amplified, 
purified using ExoSAP-IT and then sequenced (methods described in section 2.9). The 
sequences  were  analysed  with  Seqman  software  (DNASTAR  Lasergene 8),  aligning 
them to the corresponding exonic reference sequence (from Ensembl). The screening 
allowed  the  recognition  of  the  known  exonic  SNPs  (eight,  according  to  Ensembl, 
accessed January 2009), of which one is represented in Figure 7.11 as an example (A/G 
change: c.2484A>G).     7. Retina Isoforms and Mutation Screening 
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Figure 7.11. Known single nucleotide polymorphism in exon 15 of MAGI3. 
The panels A, B and C represent a portion of the DNA sequence encompassing the c.2484A>G SNP in 
exon  15,  indicated  by  a  black  arrow  in  each  panel.  The  three  sequences  belong  to  three  different 
individuals: two homozygous (G/G and A/A in panels A and B respectively) and one heterozygous (A/G 
in panel C).     7. Retina Isoforms and Mutation Screening 
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The sequencing of the exons allowed the identification of four novel nucleotide changes 
(shown in Figure 7.12), in a heterozygous state: 
1.  c.793G>A, codon 265: non-synonymous change in exon 5 displayed by one patient 
(Aspartic acid to Asparagine; Figure 7.12, panel A); 
2.  c.853T>C, codon 285: non-synonymous change in exon 5 displayed by three patients 
(Tyrosine to Histidine; Figure 7.12, panel B); 
3.  c.2303G>A,  codon  768:  non-synonymous  change  in  exon  14  displayed  by  two 
patients (Arginine to Histidine; Figure 7.12, panel C); 
4.  c.4074C>T, codon 1358: synonymous change in exon 21 displayed by one patient 
(Isoleucine to Isoleucine; Figure 7.12, panel D). 
The  sequences  underwent  a  second  amplification  with  fresh  reagents:  changes  were  
re-confirmed after direct sequencing with both forward and reverse primers. 
Sequence analysis of the remaining exons did not show any unknown alteration. 
The three patients bearing the mutations were Caucasians, therefore 105 DNAs from 
unaffected Caucasian subjects  were screened  for  the non-synonymous  changes. Two 
subjects out of 105 presented a heterozygous change T>C (c.853T>C, #2 on the list 
above), suggesting the change may be a single nucleotide polymorphism. For changes 
#1 and #3, no alteration was observed in the control population. Therefore, the DNAs of 
the patients’ relatives were analysed and sequenced: 
- patient  RR4691  (change  #1):  DNAs  were  available  from  two  affected  family 
members. The relatives’ sequences corresponding to exon 5 did not show the change 
described in patient RR4691; 
- patient KOS3396 (change #3): seven affected family members’ DNAs were analysed 
for exon 14, however the change was not detected; 
- patient PR3713 (change #3): DNA from one affected relative was analysed for exon 
14, however the base-change was not detected. 
The analysis suggested that the changes did not segregate within the family. 
The comparison of the human MAGI3 protein sequence with other species than human 
(mouse, rat, pig, cow, gorilla, macaca, dog and chicken) showed that the aminoacids    7. Retina Isoforms and Mutation Screening 
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Figure 7.12. Electropherograms showing the nucleotide changes detected in MAGI3. 
In each panel, the single nucleotide change is indicated by a black arrow. A: c.793G>A; B: c.853T>C; C: 
c.2303G>A; D: c.4074C>T. Nomenclature based on the RefSeq sequence NM_001142782 (March 2009).     7. Retina Isoforms and Mutation Screening 
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generated  by  the  triplets  bearing  the  nucleotide  changes  are  conserved.  Change  #1 
represent  an  alteration  from  a  negatively  charged  aminoacid  (Aspartic  acid)  to  a  
non-charged polar one (Asparagine); change #2 is a modification from a non-charged 
polar aminoacid (Tyrosine) to a positively charged one (Hystidine). To affirm whether 
they  do not affect  the protein folding  and/or  function, more investigation is needed; 
however, as the changes were not segregating within the families, we decided not to 
pursue further the study. Change #3 is instead a substitution of two positively charged 
aminoacids (Arginine to Hystidine), hence it may be that this change does not affect to a 
great extent the protein. 
Finally, the nucleotide changes can still affect the codon usage during translation, and 
may perhaps influence the production of the protein. 
 
 
7.4  Allele and Genotype Frequencies 
The allele and genotype frequencies relative to the changes listed in the previous section 
were calculated according to section 2.8 of Chapter 2. As the changes were believed to 
be  non-causative  of  adRP,  the  95  patients  were  considered  as  part  of  a  normal 
population. For changes #1-3, the population size was 200 individuals (95 patients + 105 
controls),  for  change  #4,  the  population  was  95  individuals.  The  frequencies  are 
summarised in the following tables. 
 
 
Allele frequencies: 
Table 7.7. Summary of allele frequencies for the changes detected in the MAGI3 gene. 
Change #  1.G>A  2.T>C  3.G>A  4.C>T 
Allele p  0.9975 (G)  0.9875 (T)  0.995 (G)  0.995 (C) 
Allele q  0.0025 (A)  0.0125 (C)  0.005 (A)  0.005 (T) 
For each change, the allele is indicated in brackets. 
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Genotype frequencies: 
Table 7.8. Summary of genotype frequencies within the population considered. 
Change #  1.G>A  2.T>C  3.G>A  4.C>T 
Genotype pp  0.995 (GG)  0.975 (TT)  0.99 (GG)  0.989 (CC) 
Genotype qq  0 (AA)  0 (CC)  0 (AA)  0 (TT) 
Genotype pq  0.005 (GA)  0.025 (TC)  0.01 (GA)  0.011 (CT) 
For each change, the genotype is indicated in brackets following its frequency. 
 
 
Genotype frequencies according to the Hardy-Weinberg equilibrium: 
Table 7.9. Genotype frequencies calculated according to Hardy-Weinberg. 
Change #  1.G>A  2.T>C  3.G>A  4.C>T 
Genotype pp  0.9950062 (GG)  0.9751562 (TT)  0.990025 (GG)  0.990025 (CC) 
Genotype qq  0.0000062 (AA)  0.0001562 (CC)  0.000025 (AA)  0.000025 (TT) 
Genotype pq  0.0049874 (GA)  0.0246874 (TC)  0.00995 (GA)  0.00995 (CT) 
For each change, the genotype is indicated in brackets. 
 
 
The  real  genotype  frequencies  (Table  7.8)  agree  with  the  predicted  frequencies 
(Hardy-Weinberg  equilibrium,  Table  7.9),  inferring  that  there  are  no  evolutionary 
mechanisms operating on this locus in the examined population. 
 
 
7.5  Conclusion 
The  aim of  the study  presented in the first section of this chapter was  to obtain an 
overview  of  the  retinal  transcripts  generated  by  the  interacting  partners’  genes.  The 
purpose  was  to  investigate  whether  any  alternatively-spliced  retina-specific  isoform 
existed, leading to a different protein(s) being translated. For this reason, overlapping 
DNA fragments were amplified to be aligned to a reference sequence. We opted for this 
approach  as  both  MAGI3  and  TRAK2  genes  showed  a  degree  of  characterisation 
according to the consulted database (Ensembl). However, no major differences from the 
deposited sequences were observed. 
MAGI3 appears to be expressed principally in two isoforms: they both share the 5’ UTR 
of MAGI-001/MAGI-002 (long 5’ UTR), they do not present the extra exon 7a, but they     7. Retina Isoforms and Mutation Screening 
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differ from these two splice variants for the 3’ UTR: one shows the 3’ UTR of variant 
003 and the second shows an alternative exon 21 and a different 3’ UTR (as variant 
004). Therefore, two transcripts appear to be present, exhibiting a long 5’ UTR, and an 
alternatively spliced exon (#21), generating two proteins which are similar for most of 
their length, but differ at the C-terminal region. 
TRAK2 does not present any splice variant according to both literature and Ensembl 
database  (accessed  January  2009);  however,  it  was  observed  that  exon  2  extended 
towards the 5’ upstream sequence, suggesting a different 5’UTR region. 
In conclusion, the experiments showed that retina presents splice variants which were 
already documented or predicted, hence making the initial hypothesis of a retina-specific 
isoform  less probable. Yet,  the study does  not exclude  that a retinal isoform exists, 
which could not be detected with the chosen methodology. As the aim was to investigate 
transcript differences affecting the translated sequence, due to time limitations and to the 
degree of characterisation of the transcripts in the Ensembl database, the variations on 
the UTR regions for both genes were not investigated further.  
 
The  chromosomal  localisation  of  MAGI3  (chromosome  1,  p13.2)  and  TRAK2 
(chromosome 2, q33.1) was compared to the position of mapped loci for non-syndromic 
and syndromic RP, however no references were found. Nevertheless, unrelated adRP 
patients were screened for mutation in the MAGI3 gene, considering the interaction of 
MAGI3 with PRPF31 and their co-localisation in epithelial cells (overlap at intercellular 
junctions, co-localisation in nucleoli). From the analysis of the patients, the controls and 
the affected family members, it appears that none of the observed changes may be a 
cause for adRP. Three of the four changes resulted in amino acid changes; however, two 
out of three mutations were not present in the affected family members, thus ruling out 
each change as a cause of eye disease. Even though the screening did not allow the 
discovery of a new RP gene, these changes represent polymorphisms appearing at low 
frequencies. 
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8.  Discussion and Further Perspectives 
 
 
Retinitis Pigmentosa 11 (RP11) is caused by mutations in the PRPF31 gene. PRPF31 
codes for a splicing factor expressed in many tissues (Vithana et al., 2001), nevertheless 
the effects of the mutations are detrimental only in the retina, confining the phenotype to 
this tissue. 
To explain RP11 aetiology, it was hypothesised that retinal degeneration arises either 
from 1) haploinsufficiency of the PRPF31 gene and hence the levels of splicing activity 
in  retina are not  sufficient to  maintain a healthy  tissue, perhaps  also influencing  the 
splicing of a gene crucial for retina physiology; or 2) the disruption of an interaction 
between PRPF31 and a partner in retina; or 3) a different function of PRPF31 performed 
in retina. The study described in this thesis focused on the second hypothesis, using the 
yeast two-hybrid approach to screen for potential partners of PRPF31 in the retina. 
During  the  time  this  research  took  place,  mounting  scientific  evidence  favours 
haploinsufficiency as the cause of RP11. Haploinsufficiency occurs when only one of 
the two copies of a gene is functional (with the other inactivated by a mutation, as the 
case for PRPF31), and its protein product cannot suffice the requirements, leading to an 
abnormal state. Hence it may be that RP11 is caused by an insufficiency in splicing 
function, and either some or all the proteins of the photoreceptor outer segment are not 
appropriately  replenished.  Lymphoblastoid  cell  lines  from  asymptomatic  and 
symptomatic  patients  were  used  to  analyse  the  expression  of  the  mutant  allele:  the 
expression of the disease transcript showed a 50-80% decrease, likely due to nonsense-
mediated decay. Such expression was lower than the asymptomatic individuals carrying 
the same mutations, suggesting the presence of PRPF31 isoalleles, exhibiting either low 
or high expression (Rivolta et al., 2006). At the time, the authors did not exclude the 
possibility of a  retina-specific partner interacting with PRPF31 and perhaps with the 
other splicing-implicated proteins causing RP (PRPF3, PRPF8, PAP1, BRR2). Recently, 
Rio Frio and co-workers (2008b) showed that the level of total PRPF31 protein was 
decreased and no truncated protein was detected, suggesting degradation of  PRPF31 
mutant transcripts through nonsense-mediated decay. The scientific team also showed     8. Discussion and Further Perspectives 
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the  existence  of  two  genetic  modifiers,  modulating  the  expression  of  non-mutant 
PRPF31 alleles: one is associated with the PRPF31 gene, while the second is located on 
chromosome 14 (Rio Frio et al., 2008a). Finally a recent work showed evidence that the 
PRPF31  gene  does  not  exhibit  retina-specific  isoforms  and  is  not  differentially 
expressed in retina (Tanackovic & Rivolta, 2009). Taken together, these results suggest 
that subtle variations of the pre-mRNA splicing process may lead to the development of 
retinitis pigmentosa in conjunction with mutations in the PRPF31 gene. However, it is 
not yet understood whether retina requires a higher threshold of splicing activity than 
other  tissues,  threshold  not  met  if  one  PRPF31  allele  is  not  expressed;  or  if  the 
decreased level of PRPF31 does influence splicing activity, but still acceptable for the 
tissue to be healthy: in this case it may be that a transcript crucial for retina survival is 
not  adequately  spliced,  and  the  consequent  lower  level  of  protein  may  lead  to 
degeneration of the retina. 
Besides, our research provided new insights into the PRPF31 protein, which will be 
discussed  in  the  following  sections.  Experiments  presented  in  Chapters  3  and  4 
constitute  the  core  of  the  project,  as  they  show  the  identification  and  the  partial 
validation of novel PRPF31 interacting partners. Chapters 5 support to some degree the 
findings of the previous chapters (Chapter 5). Chapter 6 provides observations regarding 
PRPF31  and  its  localisation  in  cells  and  retina.  Finally  Chapter  7  presents  studies 
regarding the novel partners in terms of genetic screening and isoform analysis. 
 
8.1  Yeast Two-Hybrid and Co-IP Experiments 
In the first results chapter (Chapter 3), a screening of human and bovine retinal libraries 
for  novel,  direct  interacting  partners  for  PRPF31  was  described.  The  methodology 
consisted  of  using  yeast  cells,  engineered  to  facilitate  the  detection  of  interacting 
partners of a desired protein from a library of cDNA clones; this methodology is the 
yeast two-hybrid system. The approach involved screening the libraries using different 
baits of PRPF31 (four in total, three short fragments and one full length), to maximise 
chances of interactions. 
The  screening  allowed  the  detection  of  three  potential  candidate  partners  from  the 
bovine  library,  which  corresponded  to  the  human  proteins  MAGI3,  TRAK2  and     8. Discussion and Further Perspectives 
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ZNF143.  MAGI3  belongs  to  the  MAGUK  (membrane-associated  guanylate  kinase) 
family  of  proteins,  which  are  ubiquitous  scaffolding  proteins  concentrated  at  cell 
junctions. MAGI3 encompasses a GK domain, two WW domains and six PDZ domains 
(Funke et al., 2005) and was first discovered as a partner of PTEN/MMAC (Wu et al., 
2000).  The  role  of  scaffolding  proteins  is  to  organise  macromolecular  protein 
complexes, tethering receptors, intracellular signalling enzymes and adhesion molecules; 
therefore  they  are  involved  in  specialised  cellular  adhesion  and  signal  transduction 
mechanisms. MAGI3 was localised at the tight junctions of epithelial cells (Adamsky et 
al., 2003). The rat orthologue of TRAK2 was discovered as an interacting partner of the 
GABAA  receptor (Beck et al.,  2002).  TRAK2 is believed to  take part in  membrane 
trafficking of vesicles and/or organelles, via motor proteins as it interacts with kinesin (a 
protein involved in anterograde transport). Thus, TRAK2 was proposed as an adaptor 
protein involved in motor-dependent trafficking of proteins to synapses (Brickley et al., 
2005). ZNF143 is a transcription factor, comprising seven zinc finger domains, and it is 
expressed in all normal adult tissues; it is involved in the transcriptional activation of 
snRNA and snRNA-type genes transcribed by RNA polymerase II and III (Myslinski et 
al., 1998). 
The next step was the confirmation of the interactions with a second technique. Ideally, 
all the interactants identified through a technique (such as the yeast two-hybrid) should 
be confirmed with a second one; however this is not feasible due to time and resources 
available.  Hence  we narrowed  down  according to  the  results obtained:  in  yeast,  the 
interaction  between  PRPF31  and  human  species  of  the  three  interactants  favoured 
MAGI3  and  TRAK2,  whereas  ZNF143  appeared  to  be  a  weak  interacting  partner 
(section 3.8). As ZNF143 is a nuclear protein, it is more likely to interact with a splicing 
factor;  moreover,  the  blue  colour  developed  in  the  β-galactosidase  assay  by  the 
interaction of ZNF143 with PRPF31 was comparable to the one developed by PRPF6 
with  PRPF31,  symptomatic  that  perhaps  it  should  have  been  included  for  further 
validation together with MAGI3 and TRAK2. However ZNF143 was not pursued for the 
following reason: at the time of this choice, the auto-activation test for the isolated prey 
species had not been done, and in parallel to it the immunoprecipitation experiments 
were set up. Interactants were then chosen according to which were less likely to bind     8. Discussion and Further Perspectives 
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DNA spuriously (i.e. without the presence of a bait), thus excluding ZNF143. However, 
after the auto-activation test, it appeared that ZNF143 was not a false positive, but a true 
interacting partner, and hence it should have been included in the downstream work. 
Furthermore, a negative auto-activation test does not exclude a candidate from being a 
false positive: even though MAGI3 and TRAK2 have failed to auto-activate the reporter 
genes and hence may represent good interacting candidates, it may be that these proteins 
are to  some extent “sticky”, and  will  attach to any bait, consequently triggering  the 
expression of the reporter genes and falling into the false positive category. 
Only few potential interacting partners were isolated from the libraries. Several factors 
could have influenced this outcome: 
1.  Knowledge and good practice of the methods, necessity to implement the system in 
our lab; 
2.  Time-frame allowed; 
3.  Richness of the libraries; 
4.  Expression of the bait; 
5.  Stringency of the system; 
6.  Type of protein screened for. 
Therefore, many factors may influence the process of a yeast two-hybrid screening. On 
one hand, some factors may relate to how the screening was conducted (points 1 and 2). 
The fact that the facilities and knowledge were not in our hands, and that we had to 
implement the system in our lab had played a part. Thus it may be that the methods were 
involuntarily not performed as appropriate: as an example, a low mating efficiency may 
be caused by a too vigorous shaking after combination of the yeast mating types, thus 
inhibiting the mating. 
Also, the time-frame allowed for the exchange to learn the technique maybe should have 
been  extended  to  allow  a  less  tight  schedule  for  the  initial,  crucial  steps,  as  they 
constitute the core of a screening (i.e. the mating process and the initial selection of 
positive clones). 
On the other hand, the remaining factors relate to the nature of the parts constituting the 
chosen method. Again, a low mating efficiency can be due to a lower viability of the 
library cells (as in this case, as they were aliquoted and store frozen at -80°C).     8. Discussion and Further Perspectives 
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Another factor is that the libraries may not be fully comprehensive,  and may not be 
representative of all the genes: this may hinder them from being singled out (it could be 
the case of PRPF6 since it was not detected in any screen). The amplification of the 
libraries (section 3.9) showed that PRPF6 was present in both libraries; however this is 
debatable as the amplification of the aliquots may have favoured some plasmids against 
others. Regardless, the number of independent clones screened was more than a million 
per bait and per library, which is the minimum number recommended  in order for a 
screening to be valid (using less than a million of clones reduces the chance of detecting 
genuine interactions). 
In  addition,  the  stringency  of  the  system  was  high,  which  brings  the  advantage  of 
keeping false positives to a minimum, but on the other hand has the disadvantage of 
missing  interacting  partners,  especially  weak  ones.  Therefore  the  screen  could  be 
repeated, using less stringent conditions (no selection against the adenine reporter gene), 
but with the disadvantage of more false positives. In addition, it was later discovered 
that it is not necessary for all the reporter genes to be expressed to declare a clone is a 
genuine interacting partner: this is due to the accessibility of the UAS to the recombinant 
proteins complex, therefore even if the clone elicits the expression of two out of three 
reporter  genes,  it can  be a  true positive and  therefore can be considered  for  further 
studies. This way, it may appear that many interacting partners can be considered, but 
care must be taken in deciding which could be true positives and which could be false, 
and the choice is upon the characteristics of the interactants. On these considerations, the 
following interactants did not activate the LacZ gene after co-transformation but could 
have been followed-up as they  appeared to be  in frame with the activation domain: 
PNMA1 (paraneoplastic Ma antigen 1), USP47 (ubiquitin specific peptidase 47), SV2B 
(synaptic vesicle glycoprotein 2B). Other clones could be considered too, knowing that 
yeast has the capacity of skipping termination codons and translating the downstream 
sequence (yeast tolerates translational frameshift, skipping stop codons and continues 
the translation). 
Another key factor is the type of bait used. We chose to produce four different PRPF31 
baits to increase the chances of detecting partners. Not all the baits were expressed at a 
high level, only BD-F1 was highly expressed (bait encompassing the NOSIC domain of     8. Discussion and Further Perspectives 
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PRPF31).  The  crucial  experiment  for  the  bait characterisation  is the  auto-activation, 
which excluded any spurious activation of the reporter genes (section 3.3.1), therefore 
allowing  for  the  yeast  two-hybrid  screenings  to  take  place.  Concerning  the  type  of 
protein, it is difficult to predict whether or not a protein will have plenty of interactions: 
first because of the aforementioned factors which influence a screening, and secondly 
because  of  the  nature  of  the  protein.  As  an  example,  the  PRPF31  NOP  domain  is 
involved  in  contacting RNA  and proteins, hence  perhaps  many  PRPF31  interactions 
occur when the two entities - RNA and protein - are together, such as for protein 15.5K 
and RNA: PRPF31 binds to both at the same time, but fails to bind them separately (Liu 
et al., 2007). 
In conclusion, we suggest that not many interacting partners were isolated due to the use 
of high stringency system: in fact, the control interaction of PRPF6 and PRPF31 was 
remarkably weak (section 3.4), suggesting that the high stringency may have contributed 
negatively. Makarova and co-workers (2002) reported a tight interaction between PRPF6 
and PRPF31; although the authors have used the same methodology, the characteristics 
of the methods are not comparable: a strong interaction may be a weak one in a different 
system, and/or vice versa. 
Chapter 4 focused on confirming the interactions found through the yeast two-hybrid 
system,  using  the  co-immunoprecipitation  technique.  As  previously  mentioned,  the 
results concerned only MAGI3 and TRAK2, as these two proteins showed the strongest 
interaction when using human full  length  sequences  to test direct interactions in the 
yeast two-hybrid system. 
We chose to express the proteins with N-terminal tags (6xHis for PRPF31 and V5 for 
the interactants), to render the experiments more practical, and also to mimic the yeast 
two-hybrid conditions, as the baits and preys had an N-terminal GAL4 domain. The 
tagged proteins were highly expressed in mammalian cells (HEK293), thus facilitating 
the downstream immunoprecipitation work, as the more protein is produced, the greater 
the  likelihood of  a  good performance  of  the  experiment  (i.e. detecting  a  band on  a 
western  blot  even  though  there  may  be  a  loss  of  protein  due  to  the  experimental 
procedures).     8. Discussion and Further Perspectives 
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Both MAGI3 and TRAK2 (as V5-proteins) were separately proven to be part of the 
6xHis-PRPF31 protein complex. The authenticity of these results was proven by the fact 
that PRPF6 was also found complexed with PRPF31 using the same conditions (PRPF6 
is a known interacting partner of PRPF31; Makarova et al., 2002). 
As PRPF31 binds MAGI3 and TRAK2, it is not excluded that the two proteins are part 
of the same protein complex. It would be interesting to provide evidence for this, which 
can be achieved through co-immunoprecipitation experiments, expressing the proteins 
and use the same procedure described in Chapter 4.  
The immunoprecipitation was also performed in the reverse way (coupling the anti-V5 
antibody to the support), showing a cross-reaction between the anti-V5 antibody and the 
6xHis tag. In fact, the western blot showed that 6xHis-PRPF31 was present on immune 
pellets of cells expressing V5 tag and 6xHis-PRPF31 (6xHis-PRPF31 was detected by 
the anti-V5 antibody, confirming that the antibody binds 6xHis-PRPF31 in both western 
blot  and  IP  procedures;  compare  with  Table  4.2  in  Chapter  4).  Besides,  a  band 
corresponding to the 6xHis tag was not observed, in line with the fact that the tag is very 
short and hence not detectable on the western blot, but not excluding its presence in the 
immune pellet. However, no wild type PRPF31 was observed in the immune pellet of 
cells  expressing  only  the  V5  tag,  suggesting  that  PRPF31  did  not  originate  the  
cross-reaction, and that any spurious interaction occurs when the 6xHis tag is present. 
On the other hand, this procedure allowed the detection of wild type PRPF31 when the 
V5-protein was expressed, thus confirming the results of the previous co-IP experiments. 
For future work and/or improvements to this system, we would suggest continuing using 
the V5-tag and the anti-V5 antibody, for their high specificity and robustness; instead we 
would substitute the 6xHis tag with a different one (HA tag for example), which would 
give less background and be more easily detectable in immunocytochemistry. 
It  is  to  say  that  the  experiments  discussed  above  may  have  to  be  supported  by  
co-immunoprecipitation on the endogenous complex, to support the potential biological 
significance of these interactions: so far, it has been proved that there is association only 
when overexpressing the proteins with a tag. Hence, the results must be interpreted with 
caution.      8. Discussion and Further Perspectives 
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Finally, another approach to investigate the components of the PRPF31 complex would 
be to utilise mass spectrometry. This method could also provide more insights about the 
partners in retina if the complex is purified from fresh retina preparations. 
 
8.2  Localisation Experiments 
The results from the co-localisation in epithelial cells were described in Chapter 5, in 
support of MAGI3 and TRAK2 as novel interacting partners of PRPF31. 
Unexpectedly,  the  6xHis-PRPF31  protein  localised  not  only  to  the  nucleus  but  also 
strongly throughout the cytoplasm; it also formed large aggregates in the nucleus which 
resembled the nucleoli. On the other hand, wild type endogenous PRPF31 was found 
mainly in the nucleoplasm, particularly in speckles and appeared to be absent from the 
nucleoli; moreover, it was present in the cytoplasm to a much lower level and also found 
at cell-cell contacts, supporting in part the pattern of localisation indentified with the 
6xHis-PRPF31 protein. 
Tagged PRPF31 and MAGI3 appeared to localise together to the nucleus in structures 
reminiscent of the nucleoli, in forms of aggregates in which PRPF31 lined the outside 
and MAGI3 the inside. Any cytoplasmic labelling indicative of co-localisation was quite 
weak,  therefore  suggesting  that  in  presence  of  MAGI3,  PRPF31  was 
“compartmentalised” in the nucleus, especially the “nucleoli”. The localisation of wild 
type  MAGI3  and  PRPF31  in  epithelial  cells  revealed  that  the  proteins  partially 
overlapped at intercellular junctions,  indicating  that the endogenous proteins may be 
recruited to a common site (wild type PRPF31 was shown to co-localise with E-cadherin 
to  the  adherens  junctions).  The  localisation of  endogenous  PRPF31  at  the  junctions 
supported what was previously shown with the over-expressed PRPF31, that it labelled 
the cytoplasm (although without clear distinction of subcellular structures). Adamsky 
and colleagues (2003) reported MAGI3 protein at adherens junctions of aged astrocytes, 
and also at tight junctions of epithelial cells. Hence it may be that there is a cross-talk 
between PRPF31 and MAGI3,  meaning  that either protein shuttles to/from  the other 
protein’s location, triggering a downstream effect which is yet to be elucidated. These 
data also suggest a participation of PRPF31 in MAGI3 pathways at the junctions: it is 
possible  that  PRPF31  exerts  a  modulation  of  MAGI3  activity,  thus  altering  cell     8. Discussion and Further Perspectives 
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morphology, adhesion or migration. On the other hand, the “nucleolar” localisation of 
both proteins is suggestive of other pathways, maybe related to PRPF31 RNA-binding 
activity. The  latter hypothesis is supported by the  co-localisation of  the  recombinant 
proteins, and also by the co-localisation of the wild type proteins upon hyperosmotic 
stress treatment of the cells.  
Tagged PRPF31 and TRAK2 localised both to the same sites of PRPF31 and MAGI3, 
the “nucleoli”, again in form of aggregates were PRPF31 was detected on the outer side 
and TRAK2 on the inner side. The two proteins were also observed to localise to the 
cytoplasm, and the signal was very prominent on cell extensions (on average, half of the 
cells presented  these  spike-like  structures).  It  is  possible  that  the over-expression of 
TRAK2 influences the localisation of PRPF31, hence the latter is transported to these 
peripheral cell structures; however, this does not exclude that normally a  fraction of 
PRPF31 already resides in the periphery of the cell, but is not detected. In the SK-N-SH 
cell  line  (human  neuroblastoma),  wild  type  PRPF31  and  wild  type  TRAK2  signals 
seemed to overlap at the cytoplasmic region close to the nucleus. Regarding cell-cell 
contact  sites,  both  signals  were  very  faint  and  could not  be  thoroughly  analysed  to 
understand  whether  there  was  any  co-localisation;  no  “spike-like”  structures  were 
observed hence suggesting that the over-expression of such protein in epithelial cells 
induces a change in morphology. These findings suggest a role for TRAK2 in sorting 
PRPF31 from the nucleus to the cytoplasm, hence explaining TRAK2 presence around 
the nucleus. However, the fact that both proteins co-localised to the nucleoli, as seen for 
PRPF31 and MAGI3, is suspicious that maybe the over-expression of the splicing factor 
triggered a segregation of TRAK2 in the nucleus. 
Chapter 6 comprises several observations regarding PRPF31 localisation in epithelial 
cells.  We  chose  to  continue  using  MDCK  cells  as  they  were  extensively  used  for 
localisation  studies  of  over-expressed  proteins  (Chapter  4),  and  showed  a  peculiar 
labelling for PRPF31 at the junctions, therefore we investigated this aspect further as 
PRPF31 was not reported to localise at intercellular junctions. In wild type epithelial 
cells, PRPF31 localised to the nucleoplasm in speckles, with a very faint to no presence 
in the nucleoli as the double staining with SC-35 revealed. PRPF31 also weakly labelled 
the cytoplasm and  more interestingly,  it was  found at  cell-cell contacts. We became     8. Discussion and Further Perspectives 
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more interested in the latter localisation, as PRPF31 was presumed to be nuclear due to 
its involvement in splicing; however, there are several lines of evidence documenting 
that splicing can occur in the cytoplasm too (as discussed later). Hence, it was observed 
that  PRPF31  localised  to  the  adherens  junctions,  as  confirmed  by  co-staining  with 
E-cadherin  (a  marker  for  adherens  junctions).  Moreover,  the  application  of  stress 
treatments did not alter this localisation. Interestingly, giving the cells a hyperosmotic 
stress  enhanced  the  localisation  of  PRPF31  to  the  junctions,  and  favoured  the 
localisation of the splicing factor to the “nucleoli”, where it co-localised with MAGI3. 
We also investigated the occurrence of PRPF31 at the junctions according to the cell 
stage,  and,  as  cells  in  their  physiological  environment  are  in  G0/G1  phase,  we 
investigated arresting the cells in such phase. The signal was still observed, although its 
pattern was not as clear as the wild type: perhaps the inhibitors were toxic to the cell and 
contributed in changing its morphology, or maybe PRPF31 is not as present as in the 
untreated cells. The latter hypothesis still indicates that in normal proliferative states 
PRPF31 may be found at intercellular junctions. 
Taken  together,  these  results  showed  that  in  epithelial  cells  PRPF31  has  a  dual 
localisation (nuclear and junctional) which does not appear to be dramatically affected 
by the cell stage; it also seems that junctional PRPF31 is more prominent during stress 
events. These observations may suggest that either splicing extensively occurs at the 
junctions, or PRPF31 has a moonlighting function, being involved in other cell pathways 
other than splicing. Besides, the veracity of the observations regarding V5-MAGI3 and 
6xHis-PRPF31  “nucleolar”  co-localisation  is  strengthened  by  the  fact  that  the 
corresponding  wild  type  proteins  still  co-localise  to  the  nucleolus  in  hyperosmotic 
conditions, therefore suggesting a role of the nucleolus in sequestering these proteins as 
a complex. However, how this segregation is triggered and what are the downstream 
effects remain to be elucidated. 
 
The  role  of  the  nucleolus  is  interesting  to  consider:  wild  type  PRPF31  was  not 
documented to be in the nucleolus (Makarova et al., 2002), thus suggesting to reserve 
further judgement when considering these observations, especially since no nucleolar 
marker was concomitantly used. However, PRPF31 has RNA binding activity via its     8. Discussion and Further Perspectives 
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NOP  domain:  NOP56/58  proteins  are  involved  in  small  nucleolar  RNP  biogenesis 
(Aittaleb et al., 2003). PRPF31 is known to contact a ribonucleoprotein platform formed 
by U4 RNA and protein 15.5K; interestingly, protein 15.5K is involved in the assembly 
of three RNP complexes: the U4/U6 snRNP (splicing), the box C/D snoRNP and the box 
B/C motif of U3 (involved in processing of rRNA and ribosome respectively). However, 
Liu and colleagues (2007) showed that PRPF31 contacts only U4 RNA and not other 
types  of  RNAs  despite  the  similarity  of  its  NOP  domain  with  Nop56  and  Nop58 
nucleolar proteins. Nonetheless, when PRPF31 was over-expressed in epithelial cells, it 
formed  aggregates  which  resembled  the  nucleoli,  hence  suggesting  that  in  normal 
conditions the splicing factor is naturally found in the nucleolus, but not at a detectable 
level.  Moreover,  in particular  stress  conditions  PRPF31  was  found  in  the nucleolus. 
Studies  regarding  the  nucleolar  proteome  have  not  pin-pointed  PRPF31  though 
(nucleolar proteome database http://www.lamondlab.com/NOPdb/; Leung et al., 2003). 
However,  the protein  SART1  involved  in  the  tri-snRNP  assembly  (Makarova et  al., 
2001) was found to be present in the nucleolus (Hinsby et al., 2006); in addition, the 
protein  Prp43p,  involved  in  the  removal  of  U2,  U5  and  U6  snRNP  from  the  post-
spliceosomal  complex  was purified not only with spliceosomal components but also 
with  preribosomal  complexes  (Combs  et  al.,  2006).  Therefore,  the  hypothesis  of 
PRPF31 in the nucleolus is strengthened by the fact that the splicing factor not only 
possesses domains commonly found in nucleolar proteins (NOSIC and NOP domains), 
but also by the evidence that other spliceosomal proteins are also found in the nucleolus 
or associated with ribosomal components. 
The multifunctional basis of the nucleolus was recently illustrated: it is a subnuclear 
compartment principally involved in the ribosome-subunit biogenesis, but also involved 
in  coordinating  and  regulating  cell-cycle  control  events  and  stress  responses  by 
sequestering proteins (Boisvert et al., 2007). It is plausible that cell treatment with a 
transfecting  reagent,  and  subsequently  the  overwhelming  production  of  proteins  has 
played a role, with the visible outcome of the protein being sequestered in the nucleolus, 
instead of being degraded. However, cells subjected to mock transfection appeared not 
to  be  affected;  also,  it  seems conceivable  that  as 6xHis-PRPF31 concentrates in  the 
nucleoli, the V5-MAGI3 and V5-TRAK2 will also do if there is genuine interaction.     8. Discussion and Further Perspectives 
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Regardless,  the  fact  that  each  recombinant  protein  was  found  together  with  6xHis-
PRPF31 in the nucleolus is suggestive of a direct interaction between the proteins. 
 
The immunolabelling for PRPF31 in murine retina reinforced the observations from the 
cell work as it attests that PRPF31 has different localisations, perhaps also in human 
retina. In fact, in mouse retina PRPF31 was shown to be weakly present in the outer 
nuclear layer, meaning that  splicing  in the photoreceptors may  not take place in the 
nucleus (at least at a level detectable by the method), but either takes place in the inner 
segments or at the synaptic termini; or else, it may be that in photoreceptors, PRPF31 
has a different function altogether,  for which it does not require to be in the nuclei. 
However PRPF31 was observed in between the nuclei of the photoreceptor cells, in a 
streaks-like fashion. The same localisation was shared with PRPF3 and PRPF8, other 
splicing factors that are part of the tri-snRNP with PRPF31, and mutations in which also 
cause RP: they were not present in the nuclei but visible as streaks through the outer 
nuclear layer. On the other hand, another splicing factor, PRPF16, was found to localise 
to the photoreceptor nuclei, and also very prominently to the inner nuclear layer. These 
observations suggest that perhaps in the retina the splicing factor PRPF31 (and maybe 
PRPF3  and  PRPF8)  are  involved  in  a  separate  function  and/or  which  occurs  in  a 
different subcellular compartment other than the nucleus. This hypothesis is reinforced 
by the fact that the localisation of PRPF31 in SK-N-SH cells was cytoplasmic as well as 
nuclear, hence suggesting that PRPF31 may have a different behaviour in some neuronal 
cells than epithelial cells. 
Interestingly, a recent publication (Solovei et al., 2009) pointed out that the chromatin 
pattern in mouse rod nuclei is inverted according to the canonical pattern (euchromatin 
at the centre of the nucleus, heterochromatin at the periphery and interspersed in the 
nucleoplasm).  This  inverted  nuclear  architecture  is  common  to  all  the  nocturnal 
mammals analysed by the authors, whereas the conventional arrangement is observed in 
pig and horse; cow showed an intermediate pattern. Given these considerations, it is 
plausible to reason that splicing occurs at the periphery of the (mouse) rod nuclei, hence 
supporting the observations about PRPF31 (and PRPF3, PRPF8) presence in streaks in     8. Discussion and Further Perspectives 
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between the photoreceptor nuclei. Nonetheless, this does not explain why the splicing 
factor(s) was (were) found at the inner segment and at the outer plexiform layer. 
 
So far, there is mounting evidence suggestive of a cytoplasmic localisation of PRPF31, 
thus indicating either a new function, or occurrence of splicing also outside the nucleus. 
Both options suit the type of interactants found. Interestingly, there are investigations 
which attest for cytoplasmic splicing. Firstly it was suggested by Denis and co-workers 
(2005),  who  put  forward  this  hypothesis  by  showing  that  human  platelets  contain 
spliceosome factors and they are able to process resident pre-mRNAs in response to 
external cues. Later it was also shown that neuronal dendrites are capable of splicing 
reporter pre-mRNA, but the authors failed to provide a functional significance of this 
dendritic splicing (Glanzer et al., 2005). More recent scientific data provided insights 
into a cytoplasmic segregation of the minor spliceosome (see paragraph 1.5.1 of the 
Introduction;  König  et  al.,  2007),  and  PRPF31  is  known  to  belong  to  the  protein 
machinery of the minor tri-snRNP (Will & Luhrmann 2005). Conversely, the findings 
from König and co-workers are opposed by those of Frilander’s group (Pessa et al., 
2008): they state that the minor spliceosome components are localised predominantly to 
the nucleus. 
Considering  the  spatial  organisation  of  the  retina,  it  could  be  realistic  that  splicing 
occurs outside the nucleus in photoreceptor cells. It is known that mRNAs are trafficked 
to dendrites and that their translation is regulated according to neuronal activity; such 
mRNAs are transported in form or large granules, which contain mRNAs, RNA-binding 
proteins, ribosomes and translational factors, and the transport is microtubule dependent 
(reviewed  by  Martin  &  Zukin  2006).  However,  how  unspliced  or  partially  spliced 
transcripts can evade surveillance and be exported outside the photoreceptor nucleus 
remains elusive, if at all possible. 
Assuming such pre-mRNA translocation happens, it may be that PRPF31 is part of the 
pre-mRNA-containing  granule  which  escapes  the  nucleus,  hence  explaining  why 
PRPF31  is  found  to  be  cytoplasmic,  especially  in  retina  (inner  segment  and  outer 
plexiform layer). That could explain why a protein like TRAK2 interacts with PRPF31: 
it may contact the complex via PRPF31 and carry it along microtubules through the cell.     8. Discussion and Further Perspectives 
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This  may  be  plausible  since  TRAK2  has  been  found  to  be  involved  in  the  axonal 
transport of cargoes (Brickley et al., 2005): interestingly, in the retina PRPF31 is found 
at  the  synaptic  termini  of  photoreceptor  cells,  where  also  TRAK2  was  observed 
(unfortunately, no co-localisation could be performed, see Chapter 6). 
 
It  is  known  that  the  minor  spliceosome  has  a  lower  processing  rate  than  the  major 
counterpart (Pessa et al., 2006), and that minor introns are not as common as the major 
ones  -  representing  only  0.15-0.34%  of  all  introns.  Minor  splicing  seems  to  escape 
mitotic downregulation, and it may be linked to cell proliferation (König et al., 2007). 
Considering that the minor splicing has a lower rate of processing the minor introns, and 
also that PRPF31 takes part in both spliceosomes, it may be that a decreased rate of 
processing  due  to  lack  of  PRPF31  affects  the  viability  of  minor-intron-containing 
transcripts  crucial  for  photoreceptor  survival.  Noteworthy,  PrBP/δ  contains  a  minor 
intron (as predicted by database found at http://genome.imim.es/datasets/u12/; Alioto, 
2007). PrBP/δ was formerly known as PDE6D and was believed to be a subunit of rod 
PDE6 (the phosphodiesterase which catalyses cGMP hydrolysis in the phototransduction 
cascade),  but  later  it  was  found  to  play  a  role  in  intracellular  trafficking  of  newly 
synthesised prenylated proteins, such as  PDE6 and GRK1 (rhodopsin  kinase, shared 
between rods and cones). However PrBP/δ is expressed in other tissues which do not 
express PDE6 (Norton et al., 2005); nonetheless, it was reported that PrBP/δ is present 
in  retina  at  higher  levels  than other  tissues.  Knockout of  the  Pde6d  gene  in  mouse 
resulted in an adult mouse of significantly reduced body size but of normal viability, 
development and fertility, but with a severely compromised rod and cone photoreceptor 
physiology (Karan et al., 2008). GRK1, rod PDE6 and cone PDE6α’ showed a defective 
transport to the outer segment due to absence of PrBP/δ; the Pde6d
-/- rod outer segments 
lack  GRK1  and  show  a  minor  mistargeting  of  PDE6,  showing  a  delay  in 
dark-adaptation; also cGMP may rise to toxic levels, an event linked to various retinal 
degeneration (rd mouse as an example; Karan et al., 2008).  
Given these circumstances, it is possible that a limited quantity of PrBP/δ affects PDE6 
trafficking to the outer segments, leading to impaired phototransduction first (as there is 
no stoichiometric quantity of the cascade components) and high levels of cGMP, thus     8. Discussion and Further Perspectives 
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leading  to  degeneration.  The  same  mechanism  could  be  evoked  also  by  the  other 
splicing factors causing RP, as they all take part in the minor spliceosome. It is known 
that  rhodopsin,  which  constitute  the  90%  of  the  proteins  in  the  rod  outer  segments 
(Palczewski, 2006), is produced in only two hours (von Schantz et al., 1999), hence it is 
likely that its splicing is also happening in within two hours and thus it must be efficient 
and  any  impairment  slowing  it  may  lead  to  death  of  the  rod cells  in  the  long  run, 
possibly by apoptosis. However, it is possible that instead splicing happens within 24 
hours, and partially-spliced transcripts are kept on site (such as the inner segments) and 
ready to be ultimately spliced (explaining the splicing factors’ presence  to  the  inner 
segments) and then translated in those two hours.  
 
Regarding MAGI3, we postulated before a role in the nucleolus together with PRPF31 
in particular conditions, such as stress events; we also postulated a role of PRPF31 in 
signalling  at  the  junctions,  modulating  the  role of  MAGI3  in  cell-cell  adhesion  and 
morphology. However, it is hard to speculate what is happening in the retina as MAGI3 
seemed to co-localise with PRPF31 only in few cells within the inner nuclear layer, and 
to the area corresponding to the outer plexiform layer. Retina cells are not epithelial cells 
but neurons, thus they will not form typical tight junctions, however they still may form 
other  types  of  junctions:  as  MAGI3  is  known  to  localise  to  adherens  junctions  in 
astrocytes (Adamsky et al., 2003), it is possible that the neuronal cells of the retina form 
some type of junctions/connections in which MAGI3 is localised, explaining the round 
pattern observed (see magnification on Figure 6.16 of Chapter 6). 
On the other hand, interestingly MAGI3 has two WW domains. WW domains are ~40 
residues long and characterised by two strictly spaced tryptophan residues, and they fold 
as  a  triple-stranded  -sheet,  they  recognise  and  interact  with  proline-rich  regions 
mediating  intracellular processes  (Macias et al., 2002). WW domains of CA150  and 
FBP11 (spliceosomal proteins) were found to be associated with the early spliceosome, 
particularly with the U2 snRNP and with less affinity to the other snRNPs (Lin et al., 
2004); the authors postulated that WW domain-containing proteins have the ability to 
nucleate the assembly of splicing factors at the 3’ splice site of the intron facilitating 
splicing  or exon  selection. It  may  be possible that MAGI3  exerts  a  similar role, by     8. Discussion and Further Perspectives 
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interacting with a splicing factor on U2 snRNP via its WW domains, and contacting 
PRPF31 which is part of the tri-snRNP, facilitating the transition of the spliceosome 
complex  A  (prespliceosome)  to  complex  B  (precatalytic  spliceosome).  This  could 
perhaps happen at the junctions of epithelial cells. It is known of Symplekin, a protein 
involved in 3’-mRNA processing and polyadenylation, having a dual localisation at the 
tight junctions and at the nucleus in epithelial cells (Keon et al., 1996; Hofmann et al., 
2002).  Symplekin  interacts  with  ZONAB  (Kavanagh  et  al.,  2006),  which  is  a 
transcription factor which also localises to both tight junctions and the nucleus, hence 
Symplekin  seems  to  regulate  gene  expression  not  only  through  its  polyadenylation 
activity  but  also  through  the  transcription  factor  ZONAB.  It  is  possible  to  make  a 
parallel hypothesis with PRPF31, as it is found at adherens junctions and in the nucleus 
simultaneously, hence it may similarly be involved in regulating gene expression which 
escapes  nuclear  regulation  to  facilitate  more  prompt  expression  according  to  local 
signals, in concert with MAGI3. 
 
TRAK2 is probably involved in the transport of mitochondria via kinesin to the synaptic 
termini (Brickley et al., 2005; Smith et al., 2006): nerve terminals have a high metabolic 
requirement for ATP. This could imply that there is a mechanism by which the cells are 
able to couple the splicing of transcripts to the levels of ATP or vice versa, explaining 
the interaction between PRPF31 and TRAK2; the reason for this may be that splicing 
requires ATP, hence when it is at its highest rate of splicing, PRPF31 is the link between 
ATP supply via TRAK2, which would bring mitochondria on site. 
The TRAK2 homologue, TRAK1, was found associated in vivo with RNA Polymerase 
II  and  OGT  (an  enzyme  responsible  for  the  O-GlcNAc  –acetylglucosamine– 
post-translational modification), leading to speculation that TRAK1 may target OGT to 
transcriptional  complexes  (Iyer  et  al.,  2003).  RNA  Polymerase  II  was  shown  to  be 
extensively  O-GlcNAc-modified,  hence  suggesting  an  interaction  with TRAK1-OGT 
complex, which has  a nuclear localisation. TRAK2 does not  seem to  localise to  the 
nucleus, however it does interact with OGT, hence we hypothesised that TRAK2, being 
present  at  the  border  of  the  photoreceptor  nuclei  (see  Figure  6.17,  Chapter  6)  may 
contact  RNA  Polymerase  II  in  transcriptionally  active  granules  via  OGT  (as  mouse     8. Discussion and Further Perspectives 
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photoreceptor nuclei have an inverted chromatin pattern, see before), and link them to 
PRPF31 (splicing can occur co-transcriptionally; Neugebauer, 2002). The reason for this 
is not known, although it could be a mechanism of transcription/splicing regulation, as it 
may be that TRAK2 targets OGT to transcription factors and spliceosomal proteins for 
them to be glycosylated. 
Iyer and colleagues (2003) also reported that TRAK2 homodimerises via its coiled-coil 
domain and they reasoned that it is possible that TRAK2 and TRAK1 may interact with 
each other (association proven in vitro, but authors did not provide information whether 
this interaction occurs physiologically) hence there may be a cross-talk, explaining the 
nuclear (nucleolar) presence of TRAK2 upon over-expression. 
The  C-terminal  domain  (CTD)  of  RNA  Polymerase  II  can  be  glycosylated;  this 
modification was proposed to regulate transcription (Comer & Hart, 2001). Therefore it 
may be that there is a cross-talk between PRPF31, TRAK2 and the CTD to regulate 
transcription according to splicing. This idea of a linker between the polymerase and 
splicing is also reinforced by the fact that the WW domain-containing protein CA150 
mentioned  before  interacts  with  CTD  (Lin  et  al.,  2004).  Similarly,  MAGI3  can  be 
viewed as a regulator of transcription  and splicing in epithelial cells, perhaps not in 
mouse photoreceptor nuclei. 
8.3  Isoforms and Mutation Screening 
Chapter 7 presented the results from the isoform analysis of MAGI3 and TRAK2, and 
the mutation screening regarding MAGI3. 
As  we  were  interested  in  alternatively-spliced  retina  transcripts  which  result  in new 
MAGI3 and TRAK2 proteins, we pursued the amplification of the transcripts in retina. 
The  analysis  of  the  results  from  the  amplification  of  the  transcripts  coding  regions 
suggested that neither MAGI3 nor TRAK2 may have retina-specific isoforms (which 
could therefore perhaps relate to RP11). Nevertheless, MAGI3 was found to be present 
in  two different species, 1481  and 1125  amino acids  long,  meaning  that  MAGI3  in 
human retina has an isoform of ~170 kDa, and a second one of ~130 kDa. Database 
searches did not identify any relevant domain in these C-terminal regions. TRAK2 was 
found to have only one transcript, generating a protein of 914 amino acids (~105 kDa).     8. Discussion and Further Perspectives 
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Interestingly, both genes generated 5’ UTR which differed from the sequence deposited 
in Ensembl. EST database searches focussed on these regions did support a longer 5’ 
UTR  for  MAGI3,  whereas  for  TRAK2 no  such longer 5’  UTR  was  retrieved. These 
results suggested that perhaps the transcripts undergo different types of regulation in the 
retina. Hence it would be interesting to investigate their 5’ UTRs in various tissues for 
comparison, however, the research was not pursued further as we were interested in the 
protein product of these transcripts. 
The  approach aimed to  encompass the types  of isoform which shared the annealing 
regions of the primers used: if a shorter/longer isoform was present, it would have been 
detected because the fragments were overlapping by two exons, facilitating the detection 
of missing exons or extra-exons. However, if the new isoform did not present the region 
for the primers to anneal, then no amplification would have been observed. Therefore 
the presence of a retinal isoform is not entirely excluded, and it could be identified with 
a different method, rapid amplification of cDNA ends (RACE) for example; however, 
that method was not chosen due to the level of characterisation of the transcripts in the 
Ensembl  database.  Other  ways  to  detect  isoforms  are  northern  blotting  and  western 
blotting,  done  on  human  retina  RNA  and  proteins  respectively.  The  northern  blot 
approach will rely on the detection of RNA, hence a different migration pattern in the 
gel  would  be  suggestive  of  different  splicing  products  (provided  that  the  probe  is 
annealing  to all the  species);  on  the other hand,  western blot is  quite similar to  the 
northern  blot,  as  it  will  allow  the  detection  of  protein  bands  migrating  at  different 
molecular weights (also in this case the epitope recognised by the antibody should be 
present in all the protein species). However, the latter case is not feasible for MAGI3 as 
it already displays isoforms and it would be difficult to detect any isoform of a similar 
molecular weight. 
Alternatively, a human EST database search for the entire transcript sequence would be 
a useful tool to discover any new transcribed region(s), however it has the disadvantage 
of being time-consuming, and is preferred to corroborate experimental data. 
Regarding the mutation screening, 95 patients affected by autosomal dominant RP (with 
no  mutations  in  most  common  genes)  were  subjected  to  sequence  analysis  for  the 
MAGI3  gene,  with  the  aim  to  discover  mutations  that could  perhaps  lead  to  retinal     8. Discussion and Further Perspectives 
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degeneration.  We  chose  to  screen  the  MAGI3  gene  by  virtue  of  MAGI3 
nuclear/nucleolar  localisation  with  PRPF31  and  its  WW  domains,  hence  it  may  be 
favoured to have a role in splicing. Four single nucleotide changes were detected, three 
were  non-synonymous,  meaning  that  the  translated  sequence  bore  one  amino  acid 
change. The presence of each non-synonymous change was investigated in 105 controls, 
two of which showed one change. For the remaining two changes, the DNA of affected 
family members for each patient was sequence analysed, resulting in non-segregation of 
the mutation. Therefore it is possible to infer that the observed changes are rare single 
nucleotide polymorphisms. 
Conversely, this screening should not be regarded as conclusive and exhaustive, as it has 
not entirely excluded MAGI3 from being a gene implicated in retinitis pigmentosa: the 
gene may still  cause RP, but  assuming its frequency is  very  low,  it  may  be that 95 
patients  are not  sufficient  to  detect  it.  Furthermore,  any  large deletions/insertions or 
rearrangements will be missed by direct sequencing method. Also, it may be possible 
that the change(s) lie(s) in intronic regions, which were not sequenced. TRAK2 was not 
screened due to time constraints, but also (as demonstrated by screening MAGI3) the 
chances of finding a mutation in this manner (“candidate gene” approach) are relatively 
slim,  as  there  is  no  mapping  data  from  a  family  to  refer  back  to  and  therefore  no 
indication about the mode of inheritance of the potential mutation. Subsequently it is 
difficult  to ascertain  which  type  of patients to  screen. Moreover, using  a  “candidate 
gene” approach to screening does not imply that mutations in the particular candidate 
gene cause retinal degeneration. 
 
8.4  Final Considerations and Future Perspectives 
Upon the results observed and discussed, it is hard to postulate an explanation, linking 
mutations  in  the  PRPF31  gene  and  retinitis  pigmentosa,  different  from 
haploinsufficiency:  first because of the mounting evidence in literature favouring the 
haploinsufficiency theory; secondly because this project unveiled unexpected insights 
into  PRPF31.  The  results  presented  herein  are  novel  and  relate  to  a  more  general 
background of  PRPF31  function  rather than specifically  to  the  retina and/or retinitis 
pigmentosa. In fact, before postulating any theory other than that of haploinsufficiency     8. Discussion and Further Perspectives 
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to explain RP, more information must be gathered on the role of PRPF31 in the cell, as 
the results presented herein suggest PRPF31 may play a larger role. 
 
From this work several hypotheses can be put forward: 
1.  The process of splicing can undergo several modes of regulation. One of these may 
be initiated by stress, and it may target the spliceosome, or some of its components, 
to the nucleolus. Both MAGI3 and TRAK2 may influence this process, since they 
were  found  co-localising  to  the  nucleoli  with  PRPF31;  it  does  not  exclude  that 
PRPF31 may take part in processing of rRNA; 
2.  Implication of MAGI3 in splicing, suggested by its WW domains. It may be that 
MAGI3 plays a role in linking the U2 snRNP to the tri-snRNP contacting PRPF31; 
this may happen in both the nucleus and the junctions according to regulation events; 
3.  Similar to the previous hypothesis, TRAK2 may be implicated in regulating splicing 
by coupling splicing to transcription: if TRAK2 is able to control the C-terminal 
domain (CTD) of the RNA Polymerase II through OGT, it may also contact PRPF31 
regulating the splicing process of the nascent transcript. This hypothesis would suit 
more the  (mouse) photoreceptor nuclei architecture rather  than cells displaying a 
standard chromatin arrangement. 
4.  In the case of cytoplasmic splicing, it is possible that the mitochondrial presence at 
particular  sites  is  connected  to  splicing  rates  through  a  pathway  implying  an 
interaction  between  two  key  players:  PRPF31  for  splicing  and  TRAK2  for 
trafficking of mitochondria; 
5.  Again for cytoplasmic splicing, it is possible that TRAK2 contacts RNA granules 
through  PRPF31  and  sort  them  to  different  cellular  destinations  via  kinesin  and 
microtubules; 
6.  Regarding  RP,  it  may  be  that  transcripts  crucial  for  rod  survival  contain 
minor-introns and their splicing is slowed down by the absence of half the normal 
PRPF31 protein product, triggering cell death and apoptosis in the long run; this 
could be as the case of the PrBP/δ protein as less protein would lead to mistargeting 
of PDE6 and absence of GRK1 in the outer segments, impairing phototransduction; 
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The  hypothesis  of  PRPF31  having  a  moonlighting  function  is  fascinating,  however 
considering the domains the protein bears it is likely to be a function in connection with 
RNA processing or regulation of pathways through RNA. Another interesting alternative 
would be to further investigate the relation with ZNF143: the hypothesis that can be put 
forward (in case of genuine interaction with ZNF143) is that PRPF31 is able to alter the 
transcription of U6 through ZNF143 in case U6 snRNA is needed: ZNF143 is known to 
target several snRNA genes for transcription (Myslinski et al., 1998) and activates U6 
transcription (Yuan et al., 2007). 
 
Due to the evidence gathered in the last two years about the mechanism of RP11, it is 
likely that the disease is caused by an insufficient amount of splicing factor, meaning 
haploinsufficiency. This work focuses more on PRPF31 as a key component of splicing, 
and does not fulfil the questions raised by RP11. Therefore the future work that we 
propose is directed towards answering questions regarding the biology of PRPF31 and 
splicing,  and  the  correlation  between  the  splicing  factors  and  the  new  interactors, 
MAGI3 and TRAK2. 
It is of great  interest to  investigate the role of  PRPF31  and MAGI3 and TRAK2 to 
confirm any splicing regulation due to these interacting partners or to confirm if/how 
PRPF31 plays a  role in  their  pathways.  Live cell imaging could be used  to validate 
whether the interactions are transient and where in the cell they happen. Moreover we 
would propose to knockdown one of the interacting partners in cells and follow up the 
effects on PRPF31, and vice versa (perhaps with a partial knockdown of PRPF31, as the  
Prpf31
-/- animal model was not viable, suggesting that a complete lack of the splicing 
factor  is embryonic  lethal;  Bujakowska  et al., 2009).  We  would  suggest performing 
experiments  involving  stress  and  to  detect  the  effects  on  PRPF31  and  perhaps  on 
splicing; also upon these treatments, it would be of interest to investigate the nucleolar 
interaction of MAGI3 and PRPF31. Experiments involving stress, perhaps using a stably 
transfected cell line for a partial knock down of PRPF31, could mimic the conditions in 
retina (a highly stressed tissue), which may give better indications linking to retinitis 
pigmentosa.     8. Discussion and Further Perspectives 
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Nonetheless,  the  validation  of  the  ZNF143  interaction  with  a  different  method  is 
reccommended, and, if positive, pursue co-localisation in cells and retina, as done for 
MAGI3  and  TRAK2  with  a  comprehensive  follow  up  with  other  experiments  as 
mentioned  above.  Besides,  a  further  analysis  of  the  other  isolated  yeast  two-hybrid 
clones is advised, in case any interesting protein (perhaps retina-specific) escaped our 
analysis, due to the high stringency. 
Moreover, to investigate the complex of protein surrounding PRPF31 we would suggest 
co-immunoprecipitation  experiments:  first,  to  check  whether  or  not  PRPF31  and 
E-cadherin  complex  together  (using  MDCK  cells);  secondly,  to  analyse  the  protein 
complex from cytosolic and nuclear fractions using mass spectrometry (this would be of 
interest to understand whether or not the spliceosomal complex is present in cytosol and 
with  which  components);  third,  to  perform  mass  spectrometry  of  PRPF31  protein 
complex, isolated from the retina. 
Also we would suggest comparing the splicing rates of retina (perhaps isolating each 
layer) and another tissue which is known to have a high metabolism (pancreas or liver as 
an example); also comparing the immunohistochemistry of retina with another tissue, to 
confirm  whether or not the presence of PRPF31 outside the nuclei is specific to the 
retina (and therefore suggesting a link to RP) or whether PRPF31 when investigated in 
the context of a tissue displays a different localisation than in cultured cells. 
Finally, it would be worthwhile to investigate the presence of other splicing factors, in 
both retina and cells, to observe their subcellular localisation. This should give more 
information on splicing: why three components of a spliceosome particle are causing RP 
and are all localising in an unexpected way (PAP1 and BRR2 were not tested), whereas 
PRPF16, not involved in the tri-snRNP assembly, shows a localisation more in line with 
the expectations?  It  may  be  that  either  the  tri-snRNP  can be  assembled outside  the 
nucleus,  supporting  cytoplasmic  splicing  of  transcripts  which  require  immediate 
translation “on-site”. However, it is rather controversial that a partially spliced transcript 
reaches  a  subcellular  region  with  less  difficulties of  a  completely  spliced  transcript, 
which  would  be  shorter  hence  easier  to  translocate.  It  may  be  that  a  pre-mRNA 
transcript folds and is then sorted to the extranuclear site. It appears that in retina the 
splicing  machinery  is  translocated  outside  the  nucleus,  favouring  the  hypothesis  of     8. Discussion and Further Perspectives 
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splicing happening in the minute cytoplasmic area bordering the nucleus, as the SC-35 
labelling suggested (Solovei et al., 2009). Regardless, more experimental data must be 
gathered before the patho-physiology of PRPF31 mutations can be determined.  
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A.1  Oligonucleotides for Expression Profiles 
 
Table A.1. List of the oligonucleotides used for the expression profiles on MAGI3, TRAK2 and 
ZNF143. 
Name  Sequence  Size bp  Mg  Ta 
MAGI3 F17  CATCATGGTCCACCATCAGGAA 
MAGI3 R18  ATTGTGCCGACTGCCTACAACT 
264/844  2mM  64 
TRAK2 F11  GAGATTGAGGGGACTATGCGTA 
TRAK2 R12  TCCCCTGGTTCAGGAGTGATTT 
247/544  2mM  64 
ZNF143 F4  CTCATAGATGGCCAGGTCATTC 
ZNF143 R5  TGGAGGTGTGGTGAATAAATGC 
157/682  2mM  64 
The “size” column lists both the cDNA and the genomic DNA sizes of the fragments amplified by the 
corresponding primer pair. 
 
 
A.2  Oligonucleotides for Library Amplification. 
 
Table A.2. List of the oligonucleotides used for the amplification of PRPF6 fragments from the 
human retina and the bovine retina yeast two-hybrid libraries 
Name  Sequence  Size bp  Mg  Ta 
PRP6_F7  GTGTCTGACTCCGTGAGTGGACAG 
PRP6_R9  CTTTCCGAAGAACCCGCTTCTTTG 
415  2mM  66 
PRP6_F13  TGTGTAGCCCACAATGCCCTGGAG 
PRP6_R17  TGTGGAGTGGGGACACTTCTTCAA 
582  2mM  59 
PRP6_F17  TTGAAGAAGTGTCCCCACTCCACA 
PRP6_R21  TCAGAAGGTGTTCTTGATGCGGCC 
622  2mM  68     Appendix 
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A.3  Oligonucleotides for MAGI3 Splice Variants 
 
Table A.3. List of the oligonucleotides used for the amplification of MAGI3 in retina.  
Name  Sequence  Mg  Ta 
5’ UTR 
A  GAGGAGGAGGAGGTTGCGGCTGG  1mM  60 
B  CCTTTCCCGCCGCTCGGGCGCTGAGCC  1mM  60 
C  AGTCCGGTCAGCCCCGGGGAGCGCAGC  1mM  60 
D  GCCGCCCAGGGCCCCCGGGCTGAGACG  1mM  60 
E  CACTCCTGCACCTTGCTGAGCCAGTGC  1mM  60 
Coding Sequence 
1_F  ATGTCGAAGACGCTGAAGAAGAAGAAGC 
4_R  GCCTCTCTCTGTTTTCTGCGTTTCCACTGC 
1mM  60 
2_F  AGACTGTGAAACCAGGCAAAGTCATTAATA 
8_R  GTGATTTTTCCATATCTGGTTTTGAAGACC 
1mM  60 
6_F  GATCTACTTCATTGACCACAATACCAAGAC 
10_R  TTGGTGAAGGAGGACCTCCTCTTAAGATAA 
1mM  60 
8_F  GACATACTATGTTGATCACCTTAACCAGAA 
12_R  CTTTGGTGTTTGGTGGTTTATCTTCATATA 
1mM  60 
10_F  GGAAAATTGCACCAGGCGATGTTATTGTAG 
14_R  CCTCGGGTTGTTTTTCTCCATAGAAGATCT 
1mM  60 
12_F  AAAACTGCCAAAATGAAAACAGATAAAAAG 
17_R  CCTTCTAGGGCACTTCTGTCCCCAGGTATG 
1mM  60 
15_F  AGATCTTCTATGGAGAAAAACAACCCGAGG 
21_R  CACGTAGGAGCACAGACCGGAAGGAGCC 
1mM  60 
20_F  GATGGCAGAATTCATGTTGGTGACCAGATT 
21_R  GAGAAGAGACTGATGCTTTATCTCAGGC 
1mM  60 
3’ UTR 
F  CCTACACAAGGAATCACACATACTCGAGC  1mM  60 
G  CACGTAGGAGCACAGACCGGAAGGAGCC  1mM  60 
H  CCCGAGCAACATTAAGGCTTTCAGGGC  1mM  60 
I  GAGAAGAGACTGATGCTTTATCTCAGGC  1mM  60 
Sizes of various generated fragments are discussed in chapter 5.     Appendix 
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A.4  Oligonucleotides for TRAK2 Splice Variants 
 
Table A.4. List of the oligonucleotides used for the amplification of TRAK2 in retina.  
Name  Sequence  Mg  Ta 
5’UTR 
A  CGCTGGGAACGCATTCGCCCCACCCGCGC  1mM  60 
B  CCGAGGTCGCCGAGTGATGATGTTGTG  1mM  60 
C  CCTTAGTAATTCCTCCCTTAACTCCAGGC  1mM  60 
D  GTCATGACTGTCCAAAGTATGATAATCAC  1mM  60 
E  CTCTGATGAGTCAAATGACATCCGTAGC  1mM  60 
F  CAGTGATGCTCTCCGAGTCTCTGTGATTGC  1mM  60 
M  CGGACGACAGAGGATGCCGAACCACTCC  1mM  60 
Coding Sequence 
1_F  CCGAGGTCGCCGAGTGATGATGTTGTG 
8_R  GTTTGTGCTG AAGGTCTACA ATCTGTGAC 
1mM  60 
6_F  GTTAATCAGCTGCAGCATGAGCTATGC 
12_R  AACCTCCTCT GAGCTGCTCC CCTGGTTC 
1mM  60 
10_F  CTGCACGAGTTACAAGACAGGAATATGG 
15_R  CTGGGGGTAA CCTGAGTGAT GTCAGAGG 
1mM  60 
13_F  GAGCTCCCAGAAGATGGGCCAACCAGGAC 
16_R  CTGCCTCCTGGCATCTTCCATTCTCTTGG 
1mM  60 
3’UTR 
G  TTGCAACCGCCAACCCAGGAAAGTGCCTG  1mM  60 
H  GGTTCCCTTCATTATCCTGTGGAAGTAGCG  1mM  60 
I  CAAGCTACTCATGTTTATTAACTGATCTAC   1mM  60 
L  GAATGGGCCATGAGTGTTCAGAGGGAG  1mM  60 
Sizes of various generated fragments are discussed in chapter 5.     Appendix 
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A.5  Oligonucleotides for MAGI3 Screening 
 
Table A.5. List of the oligonucleotides used for the amplification of MAGI3 exons for the mutation 
screening of adRP patients. 
name  Sequence (5’…3’)  Size  Mg  Ta  DMSO 
MAGI3_F1  GAGGAGGAGGAGGTTGCGGCTGG 
MAGI3_R1  GGACAATACG CGGTGGGGAG GTG 
967  2mM  64  10% 
MAGI3_F2  CTGGTTTAAGAGTATTCAGTTACTAGC 
MAGI3_R2  TTCATGTGAAATACTCCATCAAACTATC 
309  2mM  56  - 
MAGI3_F3  GTGAATTTTACCTTAATAAAGTTGG 
MAGI3_R3  GTCTGGCTGA TTTTTAGTAT ACTG 
508  2mM  56  - 
MAGI3_F4  CTCAAATGATTCACCCATCTCGAC 
MAGI3_R4  CTCACTTTAG CTTATAGGAT GGTC 
583  2mM  56  - 
MAGI3_F5  GACTAGCATCAGAGGTGCTATACAGAG 
MAGI3_R5  GATCCTCCTG CTCTTATAAA ACCAGAAG 
639  2mM  56  - 
MAGI3_F6  ATCTGAGGAATACAAATGGAGCCTGTTG 
MAGI3_R6  ATCAGTTGAT TATGATATCC ACCCACTG 
364  2mM  56  - 
MAGI3_F7  CATCTTCTGTTCTGGGCTTCTGATTGC 
MAGI3_R7  CCTTGATAAT TCATCTAGTC TGTTGCCC 
602  2mM  56  - 
MAGI3_F7a  TGGGTGACAGAATGAGTGCCTGTCTCC 
MAGI3_R7a  GTGCAGTGGC TCACGCCTGG AATCTC 
487  2mM  68  - 
MAGI3_F8  GCTTCACAGCTTGGCATCTTCTGCA 
MAGI3_R8  ACAGTAACAA CTAGACACTC TTTAGTGTC 
426  2mM  64  - 
MAGI3_F9  GACTTCATCTTCCTGGTATAGTACTTTGC 
MAGI3_R9  CAGATAAATG CTTGAGGAGA TGTATACCAC  
757  2mM  56  - 
MAGI3_F10  CTATCTTTTCAGCAGTTAATAGAGGTTTCC 
MAGI3_R10  TCAGACAGAA CCTTAAGGAA AATGCACAC 
882  2mM  60  - 
MAGI3_F11  CAAAGACACCAAAGTTCAATGTCACACAGG 
MAGI3_R11  TGGTACAATA GGCCTTTAGT AATCCTCCAG  
580  2mM  60  - 
MAGI3_F12  GTAAATCTGCTGTGTCTTTGATCCTGCC 
MAGI3_R12  GCTTCTGAAA GATGGGAAGG TCCTAGTC 
382  2mM  60  - 
MAGI3_F13  GTTGAATTGTGTGTGTGTGTTACACTC 
MAGI3_R13  ACTGTCTAAT TTGCAGCTGA CATATTC 
483  2mM  64  - 
MAGI3_F14  TGCCATTTTGGAGAATGGGCACTTTCTC 
MAGI3_R14  ATCCTTTTGT GTTTGCATAG CCTTCCAC 
531  2mM  64  - 
MAGI3_F15  ACTGCTGTTGCCTACATCTGCACTCAG 
MAGI3_R15  AGATAAACTT GAAGCCTGGA AGGTTCGG 
558  2mM  64  - 
MAGI3_F16  GTTTGGATGCGATGATGACGTGTGGTAC 
MAGI3_R16  GAAGAATAAG ACTCCAGCGT GCATACAC 
475  2mM  64  -     Appendix 
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MAGI3_F17  GTATAGTTCCTGGAGCTCTGTCTTCTAG 
MAGI3_R17  GGACGGTATT TGAGGAACAG GCAAGAG 
587  2mM  64  - 
MAGI3_F18  TGTCAGAGGGAAAATGGCAAGGTCGAG 
MAGI3_R18  GTCAATGTGC AATGCAACAA TCAGAGAAC 
607  2mM  60  - 
MAGI3_F19  GTTCTCTGATTGTTGCATTGCACATTGACC 
MAGI3_R19  CGAAGTTTCT AGTCTAGAGC CTGAACC 
440  2mM  60  - 
MAGI3_F20  CACATGGCAGTACTGGGTACACGTTAGG 
MAGI3_R20  CATTCCATTC CAACGAAAGT CCTGCCTAAG  
491  2mM  60  - 
MAGI3_F21  ACACCCACGCAGTACTTGCCTCATC 
MAGI3_R21  AGGAACAATA CGTTTTGAAC TTTGACAGC 
882  2mM  64  - 
MAGI3_F21a  ACTCAGGCTTTTTAAGCAGTTACGAC 
MAGI3_R21a  AATGCTGCTG TAAGAAAAGA TTACAAC 
1286  2mM  64  - 
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